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Abstract 
The following represents a variety of projects which were undertaken throughout the 
course of a 3-year PhD degree course. This thesis focuses on using perfluoro-
heteroaromatics as tools for peptide modification.  
Chapter 2 discusses the efforts towards exploring the reactivity and modification of 
pentafluoropyridine (PFP) rings in terms of peptide modification. Thiol-containing 
dipeptides were synthesised, tagged using PFP and further functionalised using 
thiophenolate resulting in a surprising substitution pattern. These compounds were 
analysed using 19F NMR, 1H NMR and LCMS.  
Chapter 3 focuses on the modification of Oxytocin and Vasopressin using PFP. The 
peptides were synthesised using Fmoc-SPPS and protecting groups exploited to tag the 
peptides with PFP resulting in mono- and di-tagged species. The enzymatic stability of 
these peptides tested, and the results discussed in Chapter 3. 
The final experimental Chapter 4 focuses on tagging longer and biologically active 
peptides with PFP. This chapter focuses on efforts made to synthesise Cys-modified 
GLP-(7-36) which can be modified using PFP and testing the stability of this compared 
to native GLP-1. GLP-1 is an interesting peptide target which has gained popularity 
recently due to the success of GLP-1 analogue Liraglutide in the treatment of diabetes.  
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Chapter 1: Introduction 
1.1 Peptides as Drug Molecules 
In general, there are two main classes of therapeutics currently marketed; small 
molecule drugs which are usually less than 500 Da and have good bioavailability and 
biologics which are typically more than 5000 Da and have poor bioavailability.1  
Aspirin (1) Herceptin® (2) 
 
 
 
 
 
 
Mw: 180.157 Da Mw: 145531.5 Da 
Molecular formulae: C9H8O4 Molecular formulae: C6470H10012N1726O2013S42 
Oral administration Administration via injection 
Table 1.1:  i) Examples of small drug molecule: aspirin (1) ii) Example of a biologic drug 
molecule: Herceptin® (2).1 
The difference in size between the two classes of therapeutic also leads to differences in 
mode of action and biological properties. For example, small molecule drugs often lack 
selectivity, leading to unwanted off-target effects, whereas biologics such as Herceptin 
(2) are much more selective towards their desired target and consequently display low 
toxicity.1 Peptide therapeutics attempt to exploit the selectivity and potency of biologics 
but also harness the bioavailability and membrane permeability of small molecules.  
It is estimated that peptide therapeutics account for 10% of the total pharmaceutical 
market and are worth upwards of $40 billion a year.2 Between 1970 and 2003, the 
number of peptide drugs approved for therapeutic use was 30, with most of these being 
simple linear peptides (e.g. Lupron).  In 2014/2015 the US FDA approved nine peptide 
drug candidates (Table 1.2) highlighting the increased interest in this area. In addition, 
15 
 
in 2015, there were 400-600 peptide drug candidates in various stages of clinical 
development with a variety of biological applications such as cancer treatments, 
cardiovascular treatments, pain medication and allergy treatments.4  
Peptide name Brand name 
(Manufacturer) 
Treatment Date of approval (FDA) 
Metreleptin  Myalept (Astra Zeneca) Complications arising from 
leptin deficiency 
Feb. 2014 
Albiglutide  Albiglutide (GSK) Type 2 diabetes- GLP-1  
 
Apr. 2014 
Dulaglutide Trulicity (Eli Lilly) 
 
Type 2 diabetes- GLP-1  
 
Sep. 2014 
Insulin degludec Tresiba (Novo Nordisk) 
 
Type 2 diabetes GLP-1 Sep. 2015 
Parathyroid hormone Natpara (NPS. Pharma) 
 
Hypocalcemia treatment 
for patients with 
hypoparathyroidism 
 
Jan. 2015 
Table 1.2: Examples of peptide therapeutics gaining market approval 2014/2015.4 
 
2017 represented a particularly successful year for the peptide therapeutic market with 
the GLP-1 agonist Ozempic (for the treatment of Type 2 diabetes) and Tymlos (for the 
treatment of Osteoporosis) being approved for commercial distribution.4 The  
emergence of peptides as viable therapeutics in recent years lends itself to the 
development of more effective methods of peptide synthesis and better understanding 
the stability of peptides within biological systems.5  
 
There are multiple areas of peptide drug development research including antimicrobial 
peptides (AMPs) and G-protein-coupled receptor-targeting peptides (GPCR). 
Approximately 39% of peptides in clinical trials are GPCR-targeting peptides which is 
mainly due to the diversity of GPCRs within the body. GPCRs are a family of cell 
surface receptors which play important roles in the regulation of cell growth, 
metabolism and cell signalling. While GPCRs are vital in regulating normal bodily 
functions such as the immune system and the nervous system, abnormal GPCR function 
can cause tumour cell growth and metastasis.  As Table 1.2 shows, one of the most 
interesting GPCR targets for drug research is Glucagon-like Peptide-1 (GLP-1) and 
Glucagon-like Peptide-2 (GLP-2) which will be discussed in Chapter 4. 5 
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AMPs represent an important field of peptide therapeutics due to the occurrence of 
antimicrobial drug resistance. As of 2014, there were 10 AMPs at various stages of 
clinical development against a range of microbial targets including parasites and 
bacteria.5  
PPI’s (Protein-Protein Interactions) are responsible for a large range of biological 
processes within the body ranging from catalysis to cell division.6 Consequently, the 
ability to disrupt or modulate PPIs offers the opportunity to provide highly selective 
treatment of a broad range of diseases including cancer.7 Finding molecules that can 
target PPIs with high affinity has proven to be challenging given that they often require 
binding to a large, relatively flat protein surface.  While some small molecules have 
been developed to act as potent PPI inhibitors,8 in recent years larger molecules, such as 
peptides, have seen increasing interest within both the academic and industrial 
communites.9  
1.1.2 Challenges with Peptide Drug Development  
Historically the use of peptides as therapeutics has been challenging, mainly due to poor 
bioavailability and poor stability within biological systems.10 Due to their size and 
hydrophilicity it is often difficult for peptide drugs to cross cell membranes including 
the blood brain barrier and this affects a drug’s ability to interact with its desired 
target.11 Once administered, peptides are often rapidly degraded by proteases which 
recognise certain residues or sequences of residues within the peptide. Once the peptide 
chain is degraded or truncated it normally loses its biological activity.  
Peptide Stability 
Peptides are susceptible to chemical degradation, for example peptides containing Cys 
and Met residues readily undergo oxidation (as seen below), which in the case of Met, is 
very difficult to reverse (Scheme 1.1i) and the oxidation of Cys can result in the 
formation of disulphide bonds (Scheme 1.1ii). Asp-containing peptides can lead to 
aspartimide formation and subsequent altered peptide sequences with the formation of 
β-peptide bonds and peptide bond degradation (Scheme 1.1iii).  
17 
 
 
Scheme 1.1: Potential chemical degradation pathways: i) oxidation of methionine (3) to 
methionine sulfone (5) ii) oxidation of cysteine (6) to sulfenic acid (7) and disulphide bridge (8) 
and iii) formation of aspartimide intermediate (10) resulting in β-aspartic acid (11).12 
Recent studies have sought to improve peptide stability by modifying residues within a 
peptide sequence.13 Several studies in this area have focused on the substitution of both 
natural and non-natural amino acids into the native sequence of a biologically active 
peptide. Deacon and co-workers13 demonstrated that by carrying out substitutions at 
position 8 of GLP-1(7-36), the properties of the original peptide could be modulated 
(Table 1.3). For example, substitution with various natural amino acids including, 
serine (Entry 2), threonine (Entry 3), glycine (Entry 4) and amino-isobutyric acid 
(Entry 5), increased the stability of the GLP-1 analogues against DPPIV. 
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Entry Structure Modification 
1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR Native GLP-1 
 
2 HSEGTFTSDVSSYLEGQAAKEFIAWLVKGR Ser substiution 
 
3 HTEGTFTSDVSSYLEGQAAKEFIAWLVKGR Thr substitution 
 
4 HGEGTFTSDVSSYLEGQAAKEFIAWLVKGR Gly substitution 
 
5 HAibEGTFTSDVSSYLEGQAAKEFIAWLVKGR Aib substitution 
 
Table 1.3: Modification of native GLP-1 resulting in increased stability to enzymatic 
breakdown. 
They found that when substituted with serine, threonine or glycine, the enzymatic 
cleavage rates were approximately 5% less than the native GLP-1 and when substituted 
with amino-isobutyric acid (Aib) there was no detectable degradation.13 Further 
strategies that have been utilised for GLP-1 modification will be discussed in more 
detail in Chapter 4.  
AMPs have provided many lead compounds in recent years for the design and 
development of new peptide antibiotics.14 Researchers have explored the possibility of 
preparing all D-amino acid isomers of natural peptides as a means to increase stability 
as well as reduce toxicity. For example, Carmona and co-workers15 investigated the 
biological activity and stability of the antimicrobial peptide, Pin-2 
(FWGALAKGALKLIPSLFSSFSKKD). In this study, the 24 residue polycationic Pin-2 
peptide was synthesised in both the D- and L-isomeric forms and tested against a variety 
of bacterial strains for biological activity and against bovine pancreatic trypsin and 
human elastase for proteolytic stability. In the stability studies against these two 
enzymes, the D-analogue was not degraded while the L-analogue was digested to 
smaller peptide fragments. In studies using human serum, the D-analogue was found to 
degrade at a reduced rate compared to the L-analogue (Figure 1.1).15 
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Figure 1.1: Analytical HPLC traces of stability profile of A) L-Pin-2 and B) D-Pin-2, to human 
serum at t = 0, 4, 8 and 24 h. (Figure reproduced with permission). 
As demonstrated by the case of Pin-2, conversion of peptides from their natural L-amino 
acid form to their D-amino acid analogues can provided an effective method for 
improving the stability of a peptide. The disadvantages of such an approach are that it 
results in a more expensive peptide and will only work in cases where the peptide does 
not bind to a chiral target.  
Peptide Targeting and Cellular Delivery 
As well as the challenges presented by an inherent susceptibility towards enzymatic 
degradation, poor cell permeability due to their hydrophilic nature also presents a hurdle 
to overcome in peptide drug development. Until recently, the concept of delivering 
peptide drug cargo into cytoplasmic and nuclear components of a cell was under 
investigated and seemed an unattainable target. Translocating the cellular membrane has 
proven a problem with conventional drug discovery and often means that large 
quantities of a drug must be administered, resulting in side effects and toxicity.16 
There have been a number of studies carried out to investigate the translocation of 
peptide fragments across cellular membranes17 and from this work short peptide 
fragments that could cross cellular membranes without assistance from transporter 
proteins were identified. This group of peptides are now known within the community 
as a “cell penetrating peptides” (CPP). Since their discovery CPPs have been exploited 
as drug delivery agents given their ability to penetrate cells and deliver drugs to 
intracellular targets.18 
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An example of one of these CPP is the Tat-derived peptide of the HIV-1 virus.19 The 
peptide itself is synthesised in HIV-infected cells and is responsible for HIV cell 
replication. The cell penetrating part of the peptide is only 10-16 amino acids long and 
contains 6 Arg residues so is overall cationic.20 These Arg (and also Lys residues to a 
lesser extent) play a pivotal role in Tat-peptide cell penetrating abilities19 and are 
thought to function by forming bidentate hydrogen bonds between the guanidinium 
groups of Arg and phosphates present in cell membranes.21 There have been a number 
of studies concentrating on conjugating Tat fragments to a variety of biomolecules 
including proteins.22 Dowdy and co-workers synthesised a Tat-caspase 3 conjugate 
which was shown to selectively target HIV infected cells. Once within the infected 
cells, HIV protease cleaves the Tat peptide from the peptide-protein conjugate resulting 
in active caspase-3 to effectively induce apoptosis.23  
A related field of peptide research is cell targeting peptides (CTP’s) which are small 
peptides that are cell specific and have a high affinity for their target. Table 1.4 
illustrates peptides sequences-including their lengths- which are shown to target specific 
tissues. 2 
Peptide sequence Sequence length Target tissue 
TSPLNIHNGQKL 12 Head and neck solid 
tumours (Andrea, 2006) 
CGKRK 5 Tumour neovasclature  
(Portoghese, 1982) 
CGNKRTRGC 7 Breast tumours (Ye, 2006) 
RGD 3 αVβ3 (Dijjkgraaf, 2007) 
VHSPKNN 7 Endothelial VCAM-1 
expressing cells (Harris , 
2007) 
EDYELMDLLAYL 12 Various tissue tumours 
(Janssen, 2002) 
LTVSPWY 7 Breast tumours (Dromi, 
2007) 
Table 1.4: Cell targeting peptide (CTP) sequences, lengths and targets. 18 
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The concept of CTPs has been applied to cancer research and an example of this is 
Arginylglycylaspartic acid (RGD). RGD analogues are used to target glycoprotein 
integrin αvβ3/ αvβ5 which is expressed in tumour cells. Integrins are a family of 
transmembrane glycoproteins that are expressed in a variety of cells and play a role in a 
number of physiological processes but integrin αvβ3 plays a significant role in tumour 
growth. Chen and co-workers24 synthesised a cyclic RGD peptide linked to a 18F-
fluorobenzoate tracer via the amino moiety of the lysine residue (Figure 1.2). They 
found that using the 18F-labelled RGD adduct (13) allowed for imaging of the selective 
inhibition of tumorous tissue cells compared to healthy tissue.  
 
Figure 1.2: The structure of a cyclic RGD peptide labelled with [18F]-fluorobenzoate (13). 
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1.2 Peptide Conjugate Applications  
A variety of strategies have been used to improve the pharmokinetic properties of 
peptides including conjugation to small molecular probes, polyethylene glycol (PEG) 
groups and carbohydrates.5  
 
Scheme 1.2: Native peptide exhibiting poor physiochemical properties and peptides modified 
with sugars, PEG and fluorescent probes to improve peptide properties. 
For example, incorporating sugars or lipids can improve the stability of a peptide and 
allow for drug delivery, but incorporating electron deficient alkynes into a peptide and 
coupling to fluorescent proteins can be used in imaging studies.25 Peptides are also 
increasingly being conjugated to nanoparticles including silica nanoparticles,26 gold 
nanoparticles27 and quantum dots.28 Bioconjugation to molecules such as these can 
improve targeting and cell penetration of a peptide.  
1.2.1 Improving Lipophilicty 
It has been previously discussed that poor oral bioavailability plays a crucial role in the 
breakdown of peptides within a biological system.29 Therefore, improving the 
bioavailability of peptides is an effective strategy for ensuring that a peptide reaches its 
desired target.30 Strategies for the addition of aliphatic moieties (e.g. fatty acid 
conjugation)31 to a peptide system have been developed and have been shown to 
improve the lipophilicity of peptides.   
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Additions of PEG groups have also been shown to increase the stability of a peptide.32 
PEGylation is shown to dramatically improve various pharmacokinetic properties of 
peptides due to the alteration of binding patterns compared to non-PEGylated peptide 
therapeutics and has also shown to improve absorption rates due to reduced breakdown 
of the peptide in the renal system.33 This provides promise in using PEGylation as a 
method to improve peptide properties and make it a more viable therapeutic option. 
This concept will be discussed using GLP-1 as an example in Section 4.1 “Case Study: 
GLP-1: Improving Pharmokinetics via Bionconjugation”.   
Investigations into cyclic peptides have found that the lipophilicity of cyclic peptides 
are increased compared to their linear counterparts. This is due to the masking of the C- 
and N-terminus charges which protects the peptide from site specific degradation and 
improves cell permeability of the cyclic peptide.34  Cilengitide (14) is a small RGD 
pentapeptide which is currently in clinical trials for the treatment of glioblastomas and 
has been the subject of bioconjugation studies in the past to improve lipophilicity.35  
Analogues of Cilengitide have been synthesied where the N-Me group was replaced 
with PEG chains of various sizes (15 and 16).   
 
 
Figure 1.3: Structure of cilengitide (14), N-PEG2 substituted cilengitide (15) and N-PEG23 
substituted cilengitide (16).35 
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It was found that by incorporating a short polyethylene glycol (PEG) chain into the 
cyclic peptides, as in compound 15, the lipophilicity was improved compared to 
Cilengitide (14) with similar biological activity. When longer chains, as in compound 
16, were incorporated, the lipophilicity was improved, but biological activity was lower 
compared to the native peptide due to steric hindrance.36 
1.2.2 Improving Cell Permeability 
Using a targeting group within drug design allows for direct delivery of the drug 
molecule to the desired target, improved cell permeability and reduced toxicity within a 
biological system.  
There have been a number of studies in recent years investigating the effect of peptide 
conjugation to nanoparticles such as silica37 and gold.38 Conjugation of Tat-peptide, 
which is a HIV-derived peptide, to mesopourous silica nanoparticles (MSN) was shown 
to target cell nuclei and successfully allowed for the delivery of DOX (doxorubicin) - an 
anticancer drug- into the nucleus.39 MSN are nanomaterials which have proven effective 
at delivering drug cargoes due to their large surface areas, pore sizes and high stability 
while Tat-peptide has been shown to translocate cellular membranes. By combining 
these with a DOX drug cargo, the peptide-drug conjugate can cross cellular membranes 
and exert anticancer properties.39 
Bioconjugation of peptides to gold nanoparticles (GNP) has become a well-documented 
method for synthesising cell permeable and potent drug candidates for the treatment of 
diseases such as cancer, as well as biosensing and diagnostics.40 GNP are biologically 
stable and therefore non-toxic and easy to synthesise. Due to GNP reactivity, thiol and 
amine containing peptides can be conjugated to the GNP surface and delivered 
selectively to diseased cells. Rotello and co-workers41 synthesised a variety of cationic 
tetra-alkyl ammonium modified GNP (17) to target the enzyme β-galactosidase (Figure 
1.4).  
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Figure 1.4: Tetra-alkyl ammonium modified GNP (17) developed by Rotello.41 
This inhibition was reversed upon addition of glutathione (GSH), which is a reducing 
agent and functions by reducing disulphides to free cysteine and has potential to act as a 
releasing agent within cells due to differing concentrations of GSH inside and outside of 
a cell.41 GNP-peptide analogues have become a well-established and successful method 
for improving cell permeability42 and targeting.43 
1.2.3. Molecular Imaging 
Molecular imaging has proven a vital diagnostic tool for a variety of diseases such as 
cancer and Alzheimer’s disease and has also proven to be an invaluable tool in drug 
development.  Molecular imaging in drug development has allowed for determination of 
the mechanism of action of a peptide, determination of the target site of various 
molecules within a biological system as well as any breakdown products that may be 
produced.44  
Tagged peptides have interesting properties which allow for imaging experiments and 
have proven an effective way to visualise the reaction of peptides within a biological 
system. They not only allow for the visualisation of an interaction but also 
quantification of an interaction between peptide and its target which can give an 
indication of the efficacy of the peptide. The peptide in question can be tagged by a 
variety of substrates including fluorescent tags such as fluorescein isothiocyanate 
(FITC) (Scheme 1.3) and phosphorescent tags such as iridium complexes (Scheme 1.4). 
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Fluorescein isothiocyanate (FITC) is a fluorescein analogue which is used routinely in a 
variety of labelling studies such as fluorescent microscopy, equilibrium studies and flow 
cytometric studies. 44 Due to its versatility, FITC (18) has featured in many imaging 
studies including animal and plant endocytosis studies. The isothiocyanate group of the 
fluorophore reacts with free amine groups and can therefore conjugate to peptides 
containing an amine in their sidechains. Zheng and co-workers used FITC coupled to 
RGD tripeptide (Scheme 1.3) to stain tumour cells.45  
 
Scheme 1.3: Bioconjuagtion of RGC pepide and FITC.45 
Techniques used to image integrin αvβ3 have included immunohistochemical staining 
with anti-integrin antibodies, but this proved to be a complicated method of imaging 
due to the instability of the antibodies in aqueous solution. Zheng and co-workers45 
were able to synthesis cyclic RGD peptides conjugated to FITC which were proven to 
selectively and efficiently target integrin αvβ3/ αvβ5. 
The iridium complex (21) below has proven an effective tag in phosphorescence studies 
due to long half-life, stability and a substantial difference between absorption and 
emission wavelengths.46 The alkynoic moiety of the complex reacted specifically with 
free cysteine, leaving unprotected serine and lysine unchanged, to give a 
phosphorescent peptide system conjugated by a vinyl sulphide linkage (Scheme 1.4). 
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Scheme 1.4: Selective modification of cysteine containing protein using [Ir(ppy)2(phen-
propiolamide). 47 
Shui and colleagues47 demonstrated the specificity of this complex by coupling the 
phosphorescent tag with a BCArg protein (20) which has been shown to exhibit anti-
cancer activity and has a variety of unprotected side chains such as Lys, Tyr, His and 
Met and a single free Cys. The phosphorescent tag attached specifically at the free 
cysteine and exhibited a longer half-life and greater stability compared to fluorescent 
tags which allowed a distinction to be made between the tagged peptide and scattering 
light from the sample.47 
1.3 Preparative Methods of Peptide Conjugates 
1.3.1 Bioconjugation at Cysteine (Cys) 
Cys is present in a range of proteins as it plays an important role in a large number of 
biological processes ranging from metabolism to apoptosis.48 Given its high reactivity 
many research groups have focused on developing approaches that would allow the 
chemical modification of Cys residues within peptide and protein systems. Many of the 
approaches look to exploit the nucleophilic nature of the thiol within the Cys residue 
(Figure 1.5). Tagging studies based on Cys have previously concentrated on the 
synthesis of disulphides and the reaction of Cys with Michael acceptors (Scheme 
1.5i).49 
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Scheme 1.5: An overview of Cys bioconjugation approaches.  
Ryan et. al50 focused on the bioconjuagation of Cys containing peptides with 
bromomaleimides (Scheme 1.5ii) and found that the reversibility of these conjugates 
could be controlled depending on reaction conditions. In theory this approach could be 
applied to peptide therapeutics which could allow for the conjugation of peptides to 
thiosugars which would have greater stability within a biological system. A popular 
method adopted for Cys modification is the use of disulphides in bioconjugation. A 
simple and effective method for the synthesis of disulphides is the use of disulphide 
exchange reagents such as pyridyl dithiol. This reaction can be carried out over a wide 
pH range and the resulting leaving group is stable, therefore driving disulphide 
exchange to completion.51 Griebrenow and co-workers52 were able to synthesise 
alkylated Terlipressin analogues which were accessed via “rebridging” of the 
disphulphide bond using substituted alkynes. These reactions were selective for the Cys 
over other nucleophilic side chains and allowed the synthesis of PEGylated Terlipressin 
analogues. 
Chudasama53 investigated the modification of Cys with bromopyridazinedione (Scheme 
1.5iii) and found that these bioconjugated peptides were more stable and the reaction 
specific for Cys. Bromopyridazinedione (29) was used to conjugate thio-glucose (31) to 
cysteine and disulphide containing peptides/proteins (28) (Scheme 1.6).  
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Scheme 1.6: Bromopyridazinedione-mediated peptide modification of Grb2 adapter protein 
(28).53 
In this study Chudasama and co-workers used a Cys mutated variant of the SH2 domain 
of Grb2 adapter protein (28) and when reacted with dibromo-1,2-dihydro-pyridazine-
3,6-diones (29) (DBPD), the bromine is selectively displaced by the free thiol of the 
mutated protein resulting in a mono-brominated intermediate (30). Thioglucose (31) is 
added to the intermediate which displaces the second bromine of the DBPD to give a 
protein-sugar conjugate (32), exhibiting increased hydrolytic stability compared to the 
native protein. In an excess of 2-mercaptoethanol (BME), a thiol alcohol, the conjugate 
is disassembled to yield the starting protein (Scheme 1.6). To further probe protein-
conjugate release, glutathione (GSH), which is found in various concentrations in a 
number of living cells, was added to the protein-conjugate, resulting in disassembly and 
release of the free protein.53 This gave the peptide-conjugate scope to be used in drug 
delivery to selectively deliver a therapeutic peptide to its target with reduced enzymatic 
breakdown.  
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Recent work from the Chudasama group has concentrated on using pyridazinediones 
(PD) to access disulphide bonds for modification.54 They focused on the modification of 
the antibody Herceptin (33) with anti-cancer compound monomethyl aurisatain E 
(MMAE) using pyridazinediones. Analogue 34 is an ADC with a MMAE payload 
conjugated via a non-cleavable linker and compound 35 utilises a cathepsin B labile 
cleavable linker (Scheme 1.7).  
 
Scheme 1.7:  Formation of Herceptin-MMAE conjugated via PD with cleavable linker (35) and 
non-cleavable linker (34).54 
 
Analogues 34 and 35 were found to be stable in human serum and also exhibited 
activity against HER2-positive cell lines in in vitro assays and mouse xenograph 
models. These analogues were particularly active due to the fact they have the ability to 
conjugate MMAE to 4 different disulphide bridges and deliver a high drug payload to 
its target.53 Davis and co-workers55 have investigated a number of strategies for Cys 
specific tagging including the synthesis of selenocysteine conjugates, elimination to 
produce dehydroalanine (Dha) (Scheme 1.5v) and nucleophilic and electrophilic 
disulphide formation. By adopting these methods, Davis and co-workers were able to 
conjugate various groups such as thiosugars and thioprenyls into a range of peptide and 
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protein systems in a selective manner. The modification of Cys via Dha (27) (Scheme 
1.8) has been an interesting and well documented method for incorporation of sugars 
and imaging labels into a peptide sequence selectively through Cys.53 
 
Scheme 1.8: Bioconjugation of Cys (22) via Dha intermediate (27) (Nu= PEG, glyscosugars, 
imaging labels etc).56 
This method has allowed for the synthesis of a diverse range of modified Cys residues 
including modified histones, PEGylated proteins and glycoproteins.57 In the studies 
involving modified histones it was established that Cys modification via Dha allowed 
for the production of a number of new analogues with interesting activities in imunoblot 
and enzymatic assays.57 Post-translational modifications (PTM) of histones occur at a 
number of different reactive sites, including alkylation of Lys residues and are 
responsible for a number of important biological functions including DNA replication. 
Davis and co-workers aimed to alkylate histone Cys residues to produce a variety of 
histone mimetics via a Dha intermediate (Scheme 1.10).  
Treatment of Cys modified H3 histone 37 with dibromide 38 resulted in the formation 
of the mono substituted compound 39. Further incubation of intermediate 39 resulted in 
the cyclised intermediate 40, followed by the elimination of the substituted furan 
leaving group, to give the Dha containing histone 41 (Scheme 1.9). 
 
Scheme 1.9: Mechanism of formation of Dha from Cys via dibromide 38. 
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The histone used in this study was a H3 mutant (37) with a Cys at position 110 and was 
found to be converted to Dha using the dibromide shown in Scheme 1.10. The Dha 
intermediate (41) did not react with Ellmans reagent, confirming the conversion of Cys 
to Dha. The Dha intermediate was then reacted with a variety of thiols (42, 43, 44 and 
45) resulting in a series of methylated lysine mimics.57 
 
Scheme 1.10: PTM of Cys (37) residues utilising Dha intermediate (41).57 
The resulting mono-(42), di-(43), and tri-methylated Lys (44) and acylated Lys (45) 
analogues were shown to exhibit activity in immunoblot and enzymatic assays as well 
as selectivity towards the antibody used in the study. As well as the methylated Lys 
analogues, Davies and co-workers57 also synthesised phosphorylated Ser and 
glycosolated Ser analogues by utilising the reaction condition described above, via the 
Dha intermediate. These modified histone analogues also exhibited activity in 
immunoblot and enzymatic assays as well as selectivity towards the antibodies tested.57 
The unique reactivity of hexafluorobenzene (HFB) (47) was utilised by Spokoyny et 
al.58 in which substitution of HFB (47) using the thiols of Cys residues as the 
nucleophile was achieved. It was determined that HFB (47) could react selectively with 
Cys to form the 1,4-disubstituted aromatic product (49 and 50). A useful feature of this 
reaction is that it can be followed using 19F NMR spectroscopy to observe the formation 
of products.  
33 
 
 
Scheme 1.11: The model preparation of the 1,4-disubstituted perfluoroaryls, 49 and 50, from 47 
and 48 respectively.  
The reactivity of HFB (47) with Cys residues inspired the investigation of HFB for 
peptide stapling. The reaction allows for quick and efficient synthesis of stapled 
peptides without the synthesis of other isomers (Scheme 1.11).59, 60  
Further work carried out by Pentalute and co-workers demonstrated the use of the ‘π-
clamp’ to induce the selective modification of cysteine.61 The ‘π-clamp’ is a sequence of 
aromatic amino acid residues (H2N-FCPF-R) (51) which can be incorporated into a 
protein and increases the reactivity of the Cys in the sequence. The incorporation of this 
small peptide sequence into a protein allows for the selective modification of Cys using 
a decafluorodiphenyl derivative (52).61 (Scheme 1.12) 
 
Scheme 1.12: Reaction of π-clamp peptide (51) with decafluorodiphenyl derivative (52).61 
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1.3.2 Bioconjugation at Lysine (Lys)  
Targeting Lys is also a popular method for bioconjugation because, as with Cys, Lys 
has a nucleophilic side chain. The nature of the Lys side chain, a free primary amine, 
allows a degree of selectivity can be applied when modifying peptides with multiple 
active sites, with an exception of the peptide N-terminus.  
Modification at Lys can be carried out using a range of reaction conditions to give a 
variety of products for example, the simple reaction between isothiocyanate and the free 
amine of Lys to give a thiourea product (Scheme 1.13i).62 These can act as a precursor 
to further modifications such as incorporation of alkyl groups or a method to conjugate 
imaging labels into the peptide backbone.  
Scheme 1.13: Some examples of approaches utilised to carry out bioconjugation at Lys 
residues.  
More complex modification directly at Lys includes the formation of an amidine 
linkage using 2-imino-2-methoxyethyl reagents (Scheme 1.13iii) more specifically 2-
imino-2-methoxy-1-thioglycosides. This strategy was adopted to synthesise α-L-
rhamnopyranosidase analogues (Scheme 1.14) which were shown to selectively target 
liver tumour cells.63 
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Scheme 1.14: Selective delivery of drug using α-L-rhamnopyranosidase.63 
The above reaction Scheme 1.14, details biocatalytic delivery system which was used 
by Davis and co-workers64 to selectively deliver L-rhamnose (Rha) capped doxorubicin 
(DOX) (60) to HepG2 disease model. The first step (Scheme 1.14i) in this reaction 
scheme is delivery of the Rha cleaving enzyme rhamnosidase (59) by receptor mediated 
endocytosis (RME). Conjugating a sugar moiety to this site allows for selective 
targeting of the diseased cell. Scheme 1.14ii describes the delivery of the Rha-capped 
drug (60) to the reaction site, whereupon its reaction with rhamnosidase, the drug cargo 
(DOX) is released (Scheme 1.14iii). These analogues were found to exhibit selective 
delivery of the drug cargo to the desired target, have enhanced stability compared to the 
non-conjugated drug cargo and exhibit an increased level of cargo delivery compared to 
the non-conjugated cargo.64  
There have also been studies focusing on the PEGylation of peptides selectively at the 
free amine of Lys (Scheme 1.13ii). Initial studies by Harris and co-workers65 centred on 
PEGylatation using PEG dichlorotriazine (63) (Scheme 1.15i) which was able to react 
with multiple side chains, but unfortunately led to cross-linked products. PEG-triflorate 
(65) (Scheme 1.15ii) was found to be a more selective PEGylating reagent towards Lys 
and Cys and was used to form linkages to a variety of proteins. 
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Scheme 1.15: Reaction of R-NH2 with “First generation” PEGylating reagents. 
These examples (63 and 65) are referred to as “first generation PEGylating reagents” 
and although the methods adopted are simple and efficient, PEGylation of proteins is 
inefficient due to contamination caused by diols in high molecular weight PEGs and 
side reactions. This has led to the synthesis of second-generation PEG reagents such as 
α-methyl branched PA-PEG analogue (67), as shown in Scheme 1.16.65 Analogues such 
as this and other second generation PEGylatin reagents were shown to have increased 
stability to hydrolysis.65 
 
Scheme 1.16: Reaction of R-NH2 with “Second-generation” PEGylating agents. 
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Finally, modification of Lys via the formation of iminoboronates (71) (Scheme 1.13iv) 
has been investigated as a method for synthesising cancer imaging conjugates by Gois 
and co-workers (Scheme 1.17).66 
 
Scheme 1.17: Protein modification at Lys utilising iminoboronates.66 
This modification proceeds via a B-N linkage which showed no detectable degradation 
after 5 h, yet was reversible upon addition of glutathione, fructose and dopamine. By 
selectively conjugating fluorescent analogues of acetylbenzeneboronic acid to the free 
amine of Lys in lysozyme, Gois and co-workers were able to use these analogues (71) to 
target folic acid receptors of cancer cells which allowed for selective internalisation of 
the described analogues.66 
Cys and Lys modifications are, by far, the most common type of peptide side chain 
modification due to their nucleophilicity and their high abundance in nature. In the 
following sections, modification strategies developed towards other naturally occurring 
amino acids will be discussed (Section 1.3.3) along with approaches that utilise non-
native amino acids (Section 1.3.4).  
1.3.3 Bioconjugation at Serine (Ser)/ Threonine (Thr) and Tyrosine (Tyr)  
The hydroxyl group, which as a functionality, is present in a large number of proteins, 
natural products and drugs is an interesting and challenging target for chemoselective 
modification and bioconjugation. Hydroxyl group bioconjugation is not an area that has 
been widely researched and in part this is due to the hydroxyl group displaying a 
reduced nucleophilicity compared to thiol and amine containing residues. This reduced 
reactivity makes it difficult to carry out chemoselective reactions of hydroxyl containing 
amino acids (e.g. Ser or Thr) in the presence of Cys and Lys.67 
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The concept of Ser tagging is a very interesting one due to the fact that approximately 
1% of the human genome contains a serine residue. A family of such enzymes are Ser 
hydrolases which are characterised by the presence of a serine residue within the active 
site which is involved in the hydrolysis of substrates. Utilising tagging strategies to 
investigate the function and mechanism of these enzymes could be useful in developing 
possible Ser hydrolase inhibitors. The ability to target these residues specifically has 
promise due to the fact Ser hydrolases are involved in the causation of a number of 
diseases such as diabetes, cancer and Alzheimer’s disease.68    
Levin and co-workers69 were able to successfully incorporate PEG-salicylaldehyde (73) 
to the N-terminal Ser of a variant of parathyroid hormone (PTH). PEG-salicylaldehyde 
was reacted with the protein fragment in the presence of pyridine-acetyl acid to form a 
mono-PEGylated species conjugated via amide bond (74) (Scheme 1.18).  
 
Scheme 1.18: Reaction of Ser (72) with PEG-salicylaldehyde (73) at the N-terminal amide 
bond.68 
The formation of the mono-PEG compound 74 occurs via an imine 75 formation 
followed by O-N shift, producing compound 77. Compound 77 is only formed in 1-
amino-2-hydroxyl containing compounds such as Ser and Thr, meaning this PEGylation 
is selective for Ser and Thr. TFA is used to cleave the acetal moiety 78, resulting in a 
mono PEGylated Ser compound 74 (Scheme 1.19). 
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Scheme 1.19: Mechanism of PEGylation of N-terminal Ser (72).69 
This method allowed for conjugation at the N-terminal Ser selectively and did not occur 
at other Lys residues within the sequence. PTH is a polypeptide which has shown 
promise in treating osteoporosis due to its ability to increase bone density, but due to is 
poor half-life has limited use as a therapeutic agent. Therefore, the reaction procedure 
mentioned above has promise in exploiting PTH as a viable therapeutic by improving 
stability.69  
Bioconjugation at Ser and Thr residues has proven to be a challenging task due to the 
reasons previously described, but bioconjugation at Tyr has met with more success. For 
example, Barbas and co-workers70 synthesised a 1,2,4-triazoldine-3,5-dione analogue 
(82) via an ene-type reaction at Tyr (Scheme 1.20). 
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Scheme 1.20: Reaction of 1, 2, 4-triazoldine-3,5-dione (83) and Tyr (82).70 
Due to the nature of the hydroxyl groups in Ser, Thr and Tyr residues studies have 
concentrated on modification of hydroxyl to more reactive species including conversion 
of the hydroxyl to a halide leaving group, oxidation to the corresponding 
aldehyde/ketone or conversion to a more reactive chemical species e.g. azide or thiol. 
Davis and co-workers71 were able to utilise Lawesson’s reagent (86) (LR) to convert 
hydroxyl of carbohydrates to thiols. 
 
Scheme 1.21: Glycosylation using LR (86) via the hydroxyl of Ser (85). 
LR has been shown to convert several chemically different hydroxyls to the 
corresponding thiol and has promise in glycosylating proteins in a one-pot reaction 
(Scheme 1.21).71 
1.3.4 Bioconjugation at UAA using Click Chemistry 
Click Chemistry commonly refers to the quick and efficient reaction between two small 
molecules to produce a larger structure. A variant of click chemistry, and perhaps the 
most widely used, is Cu(I) catalysed [3+2] cycloaddition (a variant of Huisgen 
cycloaddition reaction) and was first conceived by Sharpless, Meldal and colleagues in 
2001.72 In these reactions dipolarophiles react with 1,3-dipoles to form five-membered 
heterocycles. The reaction conditions implemented by Sharpless and co-workers 
suggested a quick, efficient and high yielding method of synthesising regio-specific 
heterocycles.   
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Scheme 1.22: Typical “click chemistry” reaction.72 
The 1,2,3-triazole systems produced from a typical click chemistry reaction, as shown 
above (Scheme 1.22), has many interesting properties which make them useful tools in 
peptide synthesis. The triazole system is more stable than a typical amide bond present 
with a peptide sequence and has been implemented as a surrogate for amide bonds 
(Figure 1.5i) to help decrease enzymatic degradation.73 Triazoles have also been 
investigated as linking agents in studies aimed at stabilising α-helices. Kawamoto and 
co-workers74 synthesised triazole stapled peptides (Figure 1.5ii) and found that these 
stapled peptides had improved potency and stability compared to the non-stapled 
analogue.  
i)   ii)  
Figure 1.5: i) Triazole acting as a substitute for amide bond. ii) Triazole acting as a linker.73
   
In recent years, click chemistry conditions have been implemented as a method of 
conjugating peptides and a variety of groups including PEG groups75 and imaging 
labels76 as a method of investigating biological systems.   
Liskamp and co-workers75 investigated the use of click chemistry to bioconjugate 
biodegradable PEG groups to peptide-based hydrogels in an attempt to synthesise an 
effective drug delivery system. Hydrogels are hydrophilic polymer networks that have 
applications in drug delivery. By incorporating PEG groups into the polymeric network, 
it becomes biodegradable and allows for the release of a drug molecule when 
hydrolysed. The utilisation of click chemistry for the synthesis of the polymeric network 
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allowed the reaction to be carried out in mild conditions, without the need for protecting 
groups and with high yields of desired product.75 
Molecules labelled with 18F allow for positron emission spectroscopy (PET) which is a 
non-invasive and efficient method of visualising biological systems at a molecular level. 
Chen and co-workers76 used click chemistry to incorporate 18F labelled moieties into a 
peptide chain which can be traced in vivo (Scheme 1.23).  
Scheme 1.23: Incorporation of labelled 18F into peptide using click chemistry. 
Several different radiolabels and peptides have been synthesised and it was found that 
PET imaging provided an effective method for visualising target peptides specifically 
and their mode of action. By synthesising a range of conjugated peptides and 18F-
labelled probes, several different targets can be investigated. These include integrin 
receptor77 - overexpression of which has been shown to facilitate metastasis in cancer 
cells, somatostatin receptor78 - which is known to facilitate insulin and glucagon release 
and neurotensin receptor- which has been implicated in many different cancers such as 
breast and pancreatic cancer.79 
Another method of click chemistry is “Cu-free click chemistry” which utilises the 1,3- 
dipolar cycloaddition of azides and cyclooctynes and has been extensively researched 
by Bertozzi and co-workers.80 This method does not use toxic Cu in its synthesis so has 
applications in in vivo studies. The reaction between the cyclooctyne ring and azides is 
rapid due to the release of ring strain which means there is no need for the use of a 
catalyst in this reaction. Antibody-drug-conjugates (ADC) synthesised using Cu-free 
click chemistry result in site specific conjugation to a variety of substrates including 
imaging labels and chemotherapeutic agents.80 
Sato and co-workers81 synthesised unnatural amino acid (UAA)-containing proteins 
(93) which were then used in the synthesis of ADC containing p-
azidomethylphenylalanine (pAMF). pAMF altered IgG antibodies were conjugated to a 
cyclooctyne tags (94) which showed potency in in vitro studies (Scheme 1.24).  
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This reaction is particularly successful due to the highly reactive cyclooctyne used in 
the reaction. Upon investigation of cyclooctyne bond angles, Bertozzi and co-workers82 
determined the alkyne bond angle of cyclooctyne was ~160°, which is the same as the 
bond angle of the transition state of the cyclo-addition reaction. The release of ring 
strain upon reaction of cyclooctyne with azides results in a rapid reaction rate 
acceleration. 
 
Scheme 1.24: Conjugation of UUA containing trastuzumab with cyclooctyne tag.81 
The antibody used in this study was a Her2- binding IgG Trastuzumab and was altered 
to include a pAMF moiety into the protein backbone. Using Cu-free click chemistry, a 
DBCO-PEG-monomethyl auristatin (DBCO-PEG-MMAF) drug cargo was conjugated 
to the antibody which, when tested, exhibited high potency in cytotoxicity assays using 
a SKBR3 model system.81 
As well as conjugation of drug cargo, Cu-free click chemistry has also been used to 
conjugate imaging agents to peptides. Bertozzi and co-workers82 used Cu-free click 
chemistry to investigate zebrafish glycoproteins. Sialic acid has proven an important 
component in cellular processes such as cell adhesion and receptor signalling. Previous 
studies to investigate sialic acid have proven difficult due to the lack of chemical tools.  
In this study, cell permeable (N-azidoacetylmannosamine) ManNAz was changed to a 
sialic acid derivative (SiaNAz) which was incorporated into glycans on the cell surface. 
Difluorinated cyclooctyne (DIFO) conjugated to an imaging probe reacted with the 
azido-sialic acid derivative via a click reaction resulting in a glycoprotein conjugated to 
an imaging tag. Bertozzi and co-workers used this strategy to visualise zebrafish 
embryos and found that they were able to successfully visualise zebrafish embryo cell 
surface sialoside biosynthesis and also visualise sialogylconjugate expression at various 
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levels of embryo development.82 Due to its versatility, mild conditions and high yields, 
click chemistry has proven a useful tool in the bioconjugation of peptides to a vast range 
of different molecules. 
1.3.5 Organometallic Mediated Peptide Bioconjugation 
Although the field of organometallic compounds in biology is a well-researched field, 
the conjugation of transition metals (TM) to peptides for biomedical research is a 
relatively new field of research. Transition metals can be used in multiple scenarios to 
alter peptide function including being incorporated into a peptide backbone using 
unnatural amino acids83, direct conjugation with the nucleophilic side chains of natural 
amino acids84, conjugation via the C- or N-termini85, and also act as catalysts to 
incorporate R groups into a peptide.86 
 
There have been a number of studies into exploiting the reactivity of natural amino 
acids to conjugate a TM to the peptide backbone. This could be achieved by exploiting 
the electron accepting ability of TM to conjugate to π-electron rich residues such as Phe 
and Tyr.  In 1998, Grotjahn and co-workers87 synthesised a Ru-modified secretin 
analogue (100). Secretin is a peptide that controls water regulation throughout the body 
and Grotjahn and co-workers synthesised a secretin analogue containing multiple sites 
for possible TM conjugation. They were able to selectively modify the Phe side chain as 
opposed to the free N-terminus or N-terminal His with a reported conversion of 70-
100%. (Figure 1.6).  
 
Figure 1.6: Ru-modified secretin analogue synthesised by Grotjahn and co-workers.87 
Organometallic compounds can also be used to catalyse cross-coupling reactions of 
peptides and small molecules.88 Davies and co-workers developed a Pd-pyrimidine 
catalyst which was used to conjugate R groups to a protein. First the Pd-pyrimidine 
coupling agent was tested on a series of small halogenated amino acids with various 
boronic acids using mild reaction conditions (Table 1.5). 
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Entry ArX Condition Coupling 
 Product 
Yield (%) 
 
1 
 
 
37 °C, 4 h 
 
 
95 
 
2 
 
 
37 °C, 4 h 
 
 
98 
 
3 
 
 
37 °C, 4 h 
 
 
0 
 
4 
 
 
 
37 °C, 4 h 
 
 
 
94 
 
5 
 
 
37 °C, 4 h 
 
 
95 
 
6 
 
 
37 °C, 6 h 
 
 
0 
 
7 
 
 
37 °C, 6 h 
 
 
92 
Table 1.5: Pd-pyrimidine mediated Suzuki-Miyaura cross coupling of halogenated aryl amino 
acids with Ph.88 
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The results from this exploratory work were promising with high yields for most of the 
test reactions, with these reactions carried out without the use of organic solvents. It was 
suggested that Entry 3 low yield was due to the inactivity of the Cl leaving group. 
Entry 6- which contains a C-terminal p-iodobenzyl cysteine (Pic)-had a yield of 0 %, 
believed to be due to the active site inhibition of the Pd-catalyst, yet Entry 7- which 
contains an internal p-iodobenzyl cysteine- was successful with a yield of 92 %.88  
Davies and co-workers proceeded to cross couple various R groups to a Pic mutated 
SBL protein (115) using the Pd-pyrimidine catalyst (116) and boronic acid, under mild 
conditions (Scheme 1.25).  
 
Scheme 1.25: Pd-pyrimidine mediated Suzuki-Miyaura cross coupling using a Pic mutated 
protein to couple various R groups. 
A variety of aryl and vinylboronic acids were used in the cross-coupling reactions with 
conversions of >95%. Using this strategy, Davies and co-workers were able to 
synthesise a glycoprotein (117) using aqueous and mild conditions in high yield.88  
With the significant advancements that have been made in the field of TM-peptide 
conjugation, it is expected that future research will concentrate on applying the 
techniques described to improve existing peptide drugs and to further explore the scope 
of this technique of peptide modification.89 
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1.4 Project Aims 
Historically the use of peptides as therapeutics has been hampered due to poor 
bioavailability and poor stability within biological systems. As discussed in Section 
1.3.2-1.3.5, there have been numerous studies into improving the chemical properties of 
peptides which include conjugation of small molecules via reactive side chain residues. 
A number of these studies have been successful in improving properties such as stability 
and solubility compared to the native peptides.  
The aim of this project is to investigate the role of fluorinated building blocks in peptide 
modification. As mentioned in Section 1.3.1 the role of HFB in peptide stapling and 
modification has been investigated by Pentalute and co-workers58 and these studies 
yielded interesting results in improving the helicity of peptides. They found that HFB 
was reactive towards Cys residues, but not reactive towards other nucleophilic side 
chains on residues such as Tyr and Lys and also that the HFB could not be further 
modified once conjugated to the peptide.  
Previous work in the Cobb group has investigated pentafluoropyridine (PFP) as a tool 
for peptide modification with Hudson and co-workers90 synthesising a PFP containing 
tripeptide (120). PFP initially undergoes nucleophilic aromatic substitution at the para 
position to the nitrogen, but it can then undergo further nucleophilic aromatic 
substitution reactions at the ortho positions leading to a multi-functionalised scaffold 
(Scheme 1.26).  
 
Scheme 1.26: i) Tagging of peptide 118 with PFP ii) Nucleophilic aromatic substitution at ortho 
position of compound 119. iii) Further nuclopehilic aromatic substitution at ortho position of 
compound 119. 
 
118 
119 120 
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The substitution pattern of PFP with nucleophiles is particularly interesting when 
applied to the modification of peptides as it can allow for conjugation of multiple PEG 
chains or thio-sugars into a peptide which may influence stability and lipophility.  
Further work carried out within the Cobb group found that PFP was reactive towards 
Cys, Tyr and Lys side chains, whereas there was no such reaction between these side 
chains and HFB making PFP a more versatile tool for peptide modification (Scheme 
1.27).91  
 
Scheme 1.27: i) Unselective tagging of Tyr and Cys residues using DIPEA, DMF, rt, 4 h ii) 
Selective tagging of Cys residues using DIPEA, TFE, DMF, rt, 4 h. 
This work provided encouragement to pursue this area of research and to investigate the 
effect of PFP modification on peptide stability. The aim of this study was to investigate 
the role of PFP itself in altering peptide properties as well as using thio-sugars and thio-
PEGs to further functionalise a peptide via aromatic substitutuion of the PFP.  
As part of the presented work the investigation of tagging of various peptides with PFP 
starting with small dipeptides will be discussed (Chapter 2: Synthesis, Tagging and 
Investigation of Dipeptides using PFP), before investigation of the effect of PFP on 
stability of Oxytocin and Vasopressin (Chapter 3: Synthesis, Tagging and Stability 
Studies of PFP-modified Oxytocin and Vasopressin).  The final aspect of this work 
will concentrate on the synthesis and modification of GLP-1 with PFP (Chapter 4: 
Introduction to GLP-1: Improving Pharmokinetics via Bioconjugation). 
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Chapter 2: Synthesis, Tagging and Modification of Dipeptides using 
Perfluoroaromatics  
2.1 Fluorine in Medicinal Chemistry  
The use of fluorine and fluorinated building blocks as tools for the modification of 
pharmaceuticals has been extensively researched. This is due to the fact they offer 
highly versatile routes to modulate the physical, electronic and chemical properties of 
drug molecules.1  
One of the earliest examples of a fluorinated pharmaceutical is 5-fluorouracil (126) the 
fluorinated analogue of uracil (125) (Figure 2.1). The fluorine atom is situated on the 5-
position of the pyrimidine ring, and this simple switch from H to F has little steric 
impact, but it significantly alters the biological properties of the molecule. Uracil (125) 
is an essential building block for DNA transcription, but the fluorinated analogue (126) 
has proven to be an effective anti-cancer agent which acts as a pyrimidine antagonist. 
Fluorouracil (126) can act as a substrate for thymidylate synthase and is converted to 
fluorouridine. This is then converted to fluorouridine triphosphate and incorporated into 
RNA as a false nucleotide, disrupting translation.  
    
Figure 2.1: Structure of uracil (125) and 5-fluorouracil (126).  
Substitution of a hydrogen atom by fluorine can also be used to alter the chemical 
properties of a drug, increasing its stability towards oxidation and unwanted metabolism 
by P450 enzymes. Ezetimibe (128) is a successful cholesterol drug that provides a good 
example of how fluorine can be used to prevent unwanted metabolic breakdown. The 
pro-drug SCH 48461 (127) was shown to have four possible sites of metabolism. By 
incorporating fluorine atoms at these specific sites, the resulting compound was found 
to be more stable to metabolism and this eventually led to the synthesis of Ezetimibe 
(128) which had 50 times higher potency than SCH 48461 (127).3  
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Scheme 2.1: Structure of SCH 48461(127) including sites of possible metabolic breakdown and 
Ezetimibe (128).3 
 
2.1.1 Nucleophilic Aromatic Substitution of Pentafluoropyridine and 
Hexafluorobenzene  
The electron withdrawing character of fluorine in hexafluorobenzene (HFB) (47) and 
pentafluoropyridine (PFP) (129) lowers the energy of their π* orbitals. This results in a 
decrease in the electron density on the aromatic ring in both PFP (129) and HFB (47), 
making them susceptible to nucleophilic aromatic substitution (SNAr).
5  
 
Figure 2.2: Structures of hexafluorobenzene (HFB) (47) and pentafluoropyridine (PFP) (129). 
Moreover, the electron withdrawing power of the fluorine atoms in PFP (129) and HFB 
(47) stabilise the anionic intermediate formed during SNAr further increasing the 
reactivity between PFP/HFB and nucleophiles.6 The reactivity of HFB (47) towards 
nucleophilic peptides has been discussed in Chapter 1 (Section 1.3.1) and here, the 
reactivity of PFP (129) with respect to SNAr, and in particular sulphur-containing 
nucleophiles, will be briefly discussed.  
Studies into the rate and regioselectivity of the SNAr reactions of fluorinated 
heteroaromatics have been investigated previously with reactions of 2,4,6-
trifluoropyridine (130) and pentafluoropyridine (129) being reported in the literature.7,8 
Comparison of the products of reaction between these two compounds found that 
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reaction between 2,4,6-trifluoropyridine (130) and the methanolate nucleophile afforded 
the para and ortho substituents with a ratio of 78:22 (Scheme 2.2i). In contrast, the 
reaction of pentafluoropyridine 129 and methanolate afforded the para substituent only 
(Scheme 2.2ii), suggesting that the position of the fluorine on the heteroaromatic ring 
plays an important role in regioselectivity.9     
 
Scheme 2.2: (i) SNAr of 2,4,6-trifluoropyrdine 130 with methanolate resulting in para and ortho 
substituted products 131 and 132 (ii) SNAr of pentafluoropyridine 129 with methanolate 
resulting in para substituted product 133 only. 
The difference in the ratio of products between 2,4,6-trifluoropyridine (130) and PFP 
(129) can be explained via investigation of the Meisenheimer intermediates and the 
activating/deactivating effects of fluorine in heteroaromatic environments.   
 
Scheme 2.3: SNAr of 2,4,6-trifluoropyridine (130) with a Nu at the i) para position and ii) ortho 
position. 
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When nucleophilic attack occurs at the para position of 130 (Scheme 2.3i), the resulting 
Meisenheimer intermediate has a negative charge located on the nitrogen and a fluorine 
positioned ortho to the charged nitrogen, which has a stabilising effect. In intermediate 
135, there is no fluorine attached to the negatively charged carbon, meaning this 
intermediate is tolerated more than the corresponding PFP analogue 138 (Scheme 2.4ii). 
Therefore, nucleophilic attack at the para position is preferable to attack at the ortho 
position, for compound 130. 
Looking at the structures of the Meisenheimer intermediates for the nucleophilic attack 
of PFP (129) at ortho, meta and para fluorine atoms, it would be expected that the 
fluorine at the ortho position would react similarly to the para position (Scheme 2.4). In 
the case of nucleophilic attack at the ortho (Scheme 2.4ii) and meta positions (Scheme 
2.4iii), the negative charge of the Meisenheimer intermediate lies on the carbon of the 
carbon-fluorine bond. The interaction between the negative charge on the carbon and 
fluorine lone pairs has a destabilising effect and is therefore unfavourable. Whereas in 
the case of nucleophilic attack at the para position (Scheme 2.4i), the negative charge is 
on the nitrogen and the fluorine ortho to this position has a stabilising effect.   
 
Scheme 2.4: SNAr of PFP (129) with Nu at the i) para position ii) ortho position and iii) meta 
position. 
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Kinetic studies have been carried out to determine the importance of fluorine at the 
ortho, meta and para positions. It was shown that the presence of fluorine at the ortho 
and meta positions have a strong activating effect whereas fluorine at the para position 
was deactivating.7 In the case of perfluoroheteroaryl compounds, the number of 
activating fluorine atoms dictates the initial site of attack. 
 
Scheme 2.5: PFP with activating (ortho and meta) fluorine atoms highlighted in red and 
deactivating (para) highlighted in blue. 
The effect of fluorine in activation/deactivation of heteroaromatic systems helps to 
explain the difference in the ratio of products between 2,4,6-trifluoropyridine (130) and 
PFP (129). In the case of 2,4,6-trifluoropyridine (130), there are no deactivating fluorine 
atoms para to the site of attack, which means attack occurs at both para and ortho 
positions to the nitrogen (Scheme 2.3). The aromatic nucleophilic substitution of 
pentafluoropyridine (129), in general, occurs at the para position which maximises the 
number of activating fluorine atoms that are ortho and meta to the site of attack and 
minimises deactivating fluorine atoms para to the site of attack (Scheme 2.5).9  
Shown in Table 2.1 are the products resulting from the nucleophilic aromatic 
substitution of PFP (129) with various nucleophiles.10,11,12,13 All of these reactions 
resulted in products with the nucleophile reacting para to the nitrogen.   
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Nucleophile Product Reaction Condition 
 
 
 
 
 
1) MeCN, rt 
2) NaBF4, MeCN, rt 
  
 
CsF, MeCN, 20°C 
 
 
 
 
CsF, 3h 
 
 
 
n-BuLi, TMEDA, THF 
Table 2.1: Reaction of PFP (129) with various nucleophiles.10,11,12,13 
Upon further treatment of PFP (129) with the same nucleophile, it cannot react para to 
the initially added nucleophile, as is the case for HFB (47), since the para position is 
blocked by a nitrogen. Therefore, the second SNAr reaction occurs ortho to the nitrogen 
(Scheme 2.6).5, 9 It has also been demonstrated that all fluorine atoms in PFP can be 
substituted when using an excess of nucleophile. However, this takes a significant 
amount of time (~6 days). 14 
 
61 
 
 
Scheme 2.6: Order of substitution of fluorine in SNAr reactions with initial substitution at the 
para position followed by ortho substitution. 
The versatility of the reactivity of PFP (129) is further illustrated in Table 2.2. A series 
of 3,5-difluoro-triayloxypyridines were synthesised using the sequential addition of 
nucleophiles to PFP. Compound 154 was synthesised using PFP as a starting material 
and stepwise nucleophilic aromatic substitution using the nucleophiles 151, 152 and 
finally 153.15 
 
 
Nuc1 Nuc2 Nuc3 Product 
 
  
 
Table 2.2: Synthesis of 3,5-difluoro-triayloxypyridine and 2,6-diphenoxypyridine analogues 
(R=alkyl).15 
These compounds were of particular interest as they proved to be biologically active 
and inhibitors of Xa and factors VII/TF which are involved in blood clotting 
pathways.15 
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2.1.2 Pentafluoropyridine and its Applications in Peptide Chemistry  
In 2013, the Cobb group reported the synthesis of novel tetrafluoropyridine-containing 
amino acids (157, 158).16 The nucleophilic nature of oxygen and the predictable 
regioselectivity of PFP was used to tag an orthogonally protected serine.16 Boc-Ser-OBn 
(156) was used as the protected amino acid and was prepared in good yield (71%) from 
the commercially available Boc-Ser-OH. Subsequent reaction of (156) with PFP (129) 
gave the the tetrafluoropyridine-containing amino acid (158) in a 55% yield (Scheme 
2.7).16 It was also possible to prepare 157 in a 30% yield using Boc-Ser-OMe (155) as 
the nucleophile.  
 
Scheme 2.7: Transformation of Boc-Ser-OBn (156) and Boc-Ser-OMe (155) when in the 
presence of PFP.16 Reagents and conditions: i) PFP, K2CO3, MeCN, rt, 20 h. 
The next step was to successfully incorporate the PFP-tagged amino acid (158) into a 
peptide. A test tetrafluoropyridine-containing peptide was synthesised using a solution 
phase peptide synthesis protocol (Scheme 2.8). It was found that the 
tetrafluoropyridine-containing amino acid (158) was robust to peptide coupling 
reactions, and resistant to Boc deprotection (e.g. strong acid).  
 
Scheme 2.8: Synthesis of PFP-tagged tripeptide (160). Reagents and conditions:  i) NH2-Ala-
OBn (158), NMM, CH2Cl, rt, 18 h ii) TFA, CH2Cl, rt, 4 h iii) Boc-Ala-OH, PyBOP, rt, 18 h. 
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The tetrafluoropyridyl group has the potential to act as a leaving group due to the 
electron withdrawing power of fluorine (Scheme 2.9ii), or, additional groups could be 
attached ortho to the ring nitrogen in order to functionalise the peptide (Scheme 2.9iv). 
This would offer a new approach for peptide modification and bioconjugation. 
 
Scheme 2.9: i) Tagging of peptide 161 with PFP and further reaction pathways for 
fluoropyridine-tagged peptide 162 via ii) Elimination resulting in a Dha containing peptide 163 
iii) Displacement of fluoropyridine using Nu iv) Aromatic substitution on PFP ring using thiol 
nucleophiles. 
However, before the PFP group could be fully exploited in peptide chemistry it would 
be important to establish the mechanism by which nucleophilic displacement (Scheme 
2.9iii) would occur.  
2.2 Chapter Aims 
As discussed in Chapter 1 (Section 1.3.1), Davies and co-workers have shown that 
reaction between cysteine residues and nucleophilic moieties can proceed via an 
elimination/addition reaction (Scheme 2.10).17 This reaction pathway results in a 
mixture of isomeric products which, in theory, can be distinguished via NMR 
spectroscopy.  
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Scheme 2.10 - Elimination/addition reaction pathway and expected stereochemistry of products 
168. 
We reasoned that by conjugating PFP (129) to a Cys-containing dipeptide, the reaction 
between the resulting “activated” di-peptide (169) and a nucleophile would proceed via 
an SN2
 reaction resulting in only one isomeric product (170). If the reaction does not 
proceed via an SN2 pathway and instead proceeds via an elimination/addition reaction, 
there will be two isomeric products, which will have distinct 1H NMR patterns. The 
nucleophile used in this study is thiophenolate which allows the reaction to be traced by 
19F NMR with the disappearance of peaks from the 19F NMR suggesting the reaction 
has reached completion. 
 
Scheme 2.11: Proposed displacement reaction of activated dipeptide 169 showing the expected 
stereochemistry of the product 170. 
We envisaged that it would also be of value to determine whether or not changing the 
amino acid residue would change the reaction mechanism. The target compounds which 
will be utilised in the mechanistic studies are shown in Figure 2.3. These include the 
PFP (129) tagged dipeptides containing cysteine (169), penicillamine (171) and 
homocysteine (172). It was expected that, upon addition of a nucleophile, attack will 
occur at the carbon of the cysteine and homocysteine residue in compound 169 and 172 
but not in 171, due to the fact it contains a tertiary carbon which will not readily 
undergo SN2 reaction.  
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Figure 2.3: Structures of pentafluoropyridine tagged di-peptides targets (169, 171 and 172). 
The reaction of 169 and 172 with a nucleophile, paired with 1H NMR data and the non-
reaction of compound 171 with a nucleophile would confirm that the reaction proceeds 
via SN2 and not an elimination-addition pathway. 
2.3 Synthesis of PFP-Tagged Dipeptide Targets 
2.3.1 Solution Phase Dipeptide Synthesis of Dipeptide Targets 
Preparation of the pentafluoropyridine-tagged dipeptides (169, 171 and 172) was first 
investigated via solution-phase peptide synthesis. Using standard reaction conditions 
below, the acetyl-capped dipeptide (177) was synthesised. 
 
Scheme 2.12: Solution phase synthesis of dipeptide 177. Reagents and conditions (i) PyBOP, 
NMM, DCM, rt, 18 h (ii) Piperidine, THF, rt, 3 h (iii) Acetyl chloride, NEt3, DCM, rt, 1 h. 
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The initial coupling of Fmoc-Cys(trt)-OH (173) and H2N-Ala-OMe (174) was carried 
out using benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate 
(PyBOP) and N-methylmorpholine (NMM). After separation via an aqueous work up, 
the presence of the desired material in the crude reaction mixture was confirmed via 1H 
NMR spectroscopy. LCMS analysis also identified a peak at m/z 692.1 which 
corresponds to the [M+Na]+ peak of the desired material. A pure sample of 175 was 
obtained using column chromatography on silica gel. 
Deprotection of the Fmoc protecting group in 175 was carried out using piperidine and 
acetyl chloride was used to acetylate the resultant free amine. This reaction was 
monitored by TLC and purified via column chromatography (Yield: 85%). 1H NMR 
spectroscopy of the pure reaction mixture confirmed the presence of the capped 
dipeptide (177) with the presence of a signal of 3H at 2.10 ppm which corresponds to 
the CH3 of the AcNH. 
Upon reaction of the acetyl-capped dipeptide (177) with PFP (129) there was the 
expected peaks in the 19F NMR of -94.2 ppm (m, 2F) and -164.0 ppm (m, 2F) and 
expected mass in the LCMS [M+H]+ 398.  However, the 1H NMR and analytical HPLC 
of the crude reaction mixture also showed a number of side products.  
 
Scheme 2.13: Solution phase synthesis of the activated dipeptide 169. Reagents and conditions: 
(i) PFP, DIPEA, DMF, rt, 4 h. 
The tagging reaction was carried out on a 50 mg scale with a resulting purified yield of 
12%. The purity of the collected fractions was not satisfactory, with the presence of 
starting material signals (Trt group) at 7.26- 7.44 ppm being apparent (Figure 2.4). 
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Figure 2.4: 1H NMR of dipeptide 169, synthesised using solution phase dipeptide synthesis. 
Due to the unsatisfactory purity of the PFP-tagged peptide (169) and low-yielding 
reaction conditions, it was decided to investigate alternative reaction conditions for the 
synthesis of the pentafluoropyridine-tagged dipeptides. 
2.3.2 Solid Phase Dipeptide Synthesis of Dipeptide Targets  
It was decided that synthesis of the dipeptide analogues would be attempted using solid-
phase peptide synthesis. The resin that would be used in the synthesis was RINK amide 
(RAM) resin and peptide couplings were to be carried out at rt using PyBOP, DIPEA in 
DMF. Shown in Scheme 2.14 is the proposed synthesis of the dipeptide analogue using 
SPPS.   
δH (ppm) 
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Scheme 2.14: Solid phase synthesis of dipeptide 180. Reagents and conditions i) Manual Fmoc 
SPPS- Fmoc-Ala-OH, PyBOP, DIPEA and DMF, rt, (2 × 1 h) couplings ii) Fmoc 
deporotection- 20% piperidine/DMF, rt, 2 × 30 min iii) Manual Fmoc SPPS- Fmoc-Cys(Trt)-
OH, PyBOP, DIPEA and DMF, rt, (2 × 1 h) couplings iv) Fmoc deprotection- 20% 
piperidine/DMF, rt, 2 × 30 min v) Capping of N-terminus- 20% acetic anhydride/DMF, rt, 2 × 
30 min vi) Cleavage from resin- 95% TFA: 2.5% TIPS: 2.5 %H2O.  
The first stage in the synthesis was manual Fmoc SPPS of the first dipeptide analogue 
(180), using Fmoc-Ala-OH and Fmoc-Cys(Trt)-OH and the conditions described in 
Chapter 6 (Section 6.4). Once the peptide was capped at the N-terminus it was cleaved 
from the resin. The resulting dipeptide (180) was characterised using LCMS and NMR. 
The LCMS data with peaks at [M+H]+ 234.2 and [M+Na]+ 256.0 supported the 
successful synthesis of the target dipeptide (180).  
1H NMR of the resulting crude peptide agreed with the expected spectra with a quartet 
at 4.29 ppm corresponding to the C-Hα of Ala, a triplet at 4.59 ppm corresponding to 
the C-Hα of Cys and singlet at 2.01 ppm with an integral 3H corresponding to the CH3 
of the acetyl group.  
The solid-phase synthesis of 180 resulted in fewer side products compared to the 
solution-phase when analytical HPLC traces and 1H NMR were compared. It was 
possible to carry out the synthesis on a 0.3 mmol scale which yielded 143 mg of the 
target dipeptide (180).  The dipeptide was used directly in the next stage of the synthesis 
which was the PFP tagging (Section 2.3.3).  
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With the successful preparation of the cysteine dipeptide (180), the penicilamine and 
homocysteine analogues (183 and 186) were then also synthesised using a solid-phase 
peptide synthesis approach. The penicilamine analogue (183) was synthesised on a 0.2 
mmol scale, using the same reaction conditions as the cysteine analogue (Scheme 2.15).  
 
Scheme 2.15: Solid phase synthesis of dipeptide (183). Reagents and conditions i) Manual 
Fmoc SPPS- Fmoc-Ala-OH, PyBOP, DIPEA and DMF, rt, (2 × 1 h) couplings ii) Fmoc 
deporotection- 20% piperidine/DMF, rt, 2 × 30 min iii) Manual Fmoc SPPS- Fmoc-Pen(Trt)-
OH, PyBOP, DIPEA and DMF, rt, (2 × 1 h) couplings iv) Fmoc deprotection- 20% 
piperidine/DMF, rt, 2 × 30 min v) Capping of N-terminus- 20% acetic anhydride/DMF, rt, 2 × 
30 min vi) Cleavage from resin- 95% TFA: 2.5% TIPS: 2.5% H2O. 
The LCMS analysis of the penicilamine analogue 183 showed the expected mass of 
[M+H]+ 262.8 and [M+Na]+ 284.2. The 1H NMR of the crude dipeptide 183 was shown 
to contain the relevant peaks- a doublet at 1.31 ppm of 3H corresponding to CH3 of the 
Ala, a singlet at 1.36 ppm of 3H corresponding to one of the CH3 of the Pen side chain, 
a singlet at 1.42 ppm of 3H corresponding to the other Pen side chain, a singlet at 3.77 
ppm of 1H corresponding to the C-Hα of Pen side chain and quartet at 4.26 ppm of 1H 
corresponding to C-Hα of Ala side chain.  
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The homocysteine analogue (186) was also synthesised on a 0.2 mmol scale (Scheme 
2.16).  
 
Scheme 2.16: Solid phase synthesis of dipeptide (186). Reagents and conditions i) Manual 
Fmoc SPPS- Fmoc-Ala-OH, PyBOP, DIPEA and DMF, rt, (2 × 1 h) couplings ii) Fmoc 
deporotection- 20% piperidine/DMF, rt, 2 × 30 min iii) Manual Fmoc SPPS- Fmoc-hCys(Trt)-
OH, PyBOP, DIPEA and DMF, rt, (2 × 1 h) couplings iv) Fmoc deprotection- 20% 
piperidine/DMF, rt, 2 × 30 min v) Capping of N-terminus- 20% acetic anhydride/DMF, rt, 2 × 
30 min vi) Cleavage from resin- 95% TFA: 2.5% TIPS: 2.5% H2O. 
The LCMS of the homocysteine analogue 186 showed the expected mass [M+H]+ 248.1 
[M+Na]+ 270.3. The 1H NMR of the crude dipeptide (186) was shown to contain the 
relevant peaks- singlet at 1.31 ppm and 1.34 ppm of 3H corresponding to the CH3 of 
Ala side chain, singlet at 1.97 ppm of 3H corresponding to terminal acetyl CH3, quartet 
at 2.59 ppm of 2H corresponding to CH2 of Hcys side chain and multiplet at 4.33 ppm 
of 2H corresponding C-Hα of the Ala and Hcys side chains.    
In summary, the cysteine (180), penicilamine (183) and homocysteine (186) dipeptides 
were successfully synthesised on a multi-hundred milligram scale and after cleavage 
from the resin it was determined by analysis of the 1H NMR that further purification 
was not required.  
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2.3.3 Tagging of Dipeptides with Pentafluoropyridine 
The crude cysteine dipeptide (180) was dissolved in DMF and reacted with PFP (129) 
and DIPEA, on a 0.1 mmol scale resulting in the tagged dipeptide analogue 187 
(Scheme 2.17). The incorporation of pentafluoropyridine into the dipeptide was 
supported by 1H NMR and 19F NMR as well as LCMS.  
  
Scheme 2.17: Tagging reaction of cysteine dipeptide (187) with PFP. Reagents and conditions 
i) Pentafluoropyridine, DIPEA, DMF, rt, 4 h. 
The LCMS of the crude dipeptide analogue 187 is shown below (Figure 2.5) with the 
[M+H]+ 383.4, [M+Na]+ 405.8 and [2M+H]+ 765.4 all clearly visible. 
 
Figure 2.5: MS of tagged dipeptide 187. 
1H NMR analysis of the crude dipeptide was carried out and signals relating to the 
desired material such as the quartet of 1H at 4.41 ppm corresponding to C-Hα of the Ala 
side chain, triplet of 1H at 4.22 ppm corresponding to C-Hα of the Cys side chain, 
singlet of 3H at 1.91 ppm corresponding to terminal acetyl CH3 and doublet of 3H at 
1.23 ppm corresponding to CH3 of Ala side chain are all present in the reaction mixture. 
[M+H]+ 
[2M+H]+ 
72 
 
Upon closer inspection of the 1H NMR there appeared to be doubling of the signals. 
Shown below is an expansion of the 1H NMR for 187 in the region between 3.30 ppm 
and 4.60 ppm which illustrates the presence of a possible second dipeptide product in 
the reaction mixture. Signals at 4.19 ppm, 4.21 ppm, 4.23 ppm, 1.39 ppm, 1.41 ppm, 
1.43 ppm, and 1.45 ppm illustrate the presence of a second product.  
 
Figure 2.6: Expansion of 1H NMR region 3.30 ppm- 4.60 ppm of 187. 
It was hypothesised that the additional signals in the NMR could either be due to the 
formation of diastereomers or due to the presence of conformers. It is possible that the 
tetrafluoropyridyl group could act as a leaving group, causing the formation of a Dha 
residue. Addition could then occur between Dha dipeptide and the C5F4NS
- ion 
producing diastereomers. However, this series of events was deemed to be highly 
unlikely due to the low nucleophilicity of the C5F4NS
- ion.  
In order to determine if the additional peaks from the 1H NMR spectrum were due to the 
presence of diastereomers or conformers, a varied temperature (VT) 1H NMR 
experiment was conducted from rt to 70 °C in CD3CN. If conformers were present, then 
convergence of peaks would be observed and upon heating of the sample, convergence 
was observed. This indicated the presence of confomers as opposed to diastereomers. 
Figure 2.7 shows how the peaks in Figure 2.6 start to converge upon heating the 
sample. At lower temperature, the thermal energy barrier has not been reached and the 
molecule is stuck in two confomers. As temperature increases, the molecule gains 
δH (ppm) 
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energy, bond rotation occurs, and the protons become equivalent resulting in a 
convergence of the observed peaks in the NMR spectra. 
 
 
Figure 2.7:  VT 1H NMR spectra of compound 187 at 25 °C and 70 °C, illustrating the 
convergence of signals and the presence of confomers as opposed to diastereomers. 
 
In an effort to separate the desired material from the reaction mixture, the tagged 
cysteine dipeptide was purified via column chromatography on silica gel and analysed 
via 1H NMR and 19F NMR. Shown in Figure 2.8 is the same expansion region that was 
illustrated in Figure 2.6 and clearly shows there are no additional signals that were 
present before purification.   
δH (ppm) 
δH (ppm) 
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Figure 2.8: Expansion of 1H NMR region 3.30 ppm- 4.60 ppm of purified PFP tagged dipeptide 
187. 
The 1H NMR of compound 187 shown in Figure 2.8 has a multiplet at 4.53 ppm 
corresponding to the proton labelled H(e) and doublet at 3.62 ppm corresponding to 
proton labelled H(c) in Figure 2.9. It is expected that upon displacement of the 
tetrafluoropyridine moiety these signals will shift considerably.  
 
Figure 2.9: Labelled protons of compound 187. 
 
 
δH (ppm) 
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19F isotope is highly sensitive to NMR and is often used in conjunction with 1H NMR in 
analysis of organofluoro compounds. The multiplicity of 19F NMR provides information 
on the chemical environment and 19F-19F coupling constants are often a lot larger than 
observed in 1H NMR. 19F NMR of compound 187 was carried out and the resulting 
spectrum shown below with the relevant areas expanded. Analysis of the 19F NMR 
spectra of the purified product showed signals at -94.0 ppm and -137.9 ppm (Figure 
2.10).  
       
 
Figure 2.10: 19F NMR of purified tagged dipeptide 187 (solvent CD3CN). 
Analaysis of the splitting pattern of the 19F NMR of 187 is complicated due to the 
apparent overlap of signals. Examples of PFP-tagged amino acids have previously been 
reported as multiplets when analysed by 19F NMR due to the complex splitting 
pattern.16,19 Each fluorine of 187 is represented in the 19F NMR as a doublet of doublet 
of doublets (ddd) and, due to the fact these fluorines are inequivalent (caused by the 
proximity of the fluorines to stereocentres), signal overlap occurs resuting in the 
splitting pattern and integration pattern shown in Figure 2.10.  
 
δF (ppm) 
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For the peaks highlighted in blue (Figure 2.10), the splitting pattern of both fluorines 
are ddd with J values 7.5 Hz, 11.2 Hz and 26.3 Hz (Figure 2.11) and chemical shifts -
137.9 ppm and -138.0 ppm. The proximity of these signals results in overlap and the 
non-typical integration pattern of 1:2:3:3:2:1 (Figure 2.10). The peaks highlighted in 
red (Figure 2.10) are also in an overlapping ddd formation with J values 7.5 Hz, 15.0 
Hz and 30.0 Hz and chemical shifts -94.0 ppm and -94.1 ppm (Figure 2.11). 
 
Figure 2.11: Flourine-fluorine coupling constants of PFP moiety of compound 187. 
The presence of only two signals in the 19F NMR support that PFP is conjugated to the 
dipeptide para to the nitrogen. If PFP (129) was attached to the thiol with an alternative 
regiochemistry as shown below, then the splitting pattern in the 19F NMR would not be 
the same as the one observed in Figure 2.12.  
 
Figure 2.12: Alternative conformation of PFP-tagged peptide. 
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With reaction and purification conditions optimised it was decided to synthesise the 
penicillamine (190) and homocysteine (191) PFP tagged di-peptides. The crude 
penicillamine dipeptide (183) was dissolved in DMF and reacted with 
pentafluoropyridine and DIPEA on a 0.5 mmol scale resulting in the tagged dipeptide 
analogue 190 (Scheme 2.18).  
 
Scheme 2.18: Tagging reaction of penicillamine dipeptide 193 with pentafluoropyridine. 
Reagents and conditions i) Pentafluoropyridine, DIPEA, DMF, rt, 4 h. 
 
Peptide 190 was purified via column chromatography and analysed using LCMS, 1H 
NMR and 19F NMR. The LCMS of the purified dipeptide analogue 190 is shown below 
with the [M+H]+ 411.1. 
Figure 2.13: MS of tagged dipeptide 190. 
 
 
 
[M+H]+ 
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The 1H NMR of the purified peptide 190 is shown below.  
  
 
Figure 2.14: 1H NMR of pure dipeptide 190 (solvent CD3CN). 
The 1H NMR obtained for purified 190 confirmed its structure. At 1.43 ppm and 1.49 
ppm there are singlets corresponding to the protons labelled H(c) and H(c’) which are 
not present in the spectra of compound 187 and corresponds to the protons of the CH3 
of the Pen side chain. There is also no doublet at 3.62 ppm which corresponds to the 
CH2 group of the cysteine side chain which can be seen in Figure 2.8 but not in Figure 
2.14.  
 
Figure 2.15: Labelled protons of compound 190.  
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The peaks highlighted in Figure 2.16 are displayed as overlapping ddd patterns (as in 
Figure 2.10). The 19F NMR of the purified peptide 190 has distinct signals at -132.8 
ppm and -92.7 ppm. The peaks highlighted in red (Figure 2.16) are in an overlapping 
ddd formation with J values 7.5 Hz, 15.0 Hz and 33.5 Hz and chemical shifts -92.6 ppm 
and -92.7 ppm. The peaks highlighted in blue (Figure 2.16) are also in an overlapping 
ddd formation with J values 7.5 Hz, 15.0 Hz and 33.5 Hz and chemical shifts -132.7 
ppm and -132.9 ppm. 
 
 
 
 
Figure 2.16: 19F NMR of pure dipeptide 190 (solvent CD3CN). 
 
 
 
 
 
δF (ppm) 
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The crude homocysteine dipeptide (186) was dissolved in DMF and reacted with 
pentafluoropyridine and DIPEA on a 0.6 mmol scale resulting in the tagged dipeptide 
analogue 191 (Scheme 2.19). 
 
Scheme 2.19: Tagging reaction of homocysteine dipeptide 186 with pentafluoropyridine. 
Reagents and conditions i) Pentafluoropyridine, DIPEA, DMF, rt, 4 h.  
 
Peptide 191 was purified via column chromatography and analysed using LCMS, 1H 
NMR and 19F NMR. The LCMS of the purified dipeptide analogue 191 is shown below 
with the [M+H]+ 397.0.  
 
Figure 2.17: MS of PFP-tagged dipeptide 191. 
 
 
 
[M+H]+ 
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The 1H NMR of the purified peptide 191 is shown below. 
 
Figure 2.18: 1H NMR of purified tagged dipeptide 191 (solvent CD3CN). 
The 1H NMR of homocysteine analogue 191 also confirmed that the expected product 
had been prepared. At 2.11 ppm there is a multiplet corresponding to the proton labelled 
H(d) and the multiplet at 3.25 ppm which corresponds to H(c). The upfield shift and 
change in multiplicity of the proton H(e)corresponds to the insertion of a CH2 group.  
 
Figure 2.19: Labelled protons of compound 191. 
 
 
 
δH (ppm) 
 
82 
 
The peaks highlighted in Figure 2.20 are displayed as overlapping ddd patterns (as in 
Figure 2.10). The 19F NMR of the purified peptide 191 has distinct signals at -139.1 
ppm and -94.2 ppm. The peaks highlighted in red (Figure 2.20) are in an overlapping 
ddd formation with J values 7.5 Hz, 15.0 Hz and 30.0 Hz and chemical shifts -94.1 ppm 
and -94.3 ppm. The peaks highlighted in blue (Figure 2.20) are also in an overlapping 
ddd formation with J values 7.5 Hz, 11.2 Hz and 30.0 Hz and chemical shifts -139.1 
ppm and -139.2 ppm. 
 
 
 
Figure 2.20: 19F NMR of purified dipeptide 191 (solvent CD3CN).   
δF (ppm) 
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2.4 Displacement and Conjugation Reactions 
The conjugation of peptides to small molecules has been well investigated (Chapter 1) 
and the benefits of such analogues can include increased solubility, increased stability 
and increased cell permeability. 
By adopting the experimental procedures described within this chapter, it may be 
possible to selectively conjugate a variety of molecules such as thio-PEG and thiosugars 
to improve stability and lipophilicity of biologically active peptides. This approach is 
beneficial as the tagging reaction with PFP (129) followed by displacement using a thiol 
(Scheme 2.20i) is believed to occur via SN2 and therefore produce only one 
stereoisomer. It would also allow the direct conjugation of the nucleophile to the 
peptide.  
Before this reaction was carried out using thio-PEG and thiosugars on biologically 
active peptides, the displacement reaction was carried out on the small 
pentafluoropyridine-tagged dipeptide (187, 190 and 191) using a sodium thiophenolate. 
These model systems were characterised using 1H NMR, 19F NMR and MS to 
determine if the reaction had been successful.   
2.4.1 Determination of Displacement Reaction Mechanism 
There are four possible outcomes under the reaction conditions shown Scheme 2.20 
summarises all possible outcomes. The first outcome is the nucleophilic substitution 
reaction, which would occur via an SN2 mechanism (Scheme 2.20i). This is the 
preferred mechanism for reaction because it would retain the stereochemistry at 
cysteine.  
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Scheme 2.20: Scheme to show the possible reaction pathways which could occus upon reaction 
of compound 187 with thiophenolate (193) i) SN2 reaction, ii) SN1 reaction, iii) E1/E2/ECB 
reaction, iv) SNAr reaction. 
 
The second possible outcome is an elimination-addition mechanism which occurs via 
the Dha intermediate (Scheme 2.20iii). Conjugate addition then occurs at the alkene in 
the Dha residue. The elimination-addition mechanism would remove the 
stereochemistry at cysteine and diastereomers would be formed. Chalker et al. have 
already demonstrated that conversion of the thiol in cysteine to Dha is one way of 
selectively conjugating functional groups to cysteine.18 Finally, it is possible that further 
SNAr reactions at the tetrafluoropyridyl group could occur ortho to the nitrogen. 
(Scheme 2.20iv). This could occur instead of the intended displacement reaction since 
the carbon-fluorine bonds ortho to the ring nitrogen are easily accessible and highly 
polarised. It is only by experiment that the preferred mechanism could be determined.  
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The tagged dipeptide analogue 187 was reacted with sodium thiophenolate (193) and 
DIPEA in MeCN/H2O (Scheme 2.21).  
 
Scheme 2.21: Displacement reaction of PFP-tagged dipeptide 187 with thiophenolate. Reagents 
and conditions i) Thiophenolate, DIPEA, MeCN/H2O, rt, 4 h. 
The crude reaction mixture was analysed using LCMS and the desired product [M+H]+ 
310.0 and [2M+H]+ 618.6 was observed (Figure 2.21).  
 
Figure 2.21 LCMS of crude dipeptide 194. 
In an attempt to limit the number of side products formed in the reaction, different 
reaction conditions were tested (Table 2.3). In all entries the starting peptide is peptide 
187 and the solvent is MeCN and H2O.  
 
 
 
 
[M+H]+ 
[2M+H]+ 
 
86 
 
Entry 
Nucleo-
phile 
Base Temp. Product(s) 
1 PhSNa DIPEA rt 
 
 
2 PhSNa − rt 
 
3 PhSNa K2CO3 rt 
 
5 PhOH – rt No reaction 
Table 2.3: Reaction conditions of displacement reaction. 
The only entry in Table 2.3 in which the desired material was formed, is Entry 1. The 
reaction was purified prep TLC and compound 194 analysed. Shown below is an 
expansion of the 1H NMR in the region of 3.00 ppm- 4.50 ppm. 
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Figure 2.22: Expansion of region 3.00- 4.50 ppm in the 1H NMR of compound 194. 
When this spectrum is compared to the spectrum of the starting material there are 
distinct differences. In the spectrum of compound 187 there is a multiplet between 4.51-
4.56 ppm corresponding to proton H(e) whereas in the spectra of compound 194 there 
are 2 of these signals at 4.30- 4.42 ppm which correlates to proton H(e) of compound 
194. Another difference between the spectra of compounds 187 and 194 is the signals at 
3.61- 3.65 ppm (compound 187) and 3.34-3.40 ppm (compound 194). In compound 187 
this signal is a doublet of doublets whereas in the spectra of compound 194 there are 2 
sets of doublet of doublets in this region which corresponds to proton H(c).  
 
Figure 2.23: Labelled protons of compound 194. 
 
δH (ppm) 
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It is possible to hypothesise, due to the doubling of signals in Figure 2.22 compared to 
the starting material of Figure 2.8, that there is a diastereomeric mixture of compound 
194. This suggests that of the 4 reaction pathways shown in Scheme 2.20, the reaction 
of fluoropyridine-tagged dipeptide and thiophenolate proceeds via an ECB (Scheme 
2.20iii) reaction pathway. ECB reactions proceed when the α-carbon is acidic and 
leaving group is poor. ECB mechanisms proceed via the extraction of an acidic α-carbon 
with base to form a carbanion followed by elimination of the leaving group and 
formation of Dha (Scheme 2.22). In the case of compound 187, the Dha intermediate 
198 undergoes nucleophilic addition of the thiophenolate, resulting in diasteromers of 
substituted analogue 194. 
 
Scheme 2.22: ECB mechanism of reaction of compound 187 to form the Dha intermediate 198 
followed by addition of the thiophenolate nucleophile.  
To confirm that the signals in the 1H NMR are due to diastereoisomers, analytical 
HPLC was carried out and the spectra of compound 194 (Figure 2.24ii) was compared 
to starting material 187 (Figure 2.24i).  
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Figure 2.24: i) Analytical HPLC trace of starting material compound 187 ii) Analytical HPLC 
trace of compound 194. 
The peak at 9.5 min (Figure 2.24ii) is believed to correspond to an unknown side 
product with m/z 289.3. The peak 12.5 min in Figure 2.24i corresponds to compound 
187 and one major peak is observed, suggesting that there is only one stereoisomer in 
the compound mixture. The peaks at 11.0 mins and 11.5 mins in Figure 2.24ii 
correspond to the displaced compound 194. The presence of two signals that are 
separable by HPLC suggests that there are diastereoisomers within the sample.  
The presence of multiple signals in the analytical HPLC and the doubling of the signals 
in the 1H NMR suggests that the reaction between dipeptide 187 and thiophenolate 
proceeds via an ECB reaction. 
Upon inspection of the crude LCMS of Scheme 2.21, another product was also present 
in the reaction mixture with a mass of [M+H]+ 563.2. It was assumed that this 
corresponds to compound 196, which could arise due to nucleophilic attack on the 
fluoropyridine ring as shown in Scheme 2.23. 
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Scheme 2.23: Displacement reaction of tagged dipeptide 187 with thiophenolate. Reagents and 
conditions. Thiophenolate, DIPEA, MeCN/H2O, rt, 4 h. 
It was noted that there are a number of possible structures that could correspond to the 
LCMS signal of mass [M+H]+ 563.2 and these  are shown below (where R represents 
the dipeptide).  
 
Figure 2.25: Possible product structures from SNAr reaction with compound 187. 
Since LCMS analysis could not give any elucidation of the structure of products, NMR 
spectroscopy was consulted. The crude material obtained from the reaction of 
compound 196 in Scheme 2.23 was purified via a preparitive TLC plate. 1H NMR and 
19F NMR analysis were carried out on purified 196 to deduce the substitution pattern of 
the thiophenolate on the fluoropyridine ring (Figure 2.25). Shown in Figure 2.26 is an 
expansion of the 1H NMR spectrum between 3.00 and 4.50 ppm.  
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Figure 2.26: 1H NMR of compound 196 region 3.00- 4.50ppm. 
The 1H NMR spectrum proved that the sample was not completely pure. The sample 
was submitted for high resolution 1H NMR, but due to the dilute nature of the sample no 
improvement in resolution could be obtained. What can be observed from Figure 2.26 
are the signals at 3.34- 3.38 ppm and 3.61- 3.64 ppm which correlate to the protons 
labelled H(c) adjacent to the sulphur, 4.18- 4.21 ppm which correspond to the proton 
labelled H(d) and 4.44- 4.47 ppm which corresponds to the proton labelled H(e). The 
multiplet signal between 6.50- 7.90 ppm corresponds to the aromatic protons conjugated 
to the fluoropyridine ring, with an integration of 10H.  
Analysis of the 1H NMR spectrum could not conclusively determine the structure of 
compound 196. 19F NMR of compound 196 was carried out and the resulting spectrum 
obtained is shown in Figure 2.27. There are two distinct signals that relate to the 
structure of compound 196 with a doublet at -66.45 ppm and -119.42 ppm.  
δH (ppm) 
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Figure 2.27: 19F NMR of compound 196 with expansion of regions -65-67 ppm and -114-122 
ppm. 
Of the 4 configurations shown in Figure 2.25, there are 2 that could relate to the 
spectrum shown above. If compound 196 had the configuration shown in 200 or 201 
then there would only be one signal in the 19F NMR spectrum, therefore the structure of 
196 must either be 202 or 203. Density functional theory (DFT) calculations were 
carried out and the estimated chemical shifts shown in Figure 2.28. 
 
Figure 2.28: DFT calculations of the 19F NMR shifts of compound 204 and 205.  
According to the chemical shifts shown in Figure 2.28, the predicted structure of the di-
substituted dipeptide is 206. The 19F NMR (Figure 2.27) has a chemical shift of -66.5 
ppm which matches the predicted chemical shift -66.6 pm of the ortho-F.  The 19F NMR 
in Figure 2.27 also has a signal at -119.4 ppm which closely matches the meta-F signal 
at -124.7 ppm of the predicted structure. Therefore, the structure of the di-substituted 
dipeptide is as shown below (Figure 2.29). 
δF (ppm) 
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Figure 2.29: Structure of compound 206 according to 1H NMR, 19F NMR and molecular 
modelling calculations. 
Compound 206 is the result of displacement of two fluorine atoms from fluoropyridine 
by thiophenolate as opposed to complete displacement of the fluoropyridine moiety. 
This side reaction product is an interesting development as it could provide possible 
scope for pentafluoropyridine acting as a scaffold which could allow for the conjugation 
of multiple nucleophiles to a peptide backbone.  
With analysis of the cysteine analogue carried out, focus was shifted towards 
investigation of the displacement reaction between thiophenolate and the penicilamine 
(190) and homocysteine (191) PFP-tagged dipeptides.  
Compound 190 was reacted with thiophenolate using the reaction conditions described 
in Chapter 6, Section 6.6 (Scheme 2.24). LCMS analysis of the crude material 
confirmed the presence of the desired material [M+H]+ 591.2.  
 
Scheme 2.24:  Reaction of compound 190 with thiophenolate resulting in the di-substituted 
analogue 207. Reagents and conditions thiophenolate, DIPEA, MeCN/H2O, rt, 4 h. 
The peptide was purified via preparative TLC plate and analysed using LCMS, 1H 
NMR, 19F NMR. Figure 2.30 illustrates the 1H NMR of compound 207 with no signals 
for CH2 protons in the region that would be expected as well as the signals that 
correspond to H(d) and H(e) in the regions that are expected. 
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Figure 2.30: 1H NMR spectrum of compound 207- expansion of region 3.10- 4.80 ppm. 
Also present in the 1H NMR spectrum of compound 207 are 2 CH3 signals 
corresponding to the methyl groups of the penicilamine residue and aromatic signals 
which integrate to 10H. 
19F NMR was also carried out on compound 207 and the resulting spectra shown below 
(Figure 2.31).   
 
Figure 2.31: 19F NMR spectrum of compound 207. 
δH (ppm) 
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The 19F NMR spectrum shows 2 distinct peaks with integration of 1F at -66.9 ppm and -
121.2 ppm. These signals match the calculated chemical shifts from the molecular 
modelling calculations carried out previously.  
The homocysteine analogue (191) was also reacted with thiophenolate, purified via prep 
TLC and the resulting fractions analysed using LCMS, 1H NMR and 19F NMR. The 
LCMS contained the expected mass of [M+H]+ 577.2, relating to the di-substituted 
product (208). 
 
Scheme 2.25:  Reaction of compound 191 with thiophenolate resulting in the di-substituted 
analogue 208. Reagents and conditions i) Thiophenolate, DIPEA, MeCN/H2O, rt, 4 h. 
Figure 2.32 illustrates the region of the 1H NMR between 3.00 and 4.40 ppm of 
compound 208. In the spectra, the protons that relate to H(e) and H(d) have merged into 
one multiplet. An additional signal was observed at 3.19 ppm that relates to H(f) of the 
CH2 adjacent to the S of the homocysteine analogue. The proton signal for the other 
CH2 of the homocysteine is hidden under the MeCN solvent peak and is therefore not 
evident below.  
 
96 
 
 
Figure 2.32: 1H NMR spectrum region 2.90- 4.40 ppm of compound 208. 
There are also signals in the aromatic region which integrate to 10H which have similar 
splitting patterns to both the cysteine and penicilamine analogues, further suggesting 
that the substitution pattern on the fluoropyridine ring is as shown in compound 206, 
207 and 208. 
19F NMR was also carried out on compound 208 and the resulting spectra shown below 
(Figure 2.33).  
 
Figure 2.33: 19F NMR of compound 208. 
δH (ppm) 
δF (ppm) 
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The 19F NMR shows 2 distinct peaks with integration of 1F at -66.9 and -121.2 ppm.   
The chemical shifts shown in Figure 2.33 match the predicted chemical shifts of the 
molecular modelling calculation and therefore compound 208 has the structure shown in 
Scheme 2.23.  
2.5 Conclusions  
Efforts into the synthesis and mechanism investigation of sulphur-containing dipeptides 
and pentafluoropyridine have been carried out. A series of dipeptides were successfully 
synthesised and reacted with pentafluopyridine resulting in modified peptides (187, 190 
and 191) which were fully analysed and characterised. Upon further reaction of peptides 
(187, 190 and 191), a number of products were observed. It was expected upon reaction 
of the fluopyridine-tagged peptide (187) and thiophenolate nucleophile that the peptide 
(194) would be observed. This product was indeed observed and 1H NMR was carried 
out to determine the reaction mechanism. It was determined that due to the doubling of 
signals in the 1H NMR and the analytical HPLC that the reaction had progressed via an 
ECB
 reaction pathway and resulted in the formation of diastereomers.  
 
Scheme 2.26: Reaction of peptide 187 with thiophenolate (193) via an ECB pathway. 
An unexpected peptide (206) was observed upon reaction of peptide (187) with the 
thiophenolate nucleophile. The data obtained suggests an aromatic substitution reaction 
on the fluoropyridine ring had occurred which was confirmed via interpretation of the 
19F and 1H NMR spectrum. It was also confirmed via 19F NMR spectroscopy that 
further substitution occurred at the ortho and meta positions which was unexpected 
(Scheme 2.27).  
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Scheme 2.27: Reaction of peptide 187 with thiophenolate and the expected 196 and observed 
di-substituted products 206. 
The aromatic substitution of Pen (190) and hCys (191) dipeptides with thiophenolate 
were also investigated and it was determined, from the 19F NMR and LCMS data, that 
the primary product in those reactions were the o-m-disubstituted products (Figure 
2.34).  
 
Figure 2.34: Ortho-meta-disubstituted i) Cys dipeptide (206), Pen dipeptide (207) and hCys 
dipeptide (208). 
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Chapter 3: Synthesis, Tagging and Stability Studies of PFP-modified Oxytocin and 
Vasopressin  
3.1 Oxytocin (OT) and Vasopressin (VP)  
Oxytocin (OT) (209) and Vasopressin (VP) (210) are both cyclic peptides consisting of 
9 amino acid residues and a disulphide bridge between cysteine residues. OT (209) has 
the sequence CYIQNCPLG and VP (210) has the sequence CYFQNCPRG and both 
have C-terminal amides (Figure 3.1).  
  
Figure 3.1: Structure of OT (209) and VP (210). 
OT (209) was discovered in 1906 by Henry Dale1 and the crystal structure was 
determined in 1952. OT (209) is a neuropeptide which is released from the posterior 
pituitary into the bloodstream and has been investigated in a number of different roles. 
OT is released during childbirth and into the bloodstream after childbirth and plays a 
role in social bonding between mother and child.3 OT is used during childbirth to 
promote uterine contractions which increases the speed of labour and also reduces 
bleeding after childbirth.4 
OT has also been shown to have an effect on depressive behaviour.5 Many animal 
studies4,5 have found that lower levels of OT in animal examples can lead to depressive 
behaviour, although the studies of this behaviour in humans has been largely disputed 
and there are multiple studies to suggest both arguments.6,7 It is believed that any 
perceived depressive behaviour in humans as a result of lower OT levels may be related 
to the impaired social bonding and negative early life experiences.5  
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VP (210) was first synthesised by Vincent du Vigneaud, who was awarded the Nobel 
Prize in Chemistry in 1955 for his work in synthesising the first polypeptide hormone.1 
VP (210) and OT have different target sites and it is believed the difference in polarity 
between OT and VP is responsible for the difference in response biological response.2 
VP (210) is an antidiuretic hormone (ADH) and is used as a treatment against 
abdominal bleeding and diabetes as well as having a number of off-target effects which 
can be beneficial therapeutically. VP targets a number of GPCRs accounting for the 
range of effects it has on the body, which include mediation of blood vessels and water 
absorbance.11 
3.1.1 Oxytocin Modification Studies 
OT (209) has a relatively short half-life (t1/2= 2-5 min)
8 in vivo and is readily degraded 
via proteolysis. Collins9 and co-workers synthesised a peptide-polymer analogue with a 
maleimide linker via the disulphide bond (Scheme 3.1) in an effort to improve the 
stability.  
 
Scheme 3.1: Synthesis of OT peptide-polymer (213) via a maleimide linker. i) Reduction of 
disulphide bond using TCEP ii) Conjugation using excess dithiophenol maleimide (212). 
The stabilities of the polymer-peptide analogues in water were compared with the 
stability of native OT in water at pH 7.6. After 28 days, only 2.5% of the native OT was 
present whereas for the polymer-peptide analogues OT-(mPEGA)20 and OT-
(mPEGA)100 the amount of peptide left after 28 days was 94% and 87% respectively 
(Figure 3.2).  
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Figure 3.2: Stability test of native OT, OT-(mPEGA)20, OT-(mPEGA)100.9  
Carbetocin (214) is an OT analogue that was designed to have enhanced stability. It is 
structurally very similar to OT, but the disulfide bridge has been replaced with a 
thioether linkage (Figure 3.3 shown in red) and the Tyr residue contains a methyl ether 
rather than a free phenol (Figure 3.3 in blue).  
 
Figure 3.3: Chemical structure of Carbetocin (214).  
The in vivo stability of Carbetocin (214) was shown to be higher than OT with it having 
a half-life in vivo of 85-100 min compared to approximately 3 min for OT.8   
Further work to probe the stability of OT (209) was carried out by Barth and co-
workers10 who investigated the degradation of Carbetocin (214) using chymotrypsin and 
found that after 30 min it had been degraded to deglycineamide Carbetocin (216) 
(Scheme 3.2ii). Chymotrypsin primarily degrades amide bonds where the N-terminal 
amino acid is an aromatic residue, suggesting that the enzymatic degradation of an OT 
analogue would occur at the Tyr residue (Scheme 3.2i). Barth and co-workers were able 
to illustrate that incorporation of the methyl group onto the Tyr residue improved 
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stability as there was no degradation of the peptide at the Tyr-Leu amide bond and the 
only degradation product observed was the Gly deletion (Scheme 3.2ii).10 
 
Scheme 3.2: Enzymatic degradation using chymotrypsin of i) OT (209) to give Tyr-Leu 
cleavage product (215) and ii) Carbetocin (214) to give the Gly deletion product (216). 
3.1.2 Vasopressin Modification Studies 
Lammek and co-workers investigated the effects of amino acid substitution on the 
potency and selectivity of VP.11 One of the most interesting analogues of this study was 
217 which not only contains a 1-aminocyclohexane-1-carboxylic acid (Acc) substitution 
at position 2 but also deamination at position 1, Val substitution at position 4 and 
inversion of stereochemistry at position 8 (Figure 3.4). This pattern of substitution was 
found to be the optimal analogue (217) which was a potent V2 agonist.
12 Further studies 
into the substitution at position 2 of VP concentrated on the incorporation of 2-
aminoindane-2-carboxylic acid (Aic) at position 2 (218) (Figure 3.4).11 Incorporating 
these building blocks into VP resulted in analogues that had potent biological activity, 
believed to be due to the conformational restriction imposed by the new building 
blocks.  
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Figure 3.4:  Structures of 1-aminocyclohexane-1-carboxylic acid (Acc) (217)12 2- aminoindane-
2-carboxylic acid (Aic) (218).11 
Desmopressin (219) is a VP analogue which has been approved for the treatment of 
diabetes inspidus, haemophilia and other bleeding disorders. Desmopressin (219) is 
structurally similar to native VP apart from the incorporation of D-Arg at position 8 and 
deamination of the first Cys residue (Figure 3.5).13 
 
Figure 3.5:  Chemical structure of Desmopressin (219) a VP analogue.  
Deamination at position 1 and the inversion of stereochemistry of Arg-8 increases 
antidiuretic activity. Desmopressin (219) is shown to have antidiuretic activity close to 
2000 units per milligram compared to 400 units per milligram for VP (210) which 
suggests Desmopresssin is both more biologically active and has higher specificity than 
the native VP.14  
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3.1.3 Chapter Aims 
The aim of this chapter was to synthesise a series of OT and VP analogues tagged with 
pentafluoropyridine (PFP), in an effort to improve their stability towards enzymatic 
degradation. The peptides will be synthesised using Fmoc SPPS and tagging of the 
peptides with PFP carried out using both on-resin and solution phase techniques. By 
utilising the orthogonal protecting group strategies, the nucleophilic side chains (e.g. 
Tyr, NH2 of N-terminus) can be selectively reacted with PFP.  
Once the VP and OT analogues have been synthesised, the stability of these peptides to 
enzymatic degradation will be tested using chymotrypsin and HPLC analysis. Peptides 
209 and 210 in Figure 3.6 represent the structures of native OT and native VP, peptides 
220 and 222 represent the singular tagged OT and VP analogues and peptides 221 and 
223 represent the double-tagged OT and VP analogues which will be synthesised and 
form part of this enzymatic stability study.   
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Figure 3.6: Chemical structure of native peptides OT (209) and VP (210), singular PFP-tagged 
peptides (220 and 222) and doubly PFP-tagged peptides (221 and 223).  
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3.2 Synthesis of OT and VP and PFP-tagged Analogues using Fmoc SPPS 
Native OT (209) was synthesised via manual SPPS using RINK Amide resin.  Amino 
acids were protected using standard acid-labile protecting groups with the exception of 
Cys which was protected using the acetamidomethyl (Acm) group (Scheme 3.3). This 
protecting group was used in place of the normal trityl (Trt) group for the Cys thiol as it 
would allow for the selective PFP tagging of the peptide. 
 
Scheme 3.3: Manual SPPS of OT (209) using RINK amide resin. Reagents and conditions: i) 
Manual Fmoc SPPS- Fmoc-Gly-OH, Fmoc-Leu-OH, Fmoc-Pro-OH, Fmoc-Cys(Acm)-OH, 
Fmoc-Asn(Trt)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Ile-OH, Fmoc-Tyr(tBu)-OH,  PyBOP, DIPEA 
and DMF, rt, (2 × 1 h) couplings. Fmoc deporotection- 20% piperidine/DMF, rt, 2 × 30 min ii) 
Cleavage from resin- 95% TFA: 2.5% TIPS: 2.5% H2O, rt, 4 h iii) Acm cleavage- I2, AcOH 
(40%)/DMF, rt, 1.5 h. 
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Upon completion of the synthesis and deprotection of the N-terminal Fmoc group, a test 
cleavage of the crude linear peptide (224) from the resin was carried out and analysed 
via LCMS (Figure 3.7). The linear peptide 224 was present in the test cleave as 
indicated by 1152.5 [M+H]+ and 576.4 [M+2H]2+. 
Figure 3.7: MS of linear peptide cleaved peptide 224 with desired mass 1152.5 [M+H]+ and 
576.5 [M+2H]2+. 
To access native OT (209), the Acm protected linear peptide (224) underwent an Acm 
deprotection and disulphide bond formation using I2 (3 eq), 40% AcOH/DMF solution 
at rt.  After 1.5 h the reaction was quenched using a 1 M solution of ascorbic acid and 
diluted using H2O/MeCN until the final volume of AcOH was less than 10%. The crude 
peptide was analysed via LCMS (Figure 3.8).  
 
 
[M+H]+ 
[M+2H]2+ 
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Figure 3.8: MS of native OT (209) with desired mass [M+H]+ 1007.2, [M+Acm+H]+ 1078.3 
(225) [M+2Acm+H]+ 1149.0 (226). 
As shown in the MS above, the desired material (209) was present along with two side 
products with 1078.3 [M+Acm+H]+ (225) and 1149.0 [M+2Acm+H] (226) which relate 
to incomplete Acm deprotection of the Cys residues. The Acm deprotection was carried 
out using alternative reaction conditions to drive the reaction to completion. The Acm 
protected linear peptide (224) was dissolved in 1 ml of AcOH (40%)/DMF and the I2 
was added. In this reaction 25 eq of I2 were used instead of the 3 eq previously used 
while the percentage of AcOH remained the same. The reaction mixture was transferred 
to an Eppendorff tube and left at rt, under agitation for 1.5 h. The reaction mixture was 
quenched using 1 M ascorbic acid and diluted using H2O/MeCN until the final volume 
of AcOH was less than 10%. 
 
 
 
Cyclic Peptide 
[M+H]+ 
[M+Acm +H]+ 
Linear Peptide 
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The OT peptide (209) was purified using reverse phase HPLC (RP-HPLC) and analysed 
using LCMS. As shown in Figure 3.9, the full deprotection of the Acm group and 
cyclisation has been achieved as illustrated by the LCMS peak of 1008.2 [M+H]+. 
Figure 3.9: MS analysis of the Acm deprotection/cyclisation reaction 209 using 25 eq of I2, 
40% AcOH/DMF for 1.5 h [M+H]+1007.4. 
  
[M+H]+ 
[M+2H]2+ 
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Native VP (210) was synthesised via manual Fmoc SPPS using RINK Amide resin. The 
side chains of the Fmoc amino acids were protected using standard acid-labile 
protecting groups with the exception of Cys, which was protected using Acm (Scheme 
3.4).  
 
Scheme 3.4: Manual SPPS of VP (210) using RINK amide resin. Reagents and conditions: i) 
Manual Fmoc SPPS- Fmoc-Gly-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Pro-OH, Fmoc-Cys(Acm)-OH, 
Fmoc-Asn(Trt)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Phe-OH, Fmoc-Tyr(tBu)-OH, PyBOP, DIPEA 
and DMF, rt, (2 × 1 h) couplings. Fmoc deporotection- 20% piperidine/DMF, rt, 2 × 30 min ii) 
Cleavage from resin- 95% TFA: 2.5% TIPS: 2.5% H2O, rt, 6 h iii) Acm cleavage- I2, AcOH 
(40%)/DMF, rt, 1.5 h. 
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Upon completion of the synthesis and deprotection of the N-terminal Fmoc group, a test 
cleavage of the peptide from the resin was carried out and analysed via LCMS. To 
synthesise the cyclic VP analogue (210), the Acm protected peptide underwent a one-
pot Acm deprotection and then disulphide bond formation using I2, AcOH/DMF 
solution at rt.  After 1.5 h the reaction was quenched using a 1 M solution of ascorbic 
acid and diluted using H2O/MeCN until the final volume of AcOH was less than 10%. 
The peptide was purified using HPLC and analysed using LCMS (Figure 3.10).  
Figure 3.10: LCMS of native VP (210) with desired mass 1084.4 [M+H]+.  
LCMS of the HPLC fraction confirmed the presence of the desired linear peptide 
1008.2 [M+H]+ and charged species 504.9 [M+2H]2+. The native OT (209) and VP 
(210) used as controls in later enzymatic degradation studies (Section 3.3.2).  
[M+H]+ 
[M+2H]2+ 
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3.2.1 Tagging of Oxytocin with Pentafluoropyridine 
The linear peptide C(Acm)YIQNC(Acm)PLG (224) was synthesised on RINK Amide 
resin using Fmoc SPPS on a 0.2 mmol scale according to Section 6.4.1. 
 
Scheme 3.5: Synthesis of linear peptide 224 via Fmoc manual SPPS on a 0.2 mmol scale using 
RINK amide resin. Reagents and conditions: i) Manual Fmoc SPPS- Fmoc-Gly-OH, Fmoc-Leu-
OH, Fmoc-Pro-OH, Fmoc-Cys(Acm)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Ile-
OH, Fmoc-Tyr(tBu)-OH, PyBOP, DIPEA and DMF, rt, (2 × 1 h) couplings. Fmoc 
deporotection- 20% piperidine/DMF, rt, 2 × 30 min. 
For the synthesis of the singular PFP-tagged OT (220), the linear peptide (224) was 
tagged on-resin using PFP, DIPEA in DMF for 4 h on a 0.1 mmol scale followed by 
resin cleavage (Scheme 3.6i and ii). By carrying out the tagging reaction on resin, the 
only nucleophilic site available to react with PFP was the free terminal amine as the Tyr 
still contains a t-Butyl protecting group on the aromatic OH group (Scheme 3.6i).  
 
Scheme 3.6: Synthesis of singular-tagged OT (220). Reagents and conditions: i) On-resin PFP 
tagging- PFP, DIPEA, DMF, rt, 4 h ii) Cleavage from resin- 95% TFA: 2.5% TIPS: 2.5% H2O, 
rt, 4 h iii) Acm cleavage- I2, AcOH (40%)/DMF, rt, 1.5 h.  
 
115 
 
The presence of the PFP-tagged peptide (229) (with Acm groups attached) was 
confirmed using LCMS and the crude material was purified via RP-HPLC before it was 
used in the last stage of the synthesis.  The Acm deprotection/disulphide bond formation 
was carried out using the reaction conditions described previously (e.g. synthesis of OT 
and VP).  The crude reaction mixture was purified via RP-HPLC and the MS analysis of 
the purified PFP-tagged-peptide (220) is given below (Figure 3.11). 
 
Figure 3.11: MS of purified PFP-tagged OT (220) with desired mass [M+H]+ 1156.4 and 
[M+2H]2+ 578.8. 
The LCMS for purified tagged-peptide 220 confirmed the presence of the desired cyclic 
peptide 1156.4 [M+H]+ and charged species 578.8 [M+2H]2+. To confirm that the 
tagging of OT had occurred at the N-terminus MS-MS analysis was carried out. The 
MS-MS spectrum obtained for 220 is shown in Figure 3.12. 
 
 
 
 
 
[M+H]+ 
[M+2H]2+ 
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MS-MS (also referred to as tandem mass spectrometry) is a method of mass 
spectrometry used in the analysis of peptides and involves multiple stages of mass 
spectrometry with fragmentation of the peptide occurring between these stages (Scheme 
3.7).  
 
Scheme 3.7: Process of tandem mass spectrometry.15 
There is an intial ionisation step via electrospray ionisation and the resulting ions are 
separated before undergoing a second step of mass spectrometry via collision induced 
dissociation. This results in product ions which are detected via time-of-flight 
spectrometry and analysed. Analysis of the resulting spectra allows for the 
determination of peptide structure due to the fact amino acid fragments will correspond 
to a specific pattern in the spectra.15   
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Figure 3.12: MS-MS spectrum of the singularly PFP tagged OT (220).
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Entry Calculated Mass Observed Mass Deletion 
1 1156.2 1156.4 [M+H]- No deletion 
2 771.7 772.2 * Gly, Leu, Pro, Cys 
3 657.7 658.2 * Gly, Leu, Pro, Cys, Asn 
Table 3.1:  MS-MS data of singular PFP-tagged OT (220) detailing amino acid deletion. 
The MS-MS data obtained (Figure 3.12) confirmed the presence of a singularly tagged 
OT analogue (220). Both fragments observed corresponds to a peptide which is single 
tagged, suggesting that PFP is attached to the N-terminus of the peptide only (Figure 
3.12). 
It is predicted that the fluorine para to the nitrogen will primarily react with the free 
amine of the N-terminus (as discussed in Chapter 2). 19F NMR of the PFP-tagged 
peptide (220) was carried out to analyse the splitting pattern of the fluorines of the PFP-
tagged peptide (Figure 3.13). 
 
Figure 3.13: 19F NMR spectrum of singular PFP-tagged OT (220). 
 
 
δF (ppm) 
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It can be observed that there are two distinct fluorine environments at -96.2 ppm and -
162.0 ppm. The fluorine signal at -96.2 ppm corresponds to the fluorine atoms which 
are ortho to the nitrogen and the -162.0 ppm signal corresponds to the fluorine atoms 
which are meta to the nitrogen as shown in Figure 3.13. According to previous studies 
carried out within the group, PFP attached to different amino acids exhibits distinct 
chemical shifts when analysed via 19F NMR (Table 3.2).16   
 
 
19F NMR chemical shifts (ppm) 
X= Cys -93.42 and -137.49 
X= Lys -98.17 and -165.54 
X= Tyr -91.32 and -155.98 
X= Ser -97.10 and -165.92 
Table 3.2: 19F NMR signals of pentafluoropyrdine attached to various nucleophilic amino acids. 
Comparing the data in Table 3.2 to the 19F NMR data in Figure 3.13, it is possible to 
hypothesise that the PFP is attached the amine of the N-terminus. Although these 
chemical shifts are not reported in the above table, the data collected in the 19F NMR in 
Figure 3.13 (-96.2 and –162.0 ppm) closely resemble the data for PFP attached to a Lys 
(-98.2 and -165.5 ppm) rather than the values for Tyr or Cys.  Tagging at the N-terminus 
is also supported by the MS-MS data as previously discussed.  
For the synthesis of the doubly PFP-tagged OT (221), the linear peptide was prepared 
using Fmoc-SPPS and then it was cleaved from resin before PFP-tagging was carried 
out (Scheme 3.8ii and iii). By cleaving the peptide from resin, the nucleophilic phenol 
of Tyr is exposed and available for reaction with PFP as well as the free amine on the 
N-terminus (Scheme 3.8).   
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Scheme 3.8: Synthesis of double-tagged OT (221). Reagents and conditions: i) Cleavage from 
resin- 95% TFA: 2.5% TIPS: 2.5% H2O, rt, 4 h ii) Solution phase tagging- pentafluoropyridine, 
DIPEA, DMF, rt, 4 h iii) Acm cleavage- I2, AcOH (40%)/DMF, rt, 1.5 h. 
The presence of the double PFP-tagged peptide (231) (with Acm groups attached) was 
confirmed using LCMS and 231 was purified by HPLC from the crude reaction mixture 
before being used in the final stage of the synthesis. The Acm deprotection/disulphide 
bond formation was carried out using the reaction conditions described in Section 6.4.4. 
The crude reaction mixture was purified via RP-HPLC and the MS analysis of the 
purified PFP-tagged-peptide (221) is given below (Figure 3.14). 
 
Figure 3.14: MS of purified doubly PFP-tagged OT (221) with desired mass [M+H]+ 1305.4 
and [M+2H]2+ 653.3. 
[M+H]+ 
[M+2H]2+ 
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Shown in Figure 3.14 is the MS for the purified, double PFP-tagged OT (221) 
illustrating the presence of the desired cyclic peptide 1305.4 [M+H]+ and charged 
species 65.33 [M+2H]2+. To confirm the tagging of OT at the site hypothesised in 
Scheme 3.8, MS-MS experiments were carried out to confirm the position of PFP tag 
within the peptide (Figure 3.15).   
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Figure 3.15:  MS-MS analysis of the double PFP-tagged OT (221).
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Entry Calculated Mass Observed Mass Deletion 
1 1305.2 1305.4 [M+H]-No deletion 
2 1120.1 1120.4 * Gly, Leu 
3 920.7 920.2 * Gly, Leu, Pro, Cys 
Table 3.3: MS-MS data of double PFP-tagged OT (221) detailing amino acid deletion. 
The MS-MS data obtained (Figure 3.15) confirmed the presence of a double-tagged OT 
analogue (221). Each fragment observed corresponds to a peptide which is double 
tagged (Figure 3.15), suggesting there are modifications sites at the phenol of Tyr and 
free amine of the N-terminus.  
19F NMR was carried out in order to analyse the splitting pattern of the fluorine of the 
pentafluoropyridine-tagged peptide. It is predicted that the fluorine para to the nitrogen 
will react with the free amine of the N-terminus and the phenol of the Tyr side chain (as 
discussed in Chapter 2). 19F NMR spectroscopy was carried out using peptide (218) 
and the resulting 19F NMR spectrum is shown below (Figure 3.16).  
 
 
Figure 3.16: 19F NMR spectrum of double-tagged OT (221).  
δF (ppm) 
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It can be seen from the 19F NMR analysis of 221 (Figure 3.16) that there are 4 distinct 
fluorine environments with signals at -91.4, -96.3, -156.0 and -162.0 ppm. The signals 
at -96.3 and -162.0 ppm correspond to the fluorine atoms attached to the fluoropyridine 
ring on the amine of the N-terminus. These signals match the data for the same 
constitution within the singular-tagged OT (220) (Figure 3.13). The signals at -91.4 and 
-156.0 ppm correspond to the fluorine atoms of fluoropyridine which are attached to the 
Tyr side chain. This aligns with data observed in Table 3.2 which suggests that the 
signals observed when fluoropyridine is attached to a Tyr are -91.4 and -156.0 ppm.  
3.2.2 Attempted Tagging of Oxytocin using Hexafluorobenzene 
The selective tagging with PFP (129) was shown to be an efficient and quick method to 
alter the structure of OT and so further investigations using other fluorinated aromatic 
compounds were carried out. We chose to explore the tagging of OT using HFB (47) 
which has been extensively researched by Pentalute and co-workers16 for its ability to 
staple proteins by utilising the nucleophilic nature of cysteine. 
We hypothesised that HFB (47) could react with the nucleophilic residues in OT if the 
same reaction conditions were used as in the PFP tagging. This would give rise to novel 
HFB-tagged peptides as shown in Figure 3.17, if the same on-resin and solution phase 
tagging techniques were adopted (as with the PFP tagging of OT).  
 
Figure 3.17: Theoretical singular and double-HFB tagged peptides (232 and 233). 
Peptide 230 1152.2 [M+H]+ (1 mg) was dissolved in DMF (1 ml) and DIPEA and HFB  
(47) added. The reaction was left under agitation for 4.5 h and after this time DMF was 
removed under reduced pressure. The resulting crude mixture was analysed using 
LCMS and analytical HPLC. The MS trace of the resulting peptide is shown below in 
Figure 3.18. 
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Figure 3.18: MS of the crude HFB-tagged peptide with expected 1483 [M+H]+. 
As illustrated in Figure 3.18, there is no peak for the desired mass of 1483 and only 
presence of starting material (230) 1151 [M+H]+ and charged species 576 [2M+H]2+. 
This reaction was repeated, using fresh reagents, but the same outcome was observed. 
Given the lack of reactivity of HFB (47) towards OT tagging the decision was made to 
precede with the preparation of the VP analogues only using PFP.  
3.2.3 Tagging of Vasopressin with Pentafluoropyridine 
The linear peptide C(Acm)YFQNC(Acm)PRG was synthesised on resin using manual 
Fmoc SPPS on a 0.2 mmol scale (Scheme 3.9). Once the target sequence was prepared 
the resin was split into two equal batches.  
 
Scheme 3.9: Synthesis of linear peptide 227 synthesised via Fmoc SPPS on a 0.2 mmol scale 
using RINK amide resin. Reagents and conditions: Manual Fmoc SPPS- Fmoc-Gly-OH, Fmoc-
Arg(Pbf)-OH, Fmoc-Pro-OH, Fmoc-Cys(Acm)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Gln(Trt)-OH, 
Fmoc-Phe-OH, Fmoc-Tyr(tBu)-OH, PyBOP, DIPEA and DMF, rt, (2 × 1 h) couplings. Fmoc 
deporotection- 20% piperidine/DMF, rt, 2 × 30 min. 
[M+2H]2+ 
Starting Material 
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As with the synthesis of the OT analogues, the singular tagged VP analogue was 
synthesised using an on-resin PFP tagging reaction. By tagging the peptide on-resin it 
was possible to selectively react PFP with the amine of the N-terminus of VP while the 
hydroxyl of the Tyr remained protected by t-butyl group (Scheme 3.10). 
Scheme 3.10: Synthesis of singular tagged VP (222). Reagents and conditions: i) On-resin PFP 
tagging- PFP, DIPEA, DMF, rt, 4 h ii) Cleavage from resin- 95% TFA: 2.5% TIPS: 2.5% H2O, 
rt, 4 h iii) Acm cleavage- I2, AcOH (40%)/DMF, rt, 1.5 h. 
The presence of the PFP-tagged peptide (235) (with Acm groups attached) was 
confirmed using LCMS and purified via preperative HPLC before being used in the last 
stage of the synthesis. The Acm deprotection/disulphide bond formation was carried out 
using the reaction conditions described in Section 6.4.4. The crude reaction mixture was 
purified via RP-HPLC and the LCMS analysis of the purified PFP-tagged-peptide (222) 
is given below (Figure 3.19). 
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Figure 3.19: MS of purified PFP-VP (222) with desired mass [M+H]+ 1233.4 and [M+2H]2+ 
617.3. 
Shown in Figure 3.19 is the MS for the purified PFP-tagged VP illustrating the 
presence of the desired cyclic peptide 1233.4 [M+H]+ and charged species 617.3 
[M+2H]2+. To confirm the tagging of VP at the site hypothesised in Scheme 3.10, MS-
MS experiments were carried out to confirm the amino acid sequence of the peptide and 
the resulting spectra shown in Figure 3.20. In this figure, the relevant peaks have been 
highlighted and the corresponding structure of the fragment overlaid on the spectra.  
 
[M+H]+ 
[M+2H]2+ 
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Figure 3.20: MSMS data of singularly tagged VP analogue (222).
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Entry Calculated Mass Observed Mass Deletion 
1 1233.3 1233.5 No deletion [M+H]+ 
2 1004.2 1004.5 * Gly, Arg 
3 563.1 563.1 * Gly, Leu, Pro, Cys, Asn, Gln 
Table 3.4: MSMS analysis of singular-PFP-tagged VP (222) detailing amino acid deletion. 
The MS-MS data obtained (Figure 3.20) confirmed the presence of a single-tagged VP 
analogue (222). Each fragment observed corresponds to a peptide which is single 
tagged, suggesting that PFP is attached to the N-terminus of the peptide only (Figure 
3.20). 
19F NMR analysis was carried out to analyse the splitting pattern of the fluorines of the 
PFP-tagged peptide. It is predicted that the fluorine para to the nitrogen will primarily 
react with the free amine of the N-terminus (as discussed in Chapter 2). 19F NMR 
analysis was carried out on peptide (222) and the resulting 19F NMR spectrum is shown 
below (Figure 3.21).  
 
Figure 3.21: 19F NMR spectrum of singularly tagged VP (222). 
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As seen in Figure 3.21, there are 2 distinct chemical shifts and therefore 2 distinct 
chemical environments. The signal at -96.2 ppm corresponds to the fluorine atoms 
which are ortho to the nitrogen and -162.0 ppm signal corresponds to the fluorine atoms 
which are meta to the nitrogen. The similarity between 19F NMR spectra of singular 
tagged OT (Figure 3.13) and VP (Figure 3.20) suggests that both structures contain a 
fluoropyrdine ring attached to the amine of the N-terminus via displacement of the 
fluorine para to the nitrogen.  
As with the synthesis of the double tagged OT analogue (221), the double tagged VP 
analogue (223) was synthesised using solution phase reaction conditions. By carrying 
out the tagging reaction in solution phase, both the nucleophilic Tyr side chain and 
amine of the N-terminus are available for reaction with PFP and this was confirmed via 
LCMS of the crude reaction material (Scheme 3.11).  
Scheme 3.11: Synthesis of double tagged VP (223) i) Cleavage from resin- 95% TFA: 2.5% 
TIPS: 2.5% H2O, rt, 4 h ii) Solution phase tagging- PFP, DIPEA, DMF, rt, 4 h iii) Acm 
cleavage- I2, AcOH (40%)/DMF, rt, 1.5 h. 
The presence of the PFP-tagged peptide (237) (with Acm groups attached) was 
confirmed using LCMS and the crude peptide was purified via preparative HPLC before 
it was used in the last stage of the synthesis. The Acm deprotection/disulphide bond 
formation (Scheme 3.11) was carried out using the reaction conditions described in 
Section 6.4.4. The crude reaction mixture was purified via RP-HPLC and the MS 
analysis of the purified PFP-tagged-peptide (223) is given below (Figure 3.22).  
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Figure 3.22: MS of purified doubly tagged PFP tagged VP (223) with desired material 1382.4 
[M+H]+ and 691.7 [M+2H]2+. 
Shown in Figure 3.22 is the MS for the purified doubly PFP-tagged VP illustrating the 
presence of the desired cyclic peptide [M+H]+ 1382.9 and charged species [M+2H]2+ 
692.3. To confirm the tagging of VP at the site hypothesised in Scheme 3.11, MS-MS 
experiments were carried out to confirm the amino acid sequence of the peptide and 
resulting spectra shown in Figure 3.23. In this figure, the relevant peaks have been 
highlighted and the corresponding structure of the fragment overlaid on the spectra.  
 
[M+H]+ 
[M+2H]2+ 
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Figure 3.23:  MSMS analysis of double PFP-tagged VP (223). 
*  
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Entry Calculated Mass Observed Mass Deletion 
1 1382.3 1382.4 No deletion [M+H] 
2 954.8 955.2 * Gly, Arg, Pro, Cys 
3 712.6 713.1 * Gly, Leu, Pro, Cys, Asn, Gln 
4 537.4 537.1 * Gly, Leu, Pro, Cys, Asn, Gln, Phe 
Table 3.5: Analysis of MS-MS data of double-tagged VP (223) detailing amino acid 
deletion. 
The MS-MS data obtained (Figure 3.23) confirmed the presence of a double-tagged VP 
analogue (223). Each fragment observed corresponds to a peptide which is double 
tagged (Figure 3.23), suggesting there are modifications sites at the phenol of Tyr and 
free amine of the N-terminus.  
19F NMR spectroscopy was carried out in order to analyse the splitting pattern of the 
fluorines of the pentafluoropyridine-tagged peptide. It is predicted that the fluorine para 
to the nitrogen will react with the free amine of the N-terminus and the phenol of the 
Tyr side chain (as discussed in Chapter 2). 19F NMR spectroscopy was carried on 
peptide (223) and the resulting 19F NMR spectrum is shown below (Figure 3.24).  
 
Figure 3.24: 19F NMR spectrum of double-PFP-tagged VP (223).  
δF (ppm) 
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The signals highlighted in Figure 3.24 show there are 4 distinct fluorine signals and 
therefore 4 distinct chemical environments with signals at -91.3, -96.3, -155.9 and -
162.0 ppm. The signals at -96.3 and -162.0 ppm correspond to the fluorine atoms 
attached to the fluoropyridine ring on the amine of the N-terminus which matches the 
19F NMR data collected from the singularly tagged VP (223). The signals at -91.3 and -
155.9 ppm correspond to the fluorine atoms of fluoropyridine which are attached to the 
Tyr side chain. The similarity in 19F NMR spectra of double-tagged OT (Figure 3.16) 
and VP (Figure 3.24) suggest that both structures contain a fluoropyrdine ring attached 
to the amine of the N-terminus and phenol of the Tyr side chain via the fluorine para to 
the nitrogen. 
Using both solid phase and solution phase tagging techniques has proven an effective 
way of synthesising a series of tagged peptide analogues. These analogues were all 
purified via preparative HPLC to yield individual products which have been analysed 
by mass spectroscopy and analytical HPLC traces. With the synthesis, purification and 
analysis of the singular and doubly tagged OT and VP analogues carried out, 
investigation into the enzymatic stability of these compounds was carried out.  
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3.3 Enzymatic Degradation Studies 
The instability of peptides in vivo presents a major obstacle in developing viable 
peptide-based drugs. OT (209) has a t1/2= 5 min and VP (210) has t1/2= 10 min
17 and 
although both are used as therapeutics at present, the possibility of improving the half-
lives and the overall chemical properties of OT (209) and VP (210) is extremely 
attractive. If peptide stability could be improved via the modification with PFP (129), 
this could provide an interesting tool for improving stability as well as further 
modification of other therapeutically relevant peptides.  
The first test of stability for the PFP-tagged OT (220 and 221) and VP analogues (222 
and 223) was an enzymatic degradation test using chymotrypsin. Chymotrypsin is a 
digestive enzyme which facilitates the breakdown of proteins and peptides in the 
duodenum and functions by cleaving amide bonds at the carboxyl group of hydrophobic 
amino acids such as tyrosine (Scheme 3.12) by using Ser, His and Asp residues on the 
enzyme surface.18 
 
Scheme 3.12: Chymotrypsin cleavage mechanism.   
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3.3.1 Enzymatic Breakdown Using Chymotrypsin 
Both the OT (209) and VP (210) sequences contain a Tyr which is susceptible to 
chymotrypsin cleavage as well as undergo cleavage of the amide bonds in general. The 
enzymatic degradation of the OT and VP analogues were carried out in a water bath set 
at 23 °C. The peptides OT (209), PFP-OT (220), 2PFP-OT (221), VP (210), PFP-VP 
(222) and 2PFP-VP (223) were dissolved in Tris buffer (pH 7.6) with a resulting 
concentration of 1 mg of peptide per 1 ml of buffer. The total volume of peptide/buffer 
solution needed for the experiment was 120 µL so a total of 0.12 mg of each peptide 
was required for the degradation studies. α-Chymotrypsin from bovine pancreas was 
purchased from Sigma Aldrich and dissolved in Tris buffer (pH 7.6) to a final 
concentration of 1 mg/ml. The peptide and enzyme solutions were added to an 
Eppendorf so that the ratio of peptide to enzyme solution was 25:1 and the Eppendorf 
was placed in a water bath (set at 23 °C) (Scheme 3.13).  
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Scheme 3.13: Enzymatic degradation procedure using analytical HPLC to trace peptide 
fragments. 
At this point, an initial aliquot of 15 µL was removed from the reaction mixture and 
diluted with MeCN and H2O and analysed via analytical HPLC to give a reading for t = 
0. At t = 1, 2, 3, 4, 5, 6 and 24 h, 15 µL aliquots of the peptide/enzyme mixture were 
removed and 15µL of TFA (30%)/MeCN added, diluted with MeCN and H2O and 
analysed by analytical HPLC. 
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3.3.2 Stability Studies of Oxytocin and Pentafluoropyridine-Tagged Analogues 
The enzymatic stability of native OT (209) and VP (210) were analysed as controls. 
Shown in Figure 3.25 are the analytical HPLC traces for the enzymatic degradation of 
native OT. At t = 0 there is one major peak which corresponds to native OT and this 
was confirmed via LCMS. The deletion products, as determined by LCMS, for the 
enzymatic degradation of compound 209 are shown in Table 3.6.  
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Figure 3.25: Analytical HPLC traces of enzymatic breakdown products of native OT (209) 
taken over a 24 h period.
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Entry Time Mass (as 
observed in 
Q-ToF) 
Cleavage Main product 
1 t = 0 1008.2 - No deletion- [M+H] 1008.2 
 
(209) 
2 t = 1 1008.2, 951.5, 
934.2, 820.1  
G, L, P [M+H] 1008.2 
3 t = 2 1008.2, 951.1, 
934.2, 821.1, 
724, 644 
G, L, P, C [M+H] 1008.2 
4 t = 3 1008.2, 951.1, 
934.2, 821.1, 
724, 644 
G, L (side chain), 
L, P, C 
[M+H] 1008.2 
5 t = 4 1008.2, 951.1, 
934.2, 821.1, 
724.5, 567.2 
G, L (side chain), 
L, P, C, C 
[M-Gly] 952.5 
 
(238) 
6 t = 5 1008.2, 951.1, 
934.2, 821.1, 
724.5 
G, L (side chain), 
L, P, C, 
[M-Gly] 951.1 
7 t = 6 1008.2, 951.1, 
840, 725.5, 
639.7 
G, L, P, C, 
N(NH2) 
[M-Gly-Leu-Pro-Cys] 639.7 
 
(239) 
8 t = 24 408.3, 397.5, 
291.7, 186.8, 
146.6 
Significant 
degradation of 
peptide to small 
fragments 
[M-Gly-Leu-Pro-Cys-Asn-Gln] 397.5 
 
(240) 
Table 3.6: Deletion products resulting from enzymatic degradation of native OT (209). 
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Shown in Figure 3.25 are the analytical HPLC traces from the enzymatic degradation of the 
native OT (209) with chymotrypsin. At t = 0 there is one single peak corresponding to the 
native OT (209) which was confirmed by LCMS. At t = 1 there is a total of 4 peaks- one 
corresponding to the native OT, which is the most abundant and other that corresponds to a 
Gly deletion (238) of m/z 951.1, Gly + Leu deletion m/z 934.2, Gly+ Leu + Pro deletion m/z 
820.1.  From t = 0 to t = 3 the main product is the native OT analogue but the signal 
corresponding to this mass decreases over time until t = 4, where the most abundant peak 
becomes the Gly deletion (238) (m/z 934.2). At t = 6 the most abundant peak then becomes 
the Gly+ Leu + Pro + Cys + Asn (NH2) fragment (239) (m/z 408.3) with large amounts of 
other deletion products. After 24 h, the initial peptide has completely degraded to small 
peptide fragments (240) of under m/z 500.0. 
To ensure that the degradation observed was enzymatic and not chemical, a control reaction 
was run without enzyme. The analytical HPLC traces resulting from this study at t = 0 and t = 
24 are shown in Figure 3.26.  
t=0  
 t=24  
Figure 3.26: Analytical HPLC traces of the non-enzymatic degradation experiment of native OT 
(209) at t = 0 and t = 24 (UV wavelength 220 nm). 
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This experiment demonstrated that over the course of 24 h there was no observable 
degradation of native OT (209). This suggests that the degradation observed in Figure 3.25 is 
purely due to enzymatic degradation and not any form of chemical degradation.  
After degradation of the native OT (209) was carried out, the singular PFP-tagged OT 
analogue (220) underwent the same enzymatic degradation. Samples were removed and 
analysed using analytical HPLC and the traces of samples t = 0, 1, 2, 3, 4, 5, 6 and 24 are 
show in Figure 3.27.  
 
 
 
 
 
 
 
 
 
 
 
 
 
142 
 
t=0 t=4  
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Figure 3.27: Analytical HPLC traces of enzymatic breakdown products of singular PFP-tagged OT 
(220) (UV wavelength 220 nm) taken over a 24 h period. 
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Entry Time Mass (as observed in Q-
ToF) 
Cleavage Structure 
1 t = 0 1156.1 - [M+H] 1156.1 
 
 (220) 
2 t = 1 1156.1, 1100.0 G [M-Gly] 1100.0 
 
(241) 
3 t = 2 1156.1, 1100.0 G 
4 t = 3 1156.1, 1100.0 G 
5 t = 4 1156.1, 1100.0 G 
6 t = 5 1156.1, 1100.0 G 
7 t = 6 1156.1, 1100.0 G 
8 t = 24 1100.0 G 
Table 3.7: Deletion products resulting from enzymatic degradation of singularly tagged OT (220). 
Although over time the singularly tagged OT compound (220) is degraded to the Gly cleaved 
peptide (241), the degree of fragmentation is decreased compared to the native OT. In the 
enzymatic degradation of native OT (209), multiple peaks were observed in the HPLC- 
corresponding to multiple deletions- from t = 1 onwards whereas the PFP-tagged OT HPLC 
traces show 2 peaks throughout the experiment until full conversion to the Gly cleaved 
peptide at t = 24 (e.g. compare Figure 3.25 (t = 24) and Figure 3.27 (t = 24)). This is an 
improvement of stability of the tagged peptide to enzymatic degradation compared to native 
OT as the incorporation of PFP into OT has stabilised degradation of the cyclic moiety of 
OT.  
Shown in Figure 3.28 are the analytical HPLC traces from the enzymatic degradation of the 
doubly PFP-tagged OT (221) with chymotrypsin. At t = 0 there is a single peak 
corresponding to 221 and the degradation products that arise over 24 hrs incubation are 
shown in Table 3.8, as analysed by LCMS.  
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t=0 t=4  
t=1 t=5  
t=2 t=6  
t=3 t=24  
Figure 3.28: Analytical HPLC traces of enzymatic breakdown products of double PFP-tagged OT 
(221) (UV wavelength 220 nm) taken over a 24 h period. 
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Entry Time Mass (as observed in 
Q-ToF) 
Cleavage Structure 
1 t = 0 1305.2 - [M+H] 1305.2 
 
(221) 
2 t = 1 1305.2 - 
3 t = 2 1305.2 - 
4 t = 3 1305.2 - 
5 t = 4 1305.2 - 
6 t = 5 1305.2 - 
7 t = 6 1305.2 - 
8 t = 24 1100.1 G and PFP [M-Gly-PFP] 1100.1 
 
(242) 
Table 3.8: Deletion products resulting from enzymatic degradation of doubly tagged OT (221). 
From analyses of the analytical HPLC, it is evident that the double PFP-tagged OT (221) is 
the more stable of the two analogues synthesised. Over the first 6 h, the peptide did not 
undergo any noticeable degradation, with intact 221 being the major product present in the 
LCMS analysis. After 24 h there was degradation and the peptide converted to the Gly + PFP 
deletion product (242). This is considerably more stable than the native OT and even the 
single PFP-tagged analogue.  
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3.3.3 Stability Studies of Vasopressin and Pentafluoropyridine-Tagged Analogues 
VP is structurally similar to OT with two nucleophilic sites available for reaction with PFP. 
Native VP (210) has a half-life of 10-35 min and is degraded via vasopressinases in the 
human body.17 VP has a longer half-life than OT which may be due to the proximity of the 
Tyr and Phe which prevents chymotrypsin degradation of that site. The method used for the 
enzymatic degradation studies of VP was the same used for the studies of OT (Section 3.3.1). 
Figure 3.29 shows the analytical HPLC traces of the enzymatic degradation of native VP and 
Table 3.9 describes the LCMS data of these samples and suggested degradation structures.  
At t = 0 there is one peak which was determined by LCMS to be the native VP with a mass of 
1085.3.  
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t=0 t=4  
t=1 t=5  
t=2 t=6  
t=3 t=24  
Figure 3.29: Analytical HPLC traces of enzymatic breakdown products of native VP (210) (UV 
wavelength 220 nm) taken over a 24 h period.
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Entry Time Mass (as observed in Q-
ToF) 
Cleavage Main product 
1 t = 0 1085.3 - [M+H] 1085.3 
 
(210) 
2 t = 1 1085.3, 1028.1 G [M+H] 1085.3 
3 t = 2 1085.3, 1028.1 G [M+H] 1085.3 
4 t = 3 108.35, 1028.1 G [M+H] 1085.3 
5 t = 4 1085.3, 1028.1, 956.2 G [M+H] 1085.3 
6 t = 5 1085.3, 1028.1, 
956.2,824.5 
G, R (Side 
cahin) 
[M+H] 1085.3 
7 t = 6 1085.3, 1028.1, 956.2, 
824.5,757.7 
G,R, P,  [M-Gly] 1028.1 
 
(243) 
8 t = 24 1085.3, 1028.1, 956.2, 
757.7, 704.1 
G,R, P, C [M-Gly] 1028.1 
Table 3.9: Deletion products resulting from enzymatic degradation of native VP (210). 
At t = 0 there is one major peak corresponding to the native peptide (210) [M+H]+ 1085.3 and 
this remains the major product until t = 6 where the major product becomes the Gly deletion 
(243) (m/z 1028.1). From t = 1 there is only 2 degradation products until t = 6 where there are 
now 5 other degradation products. Even though native VP has a half-life which is double that 
of OT, efforts were still made to try and improve the stability of native VP. 
Again, to confirm that the degradation observed in this study was due to enzymatic 
degradation and not chemical degradation, a reaction void of enzyme was carried out. The 
same reaction conditions were used as discussed previously but the enzyme was not added. 
The analytical HPLC traces resulting from this study at t = 0 and t = 24 are shown in Figure 
3.30.  
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t = 0  
t = 24  
Figure 3.30: Analytical HPLC traces of the non-enzymatic degradation experiment of native VP 
(210) at t = 0 and t = 24 (UV wavelength 220 nm). 
Figure 3.30 illustrates that over the course of 24 h there was no observable degradation of the 
native VP (210) in the absence of chymotrypsin, suggesting that any degradation observed in 
Figure 3.29 is due to enzymatic degradation and not chemical degradation. 
Figure 3.31 shows the analytical HPLC data from the enzymatic degradation of single PFP-
tagged VP (222). At t = 0 there is one single peak which LCMS proved was the singular PFP-
tagged VP (222) with a mass of 1233.3. Figure 3.31 shows the analytical HPLC traces of the 
enzymatic degradation and Table 3.10 describes the LCMS data of these samples and 
suggested degradation structures.  
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t=0 t =4  
t=1 t=5  
t=2 t=6  
t=3 t=24  
Figure 3.31: Analytical HPLC traces of enzymatic breakdown products of singular tagged VP (222) 
(UV wavelength 220 nm) taken over a 24 h period.  
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Entry Time Mass ( as observed in Q-
ToF) 
Cleavage Main product 
1 t = 0 1233.3 - [M+H] 1233.3 
 
(222) 
2 t = 1 1233.3, 1177.4 G [M+H] 1232.3 
3 t = 2 1233.3, 1177.4 G [M+H] 1232.3 
4 t = 3 1233.3, 1177.4 G [M+H] 1232.3  
5 t = 4 1233.3, 1177.4 G [M+H] 1232.3 
6 t = 5 1233.3, 1177.4 G [M+H] 1232.3 
7 t = 6 1233.3, 1177.4 G [M+H] 1232.3 
8 t = 24 1233.3, 1177.4 G [M+H] 1232.3 
Table 3.10: Deletion products resulting from enzymatic degradation of singular PFP-tagged VP 
(222). 
At t = 0 there is one major peak corresponding to singular PFP-tagged VP (222) and remains 
the major product for the full 24 h. At t = 2 a second peak appears which corresponds to the 
Gly deletion of m/z 1177.4, but this remains a minor side product throughout the enzymatic 
degradation study. Compared to native VP, the singular PFP-tagged VP analogue is 
significantly more stable to enzymatic degradation. 
Figure 3.32 shows the analytical HPLC traces from the enzymatic degradation of double 
PFP-tagged VP (223). At t = 0 there is a singular peak corresponding to the whole double 
tagged peptide which was confirmed via LCMS to have a mass of 1382.1. Figure 3.32 shows 
the analytical HPLC data from the degradation study and Table 3.11 lists the LCMS data of 
these samples as well as suggested fragment structures. 
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t=0 t=4  
t=1 t=5  
t=2 t=6  
t=3 t=24  
Figure 3.32: Analytical HPLC traces of enzymatic breakdown products of double tagged VP (223) 
(UV wavelength 220 nm) taken over a 24 h period.
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Entry Time Mass ( as observed in 
Q-ToF) 
Cleavage Main product 
1 t = 0 1382.1 - [M+H] 1382.1 
 
(223) 
2 t = 1 1382.1 - [M+H] 1382.1 
3 t = 2 1382.1, 1326.0 G [M+H] 1382.1 
4 t = 3 1382.1, 1326.0 G [M+H] 1382.1 
5 t = 4 1382.1, 1326.0 G [M+H] 1382.1 
6 t = 5 1382.1, 1326.0 G [M+H] 1382.1 
7 t = 6 1382.1, 1326.0 G [M+H] 1382.1 
8 t = 24 1326.0 G [M-Gly] 1326.0 
 
(244) 
Table 3.11: Deletion products resulting from the enzymatic degradation of doubly PFP-tagged 
VP (223). 
At t = 0 and t = 1 there is a single peak corresponding to the mass 1382 and over the 
course of 24 h there is full conversion from the intact double-tagged peptide (223) to the 
Gly deletion product (m/z 1326.0) (244). At t = 2 there is the appearance of the Gly 
deletion product (244) which gradually increases over time as the intact double tagged 
peptide decreases until full degradation at t = 24. 
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It is possible to hypothesise that the double-tagged VP analogue (223) is more stable to 
enzymatic degradation than the native VP but is not as stable as the singular tagged 
analogue since there was no native peptide present at t = 24, whereas in the study of the 
singular-tagged peptide 222 the intact peptide m/z 1233.3 remained the major product 
throughout.  
3.4 Conclusions  
The synthesis of native OT (209) and VP (210) was carried out using manual Fmoc 
SPPS. PFP tagged analogues of OT (220 and 221), and VP (222 and 223) were also 
prepared.  For the synthesis of the singularly PFP tagged analogues 220 and 222, an on-
resin tagging strategy was utilised. By carrying out the tagging reaction on resin, the t-
Bu protecting group of the Tyr could be exploited to mask the nucleophilic phenol 
leaving only the amine of the N-terminus available for reaction with PFP (Scheme 3.6). 
  
Figure 3.33: Single-tagged OT (220) and VP (222). 
220 and 222 were purified via semi-preparative HPLC and analysed using LCMS. 
Analysis of the MS-MS data confirmed that the PFP was attached to the N-terminal 
NH2 group and not at any other site. 
19F NMR analysis also confirmed that the NH2 
attacks PFP at the para position for the OT analogue (220) (Figure 3.13, -96.1 ppm and 
-161.9 ppm) and the VP analogue (222) (Figure 3.22, -96.2 ppm and -161.9 ppm). 
Synthesis of the doubly PFP-tagged peptides (221 and 223) was carried out using 
solution phase tagging conditions. By adopting this technique, PFP (129) was able to 
attach to both the NH2 of the N-terminus and hydroxyl group of Tyr (Scheme 3.8). 
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Figure 3.34: Double-tagged OT (221) and VP (223). 
The peptides were, again, analysed using MS-MS and 19F NMR. The MS-MS data 
illustrated that PFP was now attached to the two positions hypothesised and was visibly 
different to the singular-tagged analogue data. 19F NMR also suggested that there were 
now 2 distinct PFP environments in both the OT analogue (221) (Figure 3.16 -91.4 
ppm, -96.3 ppm, -156.0 ppm and -162.9 ppm) and VP analogue (223) (Figure 3.24 -
91.3 ppm, -96.2 ppm, -155.9 ppm and -162.0 ppm).  
The native OT (209) and VP peptides (210) were also synthesised to act as control 
compounds in the enzymatic stability studies. These were synthesised using Fmoc 
SPPS, purified by preparative HPLC and analysed using LCMS (Section 3.2.1 and 
3.3.3). 
  
Figure 3.35: Structures of native (209) and VP (210). 
Once synthesised, the enzymatic stability of the PFP-tagged analogues and native 
peptides were tested. For each analogue, a peptide/enzyme solution was made up and 
incubated in a water bath for 24 h. Aliquots were removed and the stability of each 
analogue and analysed using analytical HPLC.  
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For the OT analogues (Section 3.3.2), native OT 209 showed significant degradation 
within 1 h and over the course of 24 h there was no native OT left in the sample (Figure 
3.25). For the singular-tagged analogue 220, stability towards chymotrypsin was 
significantly improved. After 1 h there was only one side product which remained the 
only side product (241) throughout the study (Figure 3.27). For the double-tagged 
analogue 221, the stability was further improved as over the course of 6 h there was no 
degradation of the whole peptide (Figure 3.28). In this case, modifying OT with either 
one or two PFP moieties significantly improves the stability of the peptides to 
enzymatic breakdown compared to the native peptide.  
In the case of the VP analogues (222 and 223), a similar trend was observed (Section 
3.3.3). For the native VP (210) there was degradation of the native peptide over the 
course of 24 h but the native peptide was still present along with approximately another 
4 side products (Figure 3.29). For the singular-tagged analogue 222, there was slight 
degradation with the singular tagged peptide 222 remaining the principle product 
throughout the course of 24 h (Figure 3.31). In the case of the double-tagged species 
223, there was complete degradation of the native peptide to the Gly deletion side 
product (244) over the course of 24 h (Figure 3.32). Surprisingly in the case of VP, the 
singular-tagged species (222) was the most stable analogue, as the principle product was 
the singular-tagged species after 24 h. Although degradation of native VP resulted in 4 
side products, the native peptide (210) was still present as opposed to the double-tagged 
species (223) which was completely degraded after 24 h. This could be due to fact that 
chymotrypsin is known to target aromatic side chains and the presence of the PFP-
tagged Tyr and Phe side chain promote degradation compared to the native VP or due to 
poor solubility of the double-tagged peptide in H2O.  
The chemical stabilities of the native peptides were also tested to ensure that any 
degradation observed was the result of interaction between enzyme and peptide and not 
chemical degradation occurring over time. For both OT (209) and VP (210) it was 
determined that the inclusion of either a singular or multiple PFP moieties into the 
peptide could positively impact the enzymatic stability compared to the native peptides. 
Stability tests in human serum of the tagged analogues (220, 221, 222 and 223) should 
be carried out in future to provide a more robust test of stability of the synthesised 
analogues.   
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Chapter 4: Improving the Pharmokinetics of GLP-1 via Bionconjugation 
4.1 GLP-1 Modifications and their role as Future Therapeutics 
There are several challenges in developing peptides as drug molecules. An example of 
this is the use of Glucagon-like peptide-1 receptor agonists (GLP-1 RA) as treatment 
against Type 2 diabetes mellitus (T2DM). T2DM is caused by decreased insulin 
secretion and/or insulin resistance which leads to hyperglycaemia and in long term can 
lead to heart disease, blindness and amputation.1 T2DM is caused by a variety of factors 
including poor diet and an unhealthy lifestyle while some individuals may be 
genetically predisposed to developing T2DM. With levels of obesity rising dramatically 
over the last 30 years throughout the world, the levels of T2DM have also risen 
dramatically.2 It is estimated by 2030, the number of adults diagnosed with diabetes will 
rise to 4.6 million with 90% of these being T2DM and thus, there is an urgent need for 
new and effective treatments.3 
GLP-1 (245) (Figure 4.1) is an incretin hormone which binds to the GLP-1 receptor and 
is released from intestinal cells. Once in circulation GLP-1(245) has a very short life 
(t1/2= 1.5min) and undergoes enzymatic degradation by dipeptidyl peptidase IV 
(DPPIV).  
His⁷-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp- 
Val-Ser-Ser-Tyr-Glu-Gly-Gln-Ala-Lys²⁶-Glu- 
Phe-Ile-Ala-Trp-Leu-Val-Lys³⁴-Gly-Arg-NH₂ 
245 
Figure 4.1: Primary Structure of GLP-1 (245).4 
When excreted within the body, GLP-1 modualtes a number of biological functions 
including increasing secretion of insulin, decreasing secretion of glucagon and limiting 
glucose absorption into the bloodstream. It is these properties that make it an interesting 
target molecule for the treatment of T2DM, but due to its short half-life in vivo (less 
than 2 min) developing GLP-1 as a therapeutic is not starightforward.5 
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Improving Pharmokinetics via Bioconjugation 
There have been a number of studies focusing on improving the pharmacokinetic 
properties of GLP-1 including PEGylation of the GLP-1 backbone to increase stability, 
GLP residue substitution to decrease susceptibility to enzymatic breakdown and 
bioconjugation to proteins and biopolymers to increase solubility and cell permeability.6 
Due to this and the work of others, there are a number of GLP-1 receptor agonists 
(GLP-1RA) currently in various stages of clinical trials (Table 4.1).5  
Company 
sponsoring 
clinical study 
Brand 
name/Drug code 
Molecular type Status Treatment 
Bristol-Myers 
Squibb 
Exenatide 39 aa-peptidase- 
resistant peptide 
Approved T2 diabetes, 
obesity 
 
Novo Nordisk Liraglutide 31 aa peptide linked 
to lipid 
Approved T2 diabetes, 
obesity 
 
Sanofi Lixisenatide 44 aa peptidase-
resistant peptide 
 
Approved T2 diabetes 
 
GSK Albiglutide Tandem repeat of 30 
aa peptide 
 
Regulatory 
review 
T2 diabetes 
Eli Lilly Dulaglutide 46 aa peptide fused 
with IgG4 Fc 
 
Phase III T2 diabetes 
Novo Nordisk Semaglutide 37 aa acetylated 
peptide 
 
Phase III T2 diabetes 
PhaseBio 
Phamaceuticals 
PB1023 Peptide fused with 
ELP biopolymer 
 
Phase II T2 diabetes 
Hanmi 
Pharmaceuticals 
HM11260C, 
LAPS-Exendin 
Exendin-4 analog 
conjugated to human 
Ig fragment 
 
Phase I T2 diabetes 
Hoffman-La 
Roche 
RO6811135, 
MAR709 
16 aa pegylated 
peptide; dual agonist 
 
Phase I T2 diabetes 
Table 4.1: GLP-1 peptide receptor agonists in clinical studies.5 
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PEGylation of peptides was shown to improve various properties including enzymatic 
stability and absorption.7 Lee and co-wrokers8 investigated the PEGylation of GLP-1 
and the effect this had on the pharmokinetic properties compared to native GLP-1.  
PEGylation of GLP-1 is possible at a number of sites within the sequence including the 
amines of His at position 7 and Lys at postions 26 and 34 (Figure 4.1). Two different 
approaches were used by Lee and co-workers in their PEGylation studies to produce 
mono-PEGylated GLP-1 analogues, using PEG-SPA to conjugate the mPEG2k to Lys 
residues and reductive alkylation of His with mPEG2k-ALD and NaCNBH₃ reduction.8 
These analogues were tested against rat islet cells in a high glucose concentration 
environment and the rate of insulin secretion was measured to evaluate biological 
activity. It was found that the PEG-Lys-GLP analogue showed significant insulin 
secretion, but the PEG-His-GLP analogue did not show significant biological activity. 
This is due to the fact that the free N-terminus of His in GLP is believed to be 
responsible for important interactions with the GLP-1 receptor and therefore important 
in biological activity. Conjugation of PEG to the His at the N-terminus results in a 
disruption of ligand-receptor binding and therefore affects biological activity. Stability 
studies of the PEG-Lys26-GLP analogue (half-life = 770 min) also showed significant 
resistance to DPPIV (dipeptidyl peptidase IV) breakdown compared to GLP-1 (half-
life= 15.5 min).  Overall Lee and co-workers were able to synthesise a PEGylated GLP-
1 analogue with potent biological activity, increased stability to enzymatic breakdown 
and an improvement in plasma exposure.7 
There have been a number of studies that have concentrated on improving the properties 
of GLP by altering the amino acid sequence. Liraglutide (246) (Figure 4.2), developed 
by Novo Nordisk and approved for treatment of T2DM in 2009, is structurally similar to 
GLP-1 hormone itself and has an Arg substitution at position 34 and palmitic acid 
joined to Lys via a glutamate spacer at position 26.1   
 
Figure 4.2 Structure of Liraglutide (246) substituted residues highlighted in red. 
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Liraglutide (246) exhibits prolonged stability in vivo compared to GLP-19 and is 
administered via subcutaneous injection with a half-life of 11-13 h.  Once injected the 
peptide is released via self-dissociation and is bound to serum albumin in the 
bloodstream which increases its stability towards DDPIV breakdown and reduces renal 
clearance.1  
Studies have also been carried out where the conjugation of GLP-1 analogues to 
biological molecules such as human serum albumin and immunoglobulin G (IgG) has 
been investigated. Albiglutide (247), developed by GSK, contains two repeating GLP-1 
strands linked to the N-terminus of albumin and a Gly substitution at position 2 of the 
peptide.1  
 
Figure 4.3: Structure of Albiglutide 247.  
The repeating GLP-1 unit in 247 acts as a spacer which improves potency compared to 
native GLP-1, the Gly substitution of Ala at position 8 allows DDPIV resistance and 
conjugation to albumin improves stability and half-life due to the increased molecular 
size that fusion to albumin contributes.1 Similair to Albiglutide (247), Dulaglutide (248) 
(Figure 4.4) consists of 2 GLP-1 chains and various residue substitutions which limit 
enzyme degradation, but differs due to the fact the GLP-1 peptides are joined to a IgG-
Fc heavy chain variant. This results in a long half-life and reduced renal clearance. 
Dulagutide (248) has shown superior action to Exanatide (an approved GLP-1RA) in a 
6-month phase 3 trial period and has shown great promise as a possible therapy for 
T2DM treatment.1  
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Figure 4.4: Structure of Dulaglutide 248- GLP-1 analogue linked to Fc region of 
immunoglobulin (IgG). 
Studies have concentrated on improving the pharmacokinetic properties of GLP-1 
receptor analogues and a number of these studies have been successful with 3 GLP-1RA 
currently available and a large number in various stages of development.5 
Improving Efficacy via Hybridisation of GLP-1 
Work by Matthais Tschop and co-workers10 has concentrated on synthesising a series of 
GLP-1 co-agonists to improve targeting and reduce possible side effects. One of these 
co-agonists is a GLP-1/glucagon analogue. Glucagon (GCGR) is structurally related to 
GLP-1 and has been shown to improve metabolism and lower body weight. A GLP-
1/GCGR co-agonist peptide was synthesised and tested in mice and shown to restore 
leptin responsiveness in obese mice and aid weight loss.10 Leptin is a hormone released 
by adipose tissue to regulate energy balance and functions by inhibiting hunger. It has 
been shown that obese patients exhibit a decreased sensitivity to leptin which results in 
an inability to control appetite and food consumption.11 Tschop and co-workers were 
able to illustrate that co-administration of PEG-GLP-1/GCGR restored leptin 
responsiveness and promoted weight loss when administered alongside PEG-leptin, in 
mice models. Another GLP-1 co-agonist which has been recently synthesised is a GLP-
1/GIP analogue. GIP, like GLP-1, is an incretin peptide, but functions by promoting 
insulin secretion.12 
Using the promising results from the studies into GLP-1, co-agonists with glucagon and 
GIP, Tschop and co-workers13 developed a “peptide triagonist”-synthesising a single 
peptide containing active sequences of GLP-1, glucagon and GIP. GIP was discounted 
as a therapeutic agent against T2DM due to instability and was initially reported to 
promote obesity. Recent data, however, have shown that this conclusion was not fully 
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understood, and in fact using GIP analogues to regulate glucose levels could be a 
promising area of research for anti-obesity and anti-diabetes drugs.12 Shown in Table 
4.2 are sequences of GLP-1 (Entry 1), glucagon (Entry 2) and GIP (Entry 3) with the 
sequence of the triagonist shown in Entry 4.13 
Entry Name Sequence 
1 GLP-1  HAEGTFTDSVSSYLEGQAAKEFIAWLVKGR 
 
2 Glucagon  HSQGTFTSDYSKYLDSRRAQDFVQWLMNT 
 
3 GIP  YAEGTFISDYSIAMDKIHQQDFNVWLLAQKGKKNDWKHNIT 
 
4 Triagonist  HXQGTFTSDKSKYLDERAAQDFVQWLLGGPSSGAPPPS-NH2 
 
Table 4.2: Sequence of GLP-1 (Entry1), glucagon (Entry 2), GIP (Entry 3) and Triagonist 
(Entry 4)- X represents Aib and K represents Lys(γE-C16). 
From Table 4.2, it is evident that the peptides listed are of similar sizes and sequences 
but are varied enough to ensure that, individually, they are selective for their own 
receptor. The tri-agonist was shown to be selective for GLP-1 receptors, GIP receptor 
and glucagon receptors over other GPCRs and more potent than the individual peptides. 
This work was particularly interesting because it was the first synthesis of a potent anti-
obesity drug with the ability to bind with three different metabolic receptors.13 
Improving Targeting via Hormone Bioconjugation of GLP-1 
A method for improving targeting of GLP-1 is via conjugating to oestrogen, which aids 
selective tissue targeting (Figure 4.5). Oestrogen is a hormone which has been used 
previously as a treatment for obesity and T2DM, but its use as a drug has been 
extremely limited as it promotes tumour growth.  
Figure 4.5: Structure of GLP-1-Oestrogen analogue 249. 
Compound 249 functions by exploiting the anti-obesity properties of oestrogen and 
using GLP-1 as a targeting peptide to allow intracellular transport, therefore eliminating 
side effects previously observed when oestrogen is used on its own. The GLP-1-
estrogen conjugate (249) was tested in GLP-1 receptor knockout mice to determine if 
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the activity observed for the conjugate relied on GLP-1 targeting. It was found that in 
these mice, no weight loss was observed, but in wild type mice, an 8.5% decrease in 
body weight was observed. This helped prove that the GLP-1 targeting effect of the 
conjugate was a key component to its activity.14 A later study into the GLP-1-estrogen 
conjugate (249) mode of action used single-photon emission commuted tomography 
imaging (SPECT-imaging). In this study, distribution of the 249 was monitored using 
SPECT-imaging and it was revealed that the supramammillary nucleus (SUM) area of 
the brain is the main target site for the conjugate.15 
Despite the advances that have been made there are still challenges in synthesising 
novel stable GLP-1 analogues. As discussed, previous efforts have concentrated on 
modification of the GLP-1 backbone via Lys. Somewhat surprisingly, there have been 
no studies to date that have looked at the incorporation of Cys residues into the GLP-1 
backbone and its use as a chemical handle for modification.  Future work into the 
modification of GLP-1 could concentrate on further improving the bioavailability of 
GLP-1 analogues to possibly reduce dosage or introduce an orally available GLP-1 
analogue.  
4.1.1   Aims 
As mentioned in Section 4.1, the GLP-1 receptor is an interesting pharmaceutical target 
with a number of new GLP-1 receptor agonists in various stages of development (Table 
4.1). Comparisons between the native GLP-1 (245) and modified analogues currently 
being studied show that the main area of modification is at Lys26- as in Liraglutide 
(245). 
 Figure 4.6: Native GLP-1(7-36) (245) sequence. 
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The native GLP-1(7-36) 245 sequence will be synthesised to act as a control compound 
in enzymatic degradation studies of the PEG-modified GLP-1 analogue 252. Comparing 
the degradation of the native sequence and PEG-modified analogue will illustrate the 
effectiveness of PEG to decrease enzymatic degradation. 
The aim of this aspect of the project was to synthesise a Cys-modified GLP-1 analogue 
250 which could be subsequently tagged with pentafluoropyridine (PFP) resulting in an 
activated GLP-1(7-36) analogue 251.  
This activated GLP-1 analogue (251) could undergo a displacement reaction with thio-
PEG or thiosugar analogues, resulting in a PEG-modified GLP-1 analogue 252. It is 
hypothesised that the modified GLP-1 analogue 252 will exhibit improved stability and 
solubility compared to the native GLP-1 analogue 245. 
 
Scheme 4.1: PEG-modified Cys GLP-1(7-36) 252. 
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4.2 Synthesis of Native GLP-1(7-36) (245) 
GLP-1(7-36) 245 was synthesised via automated Fmoc solid phase peptide synthesis 
(SPPS) using a Liberty1 automated microwave synthesiser.  GLP-1(15-36) 253 was 
initially synthesised on RINK amide resin (0.1 mmol scale) using 30 min single 
couplings rt + 10 min mW and the remaining amino acids were coupled using single 60 
min couplings + 10 min mW to give the target peptide 245 (Section 6.3.2). 
 
Scheme 4.2: Automated SPPS of GLP-1(7-36) 245 synthesised on 0.1 mmol scale using i) 30 
min single couplings at rt + 10min mW ii) 60 min single couplings rt + 10 min mW. 
The resulting crude 30-mer peptide (245) was cleaved from resin and was analysed 
using MALDI-ToF (Figure 4.7). 
 
Figure 4.7: MALDI-ToF analysis of peptide (245). 
Desired Material 
3295 [M+H]+ 
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As demonstrated in the above spectra, there is no noticeable peak for the desired target 
peptide 245 at 3295.7 [M+H]+. Analytical HPLC also confirmed that the synthesis had 
not proceed as expected with several peaks being observed. 
It was decided that the peptide would be resynthesised using multiple coupling 
conditions and longer reaction times. Due to the length of 245 it was decided to 
synthesise it on a 0.1 mmol scale for the first 10 amino acid residues (GLP-1(27-37)) 
and then the resin would be split into 2 equal portions and the synthesis of the last 20 
amino acids would be carried out on a 0.05 mmol scale. The advantage of using this 
method is that aggregation of the peptide on resin is minimised, resulting in a 
homogenous peptide synthesis. 
Peptide 254 (EFIAWLVKGR-amide) was synthesised using the conditions described in 
Section 6.3.2 on RINK amide resin using 30 min single couplings + 10 min mW for all 
amino acids, except for Arg (2 × 60 min couplings rt + 10 min mW) and Leu (1 × 60 
min coupling + 10 min mW). LCMS of the resulting crude peptide carried out and the 
desired material 1217.1 [M+H]+ was present. The rest of the synthesis was carried out 
using approximately 0.05 mmol of resin from the last step using single 60 min coupling 
rt + 10 min mW.   
  
Scheme 4.3: Automated SPPS of GLP-1(7-36) 245 synthesised on 0.1 mmol scale using i) 30 
min single couplings at rt +10 min mW and 254 synthesisied on a 0.5 mmol scale using ii) 60 
min single couplings rt + 10 min mW. 
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The resulting crude peptide 245 (HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-
amide) was cleaved from resin and analysed using MALDI-ToF (Figure 4.8). The 
deletion products that have occurred during the synthesis are highlighted in red.  
Figure 4.8: MALDI-ToF of crude peptide 245.  
The main deletions observed (m/z 2904.3, 3033.4, 3162.5) correspond to the final amino 
acids of the sequence. To try and eliminate these deletions in the synthesis, double 
couplings were adopted for the final four amino acids of the sequence (Scheme 4.4). 
Desired Material 
[M+H]+ 
H Deletion 
H and A 
Deletion 
H, A and E 
Deletion  
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Scheme 4.4: Automated SPPS of GLP-1(7-36) 254 synthesised on 0.1 mmol scale using i) 30 
min single couplings at rt +10 min mW, 255 synthesised on a 0.5 mmol scale using ii) 60 min 
single couplings rt + 10 min mW and 245 synthesised using double 60 min coupling rt + 10 min 
mW.  
The resulting crude peptide 245 (HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-
amide) was cleaved from resin and analysed using MALDI-ToF (Figure 4.9).  
 
Figure 4.9: MALDI-ToF of peptide 245. 
 
H Deletion 
Desired Material 
[M+H]+ 
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Figure 4.9 shows the desired material (245) 3296.9 [M+H]+ and also a side product 
corresponding to the His deletion (m/z 3159.9) at the N-terminus. Upon initial HPLC 
purification, the His deletion side product could not be successfully separated from the 
target peptide so alternative solvent gradients were used. Instead of the standard 
gradient of solvent A (95% H2O, 5% MeCN, 0.01% TFA) 100-50% over 60 min, a 
more gradual gradient of solvent A 70%- 30% over 60 min was used and the resulting 
purified peptide (245) obtained was analysed using MALDI-ToF and analytical HPLC 
(Figure 4.10 and 4.11). 
 
Figure 4.10: MALDI-ToF of 245 (HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-
amide). 
 
 
Figure 4.11: Analytical HPLC of native GLP-1 245 
(HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-amide). 
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4.3 Synthesis of Cys-modified GLP-1 (250) 
With a method for the synthesis of the native GLP-1 developed, the same approach was 
applied to prepare a Cys modified analogue of GLP-1.  
As discussed in Section 4.1, it has been shown that conjugation of a peptide to PEG 
increases its stability towards enzymatic degradation. The objective of this section of 
the study is to incorporate Cys into position 26 of the native GLP-1 backbone (250) and 
carry out tagging and thiol displacement illustrated in earlier sections (Chapter 2).  
 
Figure 4.12: Cys-modified GLP-1(7-36) analogue 250. 
Once the modified GLP-1 sequence was synthesised and displacement reactions with 
PEG have been successful the modified peptide sequence will be tested for enzymatic 
breakdown. The stability of the modified sequence will be compared to the unmodified 
sequence which will be synthesised using automated Fmoc SPPS.  
4.3.1 Synthesis of Cys-modified GLP-1 fragments 
To demonstrate that the tagging of the Cys-modified GLP-1 could be successful, a short 
15-mer fragment of the GLP-1 peptide was first synthesised.  The peptide fragment 
(GQAACEFIAWLVKGR-amide) (258) was synthesised on RINK amide resin on a 0.1 
mmol scale via automated Fmoc SPPS. With the synthesis complete the crude peptide 
was cleaved from resin and analysed using LCMS (Scheme 4.5).  
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Scheme 4.5: Automated SPPS of 256 synthesised on 0.1 mmol scale using i) 30 min single 
couplings at rt +10 min mW, 257 using ii) manual HATU coupling of the Fmoc-Cys(Trt)-OH 
and continuation of the synthesis of 258 using iii) 30 min single couplings at rt +10 min mW 
followed by acetyl capping of the N-terminus using 20% acetic anhydride/DMF. 
Peptide 258 was synthesised by adopting 30 min single couplings + 10 min mw and the 
Cys residue coupled manually using HATU as a coupling reagent (Section 6.4.2). 
Peptide 258 was cleaved from the resin and deprotected using TFA resulting in peptide 
259. The reactivity of the cleaved peptide 259 was investigated and further reacted with 
PFP. 
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Scheme 4.6: Reaction of peptide 259 using i) PFP, DIPEA and DMF, 4 h, rt and ii) PFP, 
DIPEA, TFE, 4 h, rt.  
Initial investigation into the reaction of peptide 259 with PFP (129), concentrated on 
using DMF to react PFP unselectively at both the Cys and Lys residues within the 
peptide sequence (Scheme 4.6i). Shown below is the MS of purified peptide 260 with 
the desired mass of 1970.8 [M+H]+.  
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Figure 4.13: MS of purified peptide 260 with [M+H]+ 1970.8. 
Selective tagging of peptide 259 with PFP was then carried out using TFE as the solvent 
(Scheme 4.6ii). TFE reduces the reactivity of nucleophilic side chains such as Lys but 
has a lesser effect on Cys side chains thus allowing the PFP to react selectively.17 This 
was confirmed using MS with mass of 1839.8 [M+H]+, as shown in Figure 4.14.  
Figure 4.14: MS of purified peptide 261 with [M+H]+ 1839.9. 
 [M+H]+ 
 
 [M+H]+ 
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To confirm the structure and position of PFP tagging MS-MS experiments were carried 
out on both 260 and 261. The masses shown in Table 4.3 confirm the presence of a 
double PFP-tagged peptide 260 with PFP tagged at both the Lys and Cys.  
Entry Mass Fragment 
1 1971.1 
 
 260 
 
2 1764.0 
 
260 
 
3 1082.2 
 
260 
 
Table 4.3: MS-MS data of peptide 260 (Fragment observed in MS in red). 
Entry 1 and 2 are significant in analysis of the structure of peptide 260 as the masses 
observed m/z 1971.1 and m/z 1764.0 correspond to peptides containing 2 PFP units and 
are not observed in the data for the singularly tagged peptide. Entry 1 corresponds to 
the whole peptide without any fragmentation and Entry 2 (m/z 1764.0) corresponds to a 
deletion of terminal Arg and Gly. The peak at m/z 1082.2 corresponds to a 
fragmentation of Arg, Gly, Lys(PFP), Val, Leu, Trp, Ala, Ile and Phe (Entry 3). This 
mass is also present in the MS-MS spectra of the singular tagged peptide which 
suggests that the second PFP has been cleaved.  
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To confirm the structure of peptide 261 MS-MS experiments were carried out. Shown 
in Table 4.4 are the MS-MS data for peptide 261 which was believed to be singularly 
tagged at the Cys residue only. 
Entry Mass Fragment 
1 1610.5 
 
261 
 
2 1089.7 
 
261 
 
3 829.0  
 
261 
 
4 623.2 
 
261 
 
Table 4.4: MS-MS data of peptide 261 (Fragment observed in MS in red). 
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Entry 1 in Table 4.4 corresponds to a deletion of Arg and Gly (m/z 1610.5). Entry 2, 3 
and 4 correspond to peptides which have further deletions, but still contain the 
Cys(PFP) residue. Further small fragment peptides are observed which suggest the 
Cys(PFP) has been removed.  
The data from these MS-MS experiments suggest that for the reaction of peptide 259 
using PFP, DIPEA and DMF as a solvent, a double-tagged peptide 260 is formed with 
tagging taking place at the Lys and Cys residues. For the reaction of peptide 259 with 
PFP, DIPEA and using TFE as a solvent, the MS-MS data suggest that a mono-tagged 
peptide 261 is formed with selective tagging occurring at the Cys residue.  
4.4 Synthesis of Cys-modified GLP-1 30-mer (250) 
Having established a selective tagging method towards Cys, efforts were made to 
synthesise the full 30-mer Cys modified GLP-1 (250). If 250 could be synthesised, then 
selective tagging of Cys with PFP could be carried out using the reaction conditions 
described in Section 4.3.1 (Scheme 4.7). 
 
Scheme 4.7: Selective tagging of peptide 250 with PFP using TFE.  
Analysis of the crude reaction mixture of peptide 259 revealed a significant amount of 
Cys deletion by products. It was decided that this amino acid would be manually 
coupled using HATU in an attempt to improve the overall synthesis (Scheme 4.8). 
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Scheme 4.8: i) Automated SPPS synthesis of peptide 256 and ii) HATU manual coupling 
resulting in 257. 
The synthesis of peptide 257 was successful with a test from resin showing the desired 
material 1319.7 [M+H]+ had been synthesised (Figure 4.15). 
Figure 4.15: MS of crude peptide 257 with [M+H]+ 1319.7. 
 
 
 [M+H]+ 
 [M+2H]2+ 
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Peptide 257 was then used to synthesise the 30-mer Cys modified GLP-1 27 (Scheme 
4.9). The rest of the peptide sequence was continued using automated SPPS using 60 
min single couplings at rt + 10 min mW and double 60 min couplings at rt +10 min mW 
for the final 4 amino acids (His, Ala, Glu and Gly) (Scheme 4.9). 
 
Scheme 4.9: Automated SPPS synthesis of peptide 250 and cleavage of peptide from resin. 
The resulting peptide 250 (HAEGTFTSDVSSYLEGQAACEFIAWLVKGR-amide) 
was cleaved from resin as described in Section 6.3.5, analysed using MALDI-ToF and 
was found to contain the desired peak of 3274.0 [M+H]+, His deletion of m/z 3136.9 
aswell as the signal at m/z 3033.0 which corresponds to Cys and His deletion.   
Figure 4.16: MALDI-ToF of peptide 250 with desired m/z 3274.0.  
 
Desired Material  
H Deletion 
C and H Deletion 
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Due to the significant amount of His deletion product that was obtained, the target 
peptide was resynthesized using 0.5 mmol peptide 250 and the same coupling 
conditions as in the previous synthesis of peptide 245, except that the final His coupling 
was carried out manually using HATU as a coupling agent (Scheme 4.10). 
 
Scheme 4.10: i) Automated SPPS synthesis of peptide 262 and ii) HATU manual synthesis of 
Fmoc-His(Trt)-OH resulting in peptide 250.  
The resulting peptide 250 (HAEGTFTSDVSSYLEGQAACEFIAWLVKGR-amide) 
was cleaved from resin as described in Section 6.3.5, analysed using MALDI-ToF and 
the desired mass of m/z 3272.6 [M+H]+ (Figure 4.17).  
 
Figure 4.17: MALDI-ToF of peptide 250. 
F Deletion 
Desired Material 
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HPLC purification of the peptide 250 was carried out using the conditions described in 
Section 6.7.1 and the resulting purified peptide was analysed using MALDI-ToF 
(Figure 4.18). 
 
Figure 4.18: MALDI-ToF of purified peptide 250. 
Although the peak for the desired material m/z 3272.3 [M+H]+ was present in the 
MALDI-ToF (Figure 4.18), the purification of peptide 250 resulted in a significant loss 
of product. Therefore, the synthesis and purification of peptide 250 needs to be 
optimised in future to allow for viable amounts of peptide to be produced for future 
PEGylation studies. 
 
 
 
 
 
 
 
 
Desired Material 
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4.5 Enzymatic Degradation Studies 
With synthesis of the native GLP-1 245 and PFP-modified GLP-1 fragments 261 and 
260 carried out successfully, the stabilities of the peptides towards enzymatic 
degradation were investigated. The degradation of GLP-1 (245) in vivo is extremely 
rapid and is carried out primarily by DPPIV which cleaves the N-terminal amino acids 
of the sequence resulting in an extremely short half-life.16 For the enzymatic degradation 
studies the same reaction conditions that were used for the previous work on OT and VP 
(Section 3.3.2 and 3.3.3) were applied.  
A peptide solution in Tris buffer and enzyme solution of 1 mg/ml were made up and 
transferred to an eppendorf tube with a ratio of 25:1 (peptide: enzyme solution). The 
peptide/enzyme solution was incubated in a water bath for 24 h and aliquots removed 
every hour, which were analysed using analytical HPLC.  
Shown in Figure 4.19 are the analytical HPLC traces from the enzymatic degradation of 
native GLP-1 (HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-amide) using 
chymotrypsin. At t = 0, there is a single peak which corresponds to the peptide 245 
which has not undergone any degradation. Within 1 h, peptide 245 has been completely 
degraded to smaller fragments, the masses of which are shown in Table 4.5. Over the 
course of 24 h, there was no further degradation beyond the level seen for t = 1.  
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t=0 t=1  
t=2 t=3  
t=4 t=5  
t=6 t=24  
Figure 4.19: Analytical HPLC traces (220 nm) following the enzymatic degradation of native 
GLP-1 (245). Note - Analytical HPLC analysis was carried out for a total run time of 30 min but 
for formatting reasons only t = 5- 25 min are shown in the traces above.  
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Each analytical HPLC fraction underwent Q-ToF analysis and the results are given in 
Table 4.5. As can be seen at t = 0 the analytical HPLC trace showed a single peak 
which correspond to the intact peptide (e.g. masses of 1649.3 [M+2H]2+, 1099.2 
[M+3H]3+, 825.7 [M+4H]4+ and 600.1 [M+6H]6+ in the Q-ToF). After 1 h, 242 has 
underwent significant degradation which is observed in the Q-ToF with the presence of 
many deletion products (Entry 2). Most of these deletion products are small fragments 
which have been cleaved at or near an aromatic side chain such as the fragments with 
m/z 758.5 which has been cleaved at the Trp residue and 496.0 which has been cleaved 
at Trp and Phe residues (Table 4.5, Entry 2). This would be expected as chymotrypsin 
cleaves amide bonds at the carbonyl of an aromatic side chain. Over the course of 24 h 
there was no further degradation with the same masses observed in all samples.   
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Entry Time Mass (as 
observed in Q-
ToF) 
Structure 
1 t = 0 1649.3 [2M+H], 
1099.2 [3M+H], 
825.7 [4M+H], 
660.1[6M+H] 
HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-NH2 
2 t = 1 992.2, 777.8, 
758.5, 661.1, 
571.0, 496.0, 
496.5, 389.3 
YLEGQAAKE [992.2] 
TSDVSSY [777.8] 
WLVKG [758.5] 
HAEGTF [661.1] 
GQAAKEF [571.0] 
FIAW[496.0] 
HAEGT  [496.5] 
HAE [389.3] 
 
3 t = 2 Same as above Same as above 
4 t = 3 Same as above Same as above 
5 t = 4 Same as above Same as above 
6 t = 5 Same as above Same as above 
7 t = 6 Same as above - Same as above 
8 t = 24 Same as above Same as above 
Table 4.5: MS analysis of enzymatic degradation of compound 245.  
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Enzymatic degradation of the native GLP-1 245, as expected, was found to be quick and 
efficient with complete degradation of the peptide occurring within 1 h in this 
experiment. It was thought (based on the work in Chapter 3) that incorporation of the 
PFP tag into GLP-1 could increase the stability of the peptide. To test this theory, before 
committing to the tagging reaction of the full length Cys modified GLP-1 (250) (as this 
material was not available on a large scale-See Section 4.4) enzymatic degradation of 
the small peptide analogues 263 and 261 were tested. Peptide 263 was selected to act as 
a control in the stability study as it corresponds to the first 15 amino acids of native 
GLP-1. Peptide 261 is the single PFP-tagged GLP-1 analogue and was expected to have 
a positive effect on the stability of the peptide.  
 
Figure 4.20: 15-mer fragment of native GLP-1 acting as a control (263) and singular PFP-
tagged analogue (261). 
Figure 4.21 show the analytical HPLC traces of the peptide 263. This was carried out to 
act as a control to compare the stability to the PFP-modified peptide and determine if 
the incorporation of a singular PFP into the peptide could improve stability. 
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t=0 t=1  
t=2 t=3  
t=4 t=5  
t=6 t=24  
Figure 4.21: Analytical HPLC traces (220 nm) following the enzymatic degradation of peptide 
263. Note - Analytical HPLC analysis was carried out for a total run time of 30 min but for 
formatting reasons only t = 0-20 min are shown in the traces above.   
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Entry Time Mass observed Structure 
1 t = 0 1715.0 Ac-GQAAKEFIAWLVKGR [1715.0] 
2 t = 1 1163.3, 959.2, 777.4 Ac-GQAAKEFIAW [1163.3] 
Ac-GQAAKEFIA [959.2] 
Ac-GQAAKEF [777.4] 
3 t = 2 777.4, 644.0, 397.1, 
286.5 
Ac-GQAAKEF [777.4] 
Ac-GQAAKE [644.0] 
Ac-GQAA[397.1] 
 Ac-GQA [286.5] 
4 t = 3 Same as above Same as above 
5 t = 4 Same as above Same as above 
6 t = 5 Same as above Same as above 
7 t = 6 Same as above Same as above 
8 t = 24 Same as above Same as above 
Table 4.6: MS data of enzymatic degradation of peptide 263.  
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 At t = 0 there is more than one peak but the main peak present corresponds to the 
original peptide (263) 1715.0 [M+H]+. At t = 1 there has been significant degradation of 
the native peptide with the appearance of 1163.3. At t = 2 there has been complete 
degradation of the native peptide (263) to peptides with m/z 777.4, which is the 
fragmentation product relating to a small peptide fragments cleaved near the N-terminus 
(Table 4.6, Entry 3). Over the course of 24 h there is no further degradation from this 
fragment. Although the analytical HPLC trace at t = 0 suggests the peptide was not 
pure, it is reasonable to conclude that over the course of 2 h there has been complete 
degradation of the peptide m/z 1715.0 to smaller fragments.  
Figure 4.22 shows the analytical HPLC trace of the singular PFP tagged peptide 261. 
This was expected to be more stable to enzymatic degradation than the control peptide 
263.  
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t=0 t=1  
t=2 t=3  
t=4 t=5  
t=6 t=24
Figure 4.22: Analytical HPLC traces (220 nm) following the enzymatic degradation of peptide 
261. Note - Analytical HPLC analysis was carried out for a total run time of 30 min but for 
formatting reasons only t = 5-25 min are shown in the traces above.  
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From the analytical HPLC data, it is difficult to fully visualise any degradation that is 
occurring due to the poor absorbance of the samples. This is due to the small amount of 
peptide used in the experiment (0.1 mg of peptide used in this study whereas 1 mg used 
in the previous study (Figure 4.21). For a better understanding of any degradation, mass 
spectroscopy was carried out and the data are shown in Table 4.7.  
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Entry Time Mass observed Structure 
 1 t = 0 1839.1 [M+H]+ Ac-GQAAC(PFP)EFIAWLVKGR-NH2 
2 t = 1 1839.1, 1034.2, 
929.6, 845.7, 
518.0, 412.1, 
289.0 
Ac-GQAAC(PFP)EFIAWLVKGR-NH2 [1839.1] 
Ac-GQAAC(PFP)EFI [1034.2] 
Ac-GQAAC(PFP)EF [929.6] 
C(PFP)EF [518.0] 
C(PFP)EFIAW [845.7] 
C(PFP)E [412.1] 
Ac-GQA [289.0] 
3 t = 2 Same as above - 
4 t = 3 Same as above - 
5 t = 4 Same as above - 
6 t = 5 1034.2, 929.6, 
845.7, 518.0, 
412.1, 289.0 
Ac-GQAAC(PFP)EFI [1034.2] 
Ac-GQAAC(PFP)EF [929.6] 
C(PFP)EF [518.0] 
C(PFP)EFIAW [845.7] 
C(PFP)E [412.1] 
Ac-GQA [289.0] 
7 t = 6 Same as above - 
8 t = 24 Same as above - 
Table 4.7: Mass spectroscopy data of enzymatic degradation of peptide 261.   
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At t = 0 the main product observed in the LCMS is the [M+H]+ 1839.1 peptide 261 and 
over the course of 1 h significant degradation has occurred (Table 4.7, Entry 2). The 
main product observed at t = 1 is still 1839.1, but there are approximately 5 other side 
products all relating to smaller peptide fragments (with mass 1034.2, 929.6, 518.0, 
412.1 and 289.0) (Table 4.7, Entry 2). At t = 5 the main product becomes the peptide 
corresponding to mass 1034 which is a fragment corresponding to a loss of Arg, Gly, 
Lys, Val, Leu, Trp, Ala, Phe and Glu. At this point the peptide corresponding to mass 
1839.1 has been completely degraded (Table 4.7, Entry 6). As with the degradation of 
GLP-1, it appears the enzyme has cleaved the amide bonds at a number of aromatic side 
chain sites, which is what would be expected with using chymotrypsin as an enzyme.  
Enzymatic degradation of peptide 263 showed that the peptide was fully degraded to 
smaller fragments after 2 h of the experiment and peptide 261 was fully degraded after 5 
h. Comparing the stabilities of peptide 263 and peptide 261, it is reasonable to 
hypothesise that the modified peptide 261 is more stable to enzymatic breakdown, 
which would align with what was observed in Chapter 3. 
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4.6 Conclusions  
Synthesis of GLP-1(7-36) 245 was carried out using automated Fmoc SPPS and 
analysed using MALDI-ToF (Figure 4.10). Several different coupling conditions were 
adopted to optimise the synthesis of 245. The most problematic residues in the peptide 
synthesis proved to be the last 4 residues, with these deletion products reappearing in 
multiple syntheses. To overcome these synthetic problems, longer reaction times and 
double and triple couplings were adopted. The His residue at position 7 in the sequence 
proved the most difficult of all to attach to the peptide, even when manual coupling with 
HATU was carried out (Section 4.2). It is hypothesised this was due to the bulky Trt 
protecting group of the His and using a Boc protected His may allow for easier coupling 
of the final His amino acid in the future.  
Due to the poor stability of GLP-1 (245) in vivo, various efforts have been made by 
various research groups7,8,12 to improve the enzymatic stability of peptides. Based on 
our work in Chapter 3 we hypothesised that by attaching a singular PFP to a Cys-
modified GLP-1 (250), the enzymatic stability may be improved. To achieve this aim 
and develop the selective tagging chemistry a smaller 15-mer fragement of the Cys-
modified peptide (250) was synthesised and reaction conditions were optimised to 
achieve a singular tagging of PFP using TFE as a solvent (Section 4.3.1).  
Before committing to synthesis of the full Cys-modified GLP-1, the enzymatic stability 
of the smaller modified peptide fragment 261 was compared to the native peptide 263.   
 
Figure 4.23: Structure of control peptide 263 and PFP-tagged peptide 261. 
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It was found that the modified peptide 261 was more stable to enzymatic breakdown 
than the control peptide 263. For the enzymatic degradation of peptide 263, the peptide 
was fully degraded within 2 h (Figure 4.21). The PFP-tagged peptide 261 was found to 
be more stable as this was degraded over the course of 5 h (Figure 4.22). This provided 
confirmation that modifying a peptide at a singular site with PFP does improve 
enzymatic stability. We hypothesised that a similar effect may be observed with the full 
PFP-modified GLP-1, so efforts were made towards the synthesis of peptide 250 
(Section 4.4).  
Figure 4.24: Structure of peptide Cys-modofied GLP-1 (250). 
The synthesis of this peptide proved challenging (as was the native GLP-1) with a 
variety of coupling conditions being adopted. Eventually peptide 250 was successfully 
synthesised and purified, but not enough of the resulting peptide could be recovered to 
react further.  
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Chapter 5: Conclusions and Future Work 
The aim of this study was to investigate the role of perfluoro-heteraromatics in peptide 
modification and the effects of perfluoro-heteromatics on peptide stability. Small 
dipeptides have been successfully synthesised and modified using PFP (129) and the 
substitution pattern of PFP upon nucleophilic aromatic substitution with thiophenolate 
was investigated. Biologically active peptides OT, VP and GLP-1 were synthesised and 
modified using PFP and the stabilities of these modified peptides towards chymotrypsin 
tested and compared to the native peptides.  
We have successfully illustrated during this study that PFP (129) is an interesting and 
versatile tool for peptide modification. It is highly reactive towards nucleophilic side 
chains within a peptide and has been shown to react unselectively with Cys, Lys, Tyr 
residues (Scheme 5.1i), but can also react selectively with Cys residues by altering the 
reaction conditions (Scheme 5.1ii). By utilising protecting group chemistry it is also 
possible to selectively tag reactive side chain residues (Scheme 5.1iii).  
 
Scheme 5.1: i) Non-selective tagging of peptide substrates with PFP ii) Selective tagging of 
peptide substrates with PFP iii) Selective tagging of peptide with PFP.  
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Once peptides were synthesised and tagged using PFP, the stabilities of these peptides 
were tested and compared to the native peptides. It was determined that in all cases 
investigated in this study incorporation of the PFP resulted in an improvement of 
enzymatic stability compared to the native peptide (Section 3.3.2, 3.3.3 and 4.5). Even 
mono-tagged peptides were found to be stable to enzymatic stability which could prove 
a useful tool in improving the stabilities of peptides without losing biological activity.  
In Chapter 2, it was shown that it is possible to tag dipeptides with PFP and further 
functionalise these activated peptides via nucleophilic aromatic substitution reaction. In 
this study we used thiophenolate to functionalise the attached fluoropyridine ring. It was 
determined using 19F NMR spectroscopy that upon reaction of the PFP-tagged dipeptide 
with thiophenolate, that the nucleophile reacted at both the ortho and meta positions of 
the PFP ring resulting in a di-substituted peptide.    
Building on from this initial study, future work in this area could investigate using thio-
sugars or thio-PEG as a nucleophile to give access to modified peptides (Scheme 5.2)  
 
Scheme 5.2: Potential applications of PFP tagging- Aromatic substitution reaction between 
pentafluorpyridine tagged peptide 187 with i) thio-PEG (268) and ii) thio-sugar (269).  
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Using PFP as a scaffold could allow for the conjugation of thio-PEG or thio-sugars 
resulting in multiply tagged analogues. This could be beneficial over the singularly 
tagged analogues as it could lead to possibly further increased stability and solubility. 
Examples of multiply PEGylated peptides can be found in work examining branched 
PEG analogues. These analogues cause increased peptide stability due to an “umbrella 
effect”.1 
Examples of using small molecules as scaffolds in peptides can be found in the work of 
Liskamp and coworkers. Here, Liskamp and co-workers conjugated cyclic peptides to a 
small molecule scaffold in order to synthesise protein mimetics. They were able to build 
a library of protein surface epitope mimetics of HIV—gp120 using triazacyclophane as 
the scaffold and click chemistry to conjugate cyclic peptides to the scaffold (Scheme 
5.3).1 By conjugating the cyclic peptides to the small molecule scaffold, binding affinity 
to HIV CD4 cells was increased compared to the individual cyclic peptides or linear 
forms.1  
Scheme 5.3: Click reaction of triazacyslophane scaffold and cyclic peptides 1  
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In Chapter 3, PFP-modified peptides (220, 221, 222 and 223) were synthesised using 
Fmoc-SPPS and modified with PFP using on-resin and solution phase tagging.   
  
  
Figure 5.1: Structure of PFP-modified peptides PFP-OT (220), 2PFP-OT (221), PFP-VP (222) 
and 2PFP-VP (223).  
The in vitro stability of the PFP-tagged OT (220 and 221) and VP analogues (222 and 
223) were tested and provided promising results. In the case of the OT analogues, both 
PFP analogues were found to be more stable than the native OT and for VP the singly 
tagged peptide was found to be more stable than the native peptide (Section 3.3.2 and 
3.3.3).  Over the course of 24 h compounds 220 and 221 were degraded to the Gly 
deletion product, whereas native OT was fully degraded to small peptide fragments over 
the same course of time. A similar trend was observed with the VP PFP-tagged 
analogue (222) with significant improvement in peptide stability observed compared to 
the native peptide.  
Future work into the stability of these peptides will concentrate on analysing the in vivo 
stabilities of these analogues by using human serum stability studies. The method for 
these studies is much the same as the in vitro study, but mouse or human serum is used 
instead of chymotrypsin. This in vivo study would give an indication of the stability of 
the analogues in a biological system. 
203 
 
Future work in this area may also concentrate on obtaining crystal structures of the PFP-
tagged analogues and native OT and VP peptides. The 19F NMR and MS-MS data 
provide reasonable proof that the PFP-tagged analogues have the structure shown in 
Chapter 3, but crystal structures of these compounds would provide definitive proof of 
the structures of these compounds.  
In Chapter 4, we investigated the effect of PFP modification on a larger peptide, the 
30-residue peptide GLP-1 (245). The aim of this chapter was to tag a Cys-modified 
peptide (250) with PFP (129) and compare the stability of this peptide to native GLP-1 
(245). A small 15-mer fragment of the Cys-modified GLP-1 (261) was successfully 
synthesised and tagged using PFP and the stability of this peptide was compared to that 
of the 15-mer fragment of native GLP-1 (263). It was determined that the PFP-tagged 
peptide 261 exhibited reduced enzymatic degradation compared to the native peptide 
263 (Section 4.5). 
 
Figure 5.2: Structure of singularly PFP-tagged peptide 261 and the corresponding native GLP-1 
fragment 263. 
Future work in this area of research should continue to try and firstly optimise the 
synthesis of peptide 250, which was attempted in Section 4.3.  The selective tagging 
conditions investigated in the tagging of the 15-mer GLP-1 fragment (Section 4.3.1) 
should also be adopted to selectively tag at the Cys residue to give peptide 251.  
204 
 
Scheme 5.5: Selective tagging of Cys of peptide 250 with PFP and further modification with 
PEG resulting in a PEGylated GLP-1 analogue 252. 
The stability of this peptide 251 compared to native GLP-1 245 should be investigated 
as promising results were observed when smaller fragments of GLP-1 263 and PFP-
tagged peptide 261 were compared (Section 4.5). The possible modification of peptide 
251 via the PFP moiety with PEG should also be investigated and stability tested 
(Scheme 5.5).  
Possible synthetic strategies that may be adopted in the future for the synthesis of the 
single tagged peptide 251 could concentrate on incorporating PFP-tagged amino acids 
into the peptide during the synthesis. An Fmoc-protected PFP-tagged Cys amino acid 
could be synthesised and manually coupled in the same position as peptide 250 
(Scheme 5.6). 
 
Scheme 5.6: Synthesis of peptide 251 utilising automated and manual SPPS conditions.  
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If the stability of the single tagged peptide 251 is not significantly better than native 
GLP-1 245, there are other analogues which could be synthesised, and their stabilities 
tested. By adopting non-selective tagging conditions (as discussed in Section 4.3.1), it 
should be possible to tag GLP-1 at multiple nucleophilic sites (Scheme 5.7). Using non-
selective tagging to react PFP at Tyr, Ser, Lys and Cys residues may result in a peptide 
more stable to enzymatic degradation, but possibly less biologically active due to 
modification at multiple sites.  
Scheme 5.7: Non-selective tagging of peptide 247 with PFP.  
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Chapter 6: Experimental Details and Characterisation  
6.1 General Procedures 
All reagents were purchased from Sigma-Aldrich unless stated otherwise. Peptide 
synthesis grade DMF was purchased from Fisher Scientific and amino acids purchased 
from Novabiochem(Merck) or Iris Biotech. PyBOP® was purchased from Apollo 
Scientific (Stockport, UK) and resins purchased from Novabiochem. The general 
procedure for Fmoc SPPS synthesis is detailed in the following sections. All reactions 
were carried out in fritted polypropylene reaction vessels and DMF used as a solvent. 
The amino acids were protected in the following manner, Fmoc-Thr(OtBu)-OH, Fmoc-
Arg(Pbf)-Oh, Fmoc-Ser(OtBu)-OH Fmoc-Cys(Trt)-OH, Fmoc-Cys(Acm)-OH, Fmoc-
His(Trt)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Trp(Pbf)-OH, Fmoc-
Asp(OtBu) and  Fmoc-Lys(Boc)-OH.  
6.2 Analytical Equipment and Methods 
6.2.1 Analytical liquid chromatography mass spectroscopy (LCMS) 
Analytical LCMS was carried out using an Acquity UPLC system (Waters Ltd, UK) 
with a photodiode array detector. Samples were injected onto an Acquity UPLC BEH 
C8 column and a gradient of 5–95% B (solvent A = H2O, 0.1% TFA; B = MeCN, 0.1% 
TFA) a flow rate of 0.6 ml/min. The solvent flow of the UPLC system was introduced 
into the electrospray ion source of an Aquity TQD mass spectrometer. 
6.2.2 Q-ToF 
Q-ToF MS was carried out using a QtoF Premier MS with Acquity UPLC system 
(Waters Ltd, UK). The sample was injected into a 0.2 ml/min flow of MeCN which was 
introduced via electrospray ion source. 
6.2.3 Matrixassisted laser desorption/ionization time of flight mass spectrometry 
(MALDI-TOF MS) 
MALDI-TOF mass analysis was carried out using an Autoflex II ToF/ToF mass 
spectrometer (Bruker Daltonik GmBH) with a 337 nm nitrogen laser. Peptides were 
dissolved in deionized H2O/MeCN for analysis. Sample solution (1 mg/ml) was mixed 
with matrix solution (cyano-4-hydroxycinnamic acid, 50 mg/mL) in a ratio of 1:9. MS 
data was processed using FlexAnalysis 2.0 (Bruker Daltonik GmBH). 
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6.2.4 Nuclear Magnetic Resonance (NMR) Spectroscopy 
NMR spectra were carried out using Bruker Avance 400 MHz. Multiplicities s= singlet, 
d= doublet, dd= doublet of doublets, t= triplet, quint= quintet, m= multiplet. NMR 
solvent peaks: CDCl3 (
1H NMR 7.26 ppm, 13C NMR 77.0 ppm), CD3CN (
1H NMR 1.94 
ppm, 13C NMR 1.3, 118.3 ppm) and D2O (
1H NMR 4.79 ppm).   
6.3 Automated Solid Phase Peptide Synthesis 
6.3.1 Amino Acid Loading 
Loading of the intial amino acid onto the resin was carried out in a fritted polypropylene 
reaction chamber. For every 0.1 mmol of resin, 2 ml of DMF was used for resin 
swelling. After 2 h, DMF was removed and coupling/deprotection steps continued.  
6.3.2 Automated SPPS   
Automated SPPS was carried using a CEM Liberty1 microwave peptide synthesizer 
with Discover microwave unit. All reactions were carried out using a 30 ml PTFE 
reaction vessel, with microwave heating and agitation carried out via nitrogen gas. 
Couplings were carried out using Fmoc-protected amino acid (5 eq), activator (10 eq) 
and DIPEA (20 eq). For double and triple couplings, the reaction vessel was drained 
after each cycle and fresh reagents were added. 
6.3.4 Peptide Couplings 
Peptide couplings were carried out at rt for 30 min followed by 10 min microwave 
assisted at 75 °C and 25 W power. Arginine residues were double coupled, with 30 min 
at rt and 10 min at 75 °C. Leucine couplings were carried at rt for 60 min with 10 min at 
75 °C. Removal of the Fmoc group was carried out using a solution of 20% piperidine 
in DMF for 5 + 10 min. 
6.3.5 Resin Cleavage 
Peptide-resin was incubated with a cleavage cocktail of TFA 95%, H2O 2.5% and TIPS 
2.5% for 4 h at rt. The resin was removed by filtration and the solvent removed under 
reduced pressure before precipitation using ether and decanting of the liquid. The 
resulting solid peptide was dissolved in deionized water and lyophilized.  
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6.4 Manual Solid Phase Peptide Synthesis Procedure 
6.4.1 Peptide Coupling 
Single couplings were carried out using 5 eq of amino acid (compared to resin), 5 eq of 
PyBOP®, 10 eq of DIPEA and 2 ml of DMF under agitation for 1 h. Unless stated 
otherwise, double peptide couplings were carried out: 2 × 1 h couplings for each residue 
and reaction drained after each coupling and fresh reagent added. After each amino acid 
coupling, the reaction solution was drained, and resin washed with 5 × 2 ml DMF. 
Removal of the Fmoc group was carried out using a solution of 20% piperidine in DMF 
for 5 + 10 min under agitation. Piperidine solution was drained and resin rinsed using 5 
× 2 ml of DMF.  
6.4.2 HATU Peptide Coupling 
Single couplings were carried out using 5 eq of amino acid (compared to resin), 5 eq of 
HATU, 10 equivalents of DIPEA and 2 ml of DMF under agitation for 1 h. Unless 
stated otherwise, double peptide couplings were carried out: 2 × 1 h couplings for each 
residue and the reaction drained after each coupling and fresh reagent added. After each 
set of coupling reactions, the reaction solution drained, and resin washed with 5 × 2 ml 
portions of DMF. Removal of the Fmoc group was carried out using a solution of 20% 
piperidine in DMF for 5 + 10 min under agitation. Piperidine solution was drained and 
resin rinsed using 5 × 2 ml of DMF. 
6.4.3 Resin Cleavage 
Peptide-resin was incubated with a cleavage cocktail of TFA 95%, H2O 2.5% and TIPS 
2.5% for 4 h at rt. The resin was removed by filtration and the solvent removed under 
reduced pressure before precipitation using ether and decanting of the liquid. The 
resulting solid peptide was dissolved in deionized water and lyophilized.   
6.4.4 Acm protecting group removal 
Solid peptide was dissolved in 0.5 ml of 40% AcOH/DMF solution in an Eppendorf 
tube. To the peptide solution solid iodine (25 eq) was added and left under agitation at 
rt. After 45 min, 1M ascorbic acid solution was added dropwise until the reaction 
mixture turned colourless.  The peptide was fully dissolved in MeCN/H2O to a total 
volume of 2.0 ml for purification and analysis.  
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6.5 Tagging Reactions 
6.5.1 Selective Solution Phase Tagging Reaction  
Solid peptide was dissolved in TFE (0.5 ml) in a 1.5 ml plastic Eppendorf tube, to 
which DIPEA (2.5 eq) was added. Pentafluoropyridine (10 eq) was added and the tube 
was shaken at rt for 4.5 h. After removal of volatiles under reduced pressure, the sample 
was dissolved in a 1:1 mixture of H2O/MeCN (1 ml) and analysed by Q-ToF-MS. 
6.5.2 Non-Selective Solution Phase Tagging Reaction  
Solid peptide was dissolved in DMF (0.5 ml) in a 1.5 ml plastic Eppendorf tube, to 
which DIPEA (2.5 eq) was added. Pentafluoropyridine (10 eq) was added and the tube 
was shaken at rt for 4.5 h. After removal of volatiles under reduced pressure, sample 
dissolved in a 1:1 mixture of H2O/MeCN (1 ml) and analysed by Q-ToF-MS. 
6.5.3 On-resin Tagging Reaction 
Peptide-resin was treated with DMF (2 ml), DIPEA (2.5 eq) and PFP (10 eq) for 4.5 h 
under agitation. After 4.5 h, the peptide-resin was filtered from reaction solution and 
rinsed with DMF (5 × 2 ml).  
6.6 Displacement Reactions 
To a solution of tagged peptide in MeCN (0.5 ml) and water (0.5 ml) in a 1.5 ml plastic 
Eppendorf tube, DIPEA (2.5 eq) was added. Sulphur nucleophiles were added (5 eq) 
and the tube shaken at rt for 4 h. After removal of volatiles under reduced pressure, each 
reaction mixture dissolved in a mixture of H2O/MeCN (1 ml) and analysed by Q-ToF-
MS. 
6.7 Purification  
6.7.1 Preparative High-Pressure Liquid Chromatography 
Samples were dissolved in H2O/MeCN mix, centrifuged and injected onto a Speck and 
Burke Analytical C18 Column. Purification of peptides was carried out using Perkin 
Elmer Series 200 LC pump and 785A UV/Vis detector. A gradient of 0-100% solvent B 
(solvent A= 95% H2O, 5% MeCN, 0.1% TFA, solvent B = 95% MeCN, 5% H2O, 0.1% 
TFA) with a flow rate of 2.0 ml/min was used and absorbance data collected at 220 nm, 
unless stated otherwise.  
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6.7.2 Analytical High-Pressure Liquid Chromatography 
Samples (10 µl) were injected onto a Waters XBridge BEH C18 Column using a Perkin 
Elmer Series 200 Autmosampler and Perkin Elmer Series 200 LC Pump and detected 
using a Series 200 UV/Vis detector.  A gradient of 0-100% solvent B (solvent A= 95% 
H2O, 5% MeCN, 0.05% TFA, solvent B = 95% MeCN, 5% H2O, 0.03% TFA) with a 
flow rate of 1 ml/min was used and absorbance data collected at 220 nm and processed 
using TotalChem software.  
6.8 Stability Testing 
Peptide was dissolved in Tris buffer (pH 7.6) resulting in a solution with a concentration 
of 1 mg/ml in a 0.5 ml Eppendorf tube. α-Chymotryspin from bovine pancreas was 
dissolved in Tris buffer (pH 7.6) to a concentration of 1 mg/ml and added to the peptide 
solution so that the resulting ratio of peptide to enzyme solution is 10:1. The Eppendorf 
was incubated at 23 °C using a Clifton NE5 Series Water Bath and 10 µl aliquots 
removed at t = 0, 1, 2, 3, 4, 5, 6 and 24 h.  To each 10 µl aliquot, 30% TFA/MeCN 
solution was added and injected onto a Waters XBridge BEH C18 Column using a 
Perkin Elmer Series 200 Autosampler and Perkin Elmer Series 200 LC Pump and 
detected using a Series 200 UV/Vis detector.  A gradient of 0-100% solvent B (solvent 
A= 95% H2O, 5% MeCN, 0.05% TFA, solvent B = 95% MeCN, 5% H2O, 0.03% TFA) 
over 30 min with a flow rate of 1 ml/min was used and absorbance data collected at 280 
nm and processed using TotalChem software.  
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6.9 Synthesis of Dipeptide Analogues 
6.9.1 Fmoc-Cys(Trt)-Ala-OMe (175) 
L-Alanine methyl ester hydrochloride (200 mg, 1.44 mmol) 
was dissolved in DCM (30 ml). Fmoc-L-Cys(trt)-OH (842 
mg, 1.44 mmol) and PyBOP (749 mg, 1.44 mmol) were 
added and stirred. NMM (0.37 ml, 4.32 mmol) was added 
drop-wise and the reaction mixture stirred at rt for 18 h. 
After 18 h, DCM was removed under reduced pressure and 
the resulting yellow oil purified via column chromatography 
to yield 175 as a white solid (816 mg, 84%). δH (400 MHz, CDCl3) 1.37 (d, 3H, J = 8.0 
Hz), 2.75 (dd, 2H, J = 8.0 Hz, 12.0 Hz), 3.72 (s, 3H), 4.20 (t, 1H, J = 8.0 Hz), 4.51 (q, 
1H, J = 8.0 Hz), 7.22- 7.77 (m, 28H). δC (100 MHz, CDCl3) 18.2, 47.0, 48.2, 52.4, 67.3, 
199.9, 125.0, 127.0, 128.1, 129.6, 141.3, 143.6, 144.3, 169.5, 172.7. LCMS found m/z 
692.1 [M+Na]+, calcd 670.2 [M+H]+ Experimental data agrees with literature data.1 
 
6.9.2 Ac-Cys(Trt)-Ala-OMe (177) 
Fmoc protected dipeptide (335 mg, 0.5 mmol) was dissolved 
in THF (7.5 ml) at rt and under argon. Piperidine (1.5 ml) was 
added and the reaction was run for 3 h at rt and under argon.  
The reaction was traced by TLC. Once the reaction had 
reached completion solvent was removed under reduced 
pressure to yield an off-white solid.  
This crude deprotected dipeptide was directly used in the next stage of the synthesis and 
was dissolved in DCM (7.5 ml) and cooled to 0 °C. Tritheylamine (0.08 ml, 0.55 mmol) 
and acetyl chloride (0.04 ml, 0.5 mmol) were added and the reaction mixture warmed to 
rt and stirred for 1 h under argon. The reaction was monitored by TLC and once it had 
reached completion solvent was removed to yield 177 an off-white solid. 
The crude product was purified via column chromatography (100% EtOAc to 10% 
MeOH in EtOAc). NMR of the collected fractions was carried out and it was 
determined the desired material 177 was present (207 mg, 0.42 mmol, 85%). δH (400 
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MHz, CDCl3)  1.41 (d, 3H, J = 8.0 Hz), 2.10 (s, 3H), 2.97-3.14 (m 2H), 3.27 (s, 3H), 
3.56 (t, 1H, J = 4.0 Hz), 3.95 (q, 1H, J = 8.0 Hz), 6.21 (s, 1H), 7.23-7.79 (m, 14H), δC 
(100 MHz, CDCl3) 14.2, 19.7, 24.4, 35.4, 50.7, 53.1, 67.5, 127.1, 128.2, 129.5, 142.1, 
166.5, 167.9. LCMS mass: found m/z 491.1 [M+H], calcd 490.1 [M+H]+ 
 
6.9.3 Ac-Cys-Ala-NH2 (180) 
Compound 180 was synthesised via manual Fmoc-SPPS at rt 
on a 0.3 mmol scale (according to Section 6.4.1) on RINK 
amide resin (0.82 mg/mmol loading). All couplings were 
double couplings and carried out using 5 eq of amino acid. 
Capping and cleavage of peptide from the resin was carried out following the procedure 
detailed in Section 6.4.3. 1H NMR δH (400 MHz, CD3CN) 1.34 (d, 3H, J = 4.0 Hz, 
CH3), 1.97 (s, 3H, CH3), 3.77 (d, 2H, J = 4.0 Hz, CH2), 4.29- 4.40 (m, 1H, H-𝛼), 4.44-
4.74 (m, 1H, H-𝛼), LCMS mass: found m/z [M+Na]+ 256.1.  
 
6.9.4 Ac-Pen-Ala-NH2 (183) 
Compound 183 was synthesised via manual Fmoc-SPPS at 
rt on a 0.2 mmol scale (according to Section 6.4.1) on 
RINK amide resin (0.82 mg/mmol loading). All couplings 
were double couplings and carried out using 5 eq of amino 
acid. Capping and cleavage of peptide from the resin was 
carried out following the procedure detailed in Section 6.4.3. 1H NMR δH (400 MHz, 
CD3CN) 1.31 (d, 3H, J = 4.0 Hz, CH3), 1.36 (s, 6H, CH3 ×2), 2.01 (s, 3H, CH3), 4.25-
4.37 (m, 1H, H-𝛼), 4.43- 4.58 (m, 1H, H-𝛼), LCMS mass: found m/z [M+H]+ 262.8. 
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6.9.5 Ac-hCys-Ala-NH2 (186) 
Compound 186 was synthesised via manual Fmoc-SPPS at rt 
on a 0.2 mmol scale (according to Section 6.4.1) on RINK 
amide resin (0.82 mg/mmol loading). All couplings were 
double couplings and carried out using 5 eq of amino acid. 
Capping and cleavage of peptide from the resin was carried 
out following the procedure detailed in Section 6.4.3. 1H 
NMR δH (400 MHz, CD3CN) 1.33 (d, 3H, J = 4.0 Hz, CH3), 1.97 (s, 3H, CH3), 2.12-
2.15 (m, 2H, CH2), 2.55- 2.61 (m, 2H, CH2), 4.23- 4.37 (m, 2H, H-𝛼), LCMS mass: 
found m/z [M+H]+ 248.0. 
 
6.9.6 Ac-Cys(PFP)-Ala-NH2 (187) 
Compound 187 was synthesised using the reaction conditions 
described in Section 6.5.2 using 192 mg of 177. The resulting 
crude material was purified using column chromatography to 
yield  187 as a white solid (62 mg, 20%)  δH (400 MHz, 
CD3CN) 1.30 (dd, 3H, J = 7.1, 2.9 Hz, CH3), 1.91 (d, 3H, J = 
4.2 Hz, CH3), 3.69- 3.40 (m, 2H, CH2), 4.27- 4.14 (m, 1H, H-
𝛼),  4.53 (td, 1H, J = 7.8, 5.2 Hz, H-𝛼), 6.34 (s, 1H, NH), 6.90 (s, 1H, NH),  δC (100 
MHz, CD3CN) 17.3, 21.9, 34.5, 48.9, 48.9, 53.0, 117.3, 168.9, 170.4, 173.5, 175.3, δF 
(376 MHz, CD3CN) -94.0 (ddd, 1F, J = 7.5 Hz, 15.0 Hz, 30.0 Hz), -94.1 (ddd, 1F, J = 
7.5 Hz, 15.0 Hz, 30.0 Hz), -137.9 (ddd, 1F, J = 7.5 Hz, 11.2 Hz, 26.3 Hz), -138.0 (ddd, 
1F, J = 7.5 Hz, 11.2 Hz, 26.3 Hz). Acc Mass: found m/z [M+H]+ 383.0815, calcd 
383.0801. 
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6.9.7 Ac-Pen(PFP)-Ala-NH2 (190) 
Compound 190 was synthesised using the reaction conditions 
described in Section 6.5.2 using 125 mg of 183. The resulting 
crude material was purified using column chromatography to 
yield 190 as a white solid (23 mg, 13%) δH (400 MHz, 
CD3CN) 1.37 (d, 3H, J = 8.0 Hz, CH3), 1.43 (s, 3H, CH3), 1.49 
(s, 3H, CH3), 2.02 (s, 3H, CH3), 4.29 (q, 1H, J = 8.0 Hz, H-𝛼), 
4.53 (s, 1H, H-𝛼). 5.94 (s, 1H, NH), 6.49 (s, 1H, NH), δC (100 
MHz, CD3CN) 17.4, 24.3, 24.5, 24.9, 46.5, 50.2, 57.6, 142.2, 154.3, 169.8, 175.2, δF 
(376 MHz, CD3CN)  -92.6 (ddd, 1F, J = 7.5 Hz, 15.0 Hz, 33.5 Hz), -92.7 (ddd, 1F, J = 
7.5 Hz, 15.0 Hz, 33.5 Hz) -132.7 (ddd, 1F, J = 7.5 Hz, 15.0 Hz, 33.5 Hz) -132.9 (ddd, 
1F, J = 7.5 Hz, 15.0 Hz, 33.5 Hz), Acc Mass: found m/z [M+H]+  411.1100, calcd 
411.1103. 
 
6.9.8 Ac-hCys(PFP)-Ala-NH2 (191) 
Compound 191 was synthesised using the reaction conditions 
described in Section 6.5.2 on a using 143 mg of 186. The 
resulting crude material was purified using column 
chromatography to yield 191 as a white solid (46 mg, 20%) δH 
(400 MHz, CD3CN), 1.30 (d, 3H, J = 8.0 Hz, CH3), 1.95 (s, 
1H, CH3), 2.14 (q, 2H,  J = 8.0 Hz, CH2), 3.25-3.43 (m, 2H, 
CH2), 4.25 (t, 1H, J = 8.0 Hz, H-𝛼), 4.34-4.74 (m, 1H, H-𝛼), 
6.52 (s, 1H, NH), 6.92 (d, 1H, J = 4.0 Hz, NH), δC (100 MHz, CD3CN) 17.0, 22.0, 29.6, 
31.9, 48.8, 52.5, 170.6, 171.3, 174.7 δF (376 MHz, CD3CN) -94.1 (ddd, 1F, J = 7.5 Hz, 
15.0 Hz, 30.0 Hz), -94.3 (ddd, 1F, J = 7.5 Hz, 15.0 Hz, 30.0 Hz), -139.1 (ddd, 1F, J = 
7.5 Hz, 11.2 Hz, 30.0 Hz), -139.2 (ddd, 1F, J = 7.5 Hz, 11.2 Hz, 30.0 Hz), Acc Mass: 
found m/z [M+H]+  397.0948, calcd 397.0958. 
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6.9.9 Ac-Cys(SPh)-Ala-NH2 (194) 
Compound 194 was synthesised using the reaction 
conditions described in Section 6.6  on a using 10 mg of 187 
and purified using preparative TLC plates using solvent 
system EtOAc:MeOH 9:1 to yield 194 as a white solid (8 
mg, 13%); δH (400 MHz, CD3CN) 1.30 (d, 3H, J = 4.0 Hz, 
CH3), 1.92 (s, 3H, CH3), 3.43 (dd, 1H, J = 8.0, 12.0 Hz, 
CH2), 3.64 (dd, 1H, J  = 4.0 Hz, 16.0 Hz, CH2), 4.20- 4.42 (m, 1H, H-𝛼), 4.55- 4.62 (m, 
1H, H-𝛼), 6.42 (s, 1H, NH), 7.04- 7.75 (m, 5H, CH-aromatic), δC (100 MHz, CD3CN) 
17.3, 21.9, 34.8, 48.9, 53.0, 127.56, 127.9, 128.0, 129.3, 129.4, 129.5, 135.2, 168.9, 
170.4, 173.9; Acc Mass: found m/z [M+H]+ 310.1233, calcd 310.1232 
 
6.9.10 Ac-Cys(SPh)2-Ala-NH2 (206) 
Compound 206 was synthesised using the reaction 
conditions described in Section 6.6 on a using 10 mg of 187 
and purified using preparative TLC plates using solvent 
system EtOAc:MeOH 9:1 to yield 206 as a white solid (0.8 
mg, 4%); δH (400 MHz, CD3CN) 1.27 (d, 3H, J = 4.0 Hz, 
CH3), 1.88 (s, 3H, CH3), 3.50 (dd, 1H, J = 4.0 Hz, 8.0 Hz, 
CH2), 3.61 (dd, 1H, J = 4.0 Hz, 8.0 Hz, CH2) 4.20 (q, 1H, J 
= 4.0 Hz, H-𝛼), 4.45 (dd, 1H, J = 4.0 Hz, 8.0 Hz, H-𝛼), 7.15- 7.58 (m, 10H, CH-
aromatic), δF (376 MHz, CD3CN) -66.5 (d, 1F, J = 26.0 Hz), -199.4 (d, 1F, J = 30.0 Hz)  
Acc Mass: found m/z [M+H]+ 563.1064, calcd 563.1079. 
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6.9.11 Ac-Pen(SPh)2-Ala-NH2 (207) 
Compound 207 was synthesised using the reaction 
conditions described in Section 6.6 using 10 mg of 190 and 
purified using preparative TLC plates using solvent system 
EtOAc:MeOH 9:1 to yield 207 as a white solid (4 mg, 
33.5%); δH (400 MHz, CD3CN) 1.30 (s, 6H, CH3), 1.46 (s, 
3H, CH3), 1.95 (s, 3H, CH3), 4.25 (q, 1H, J = 8.0 Hz, H-𝛼), 
4.50 (d, 1H, J = 8.0 Hz, H-𝛼), 7.08 (d, 1H, J = 4.0 Hz, NH), 7.16- 7.59 (m, 10H, CH-
aromatic), 7.80 (d, 1H, J = 4.0 Hz, NH), δC (100 MHz, CD3CN) 16.9, 22.0, 48.9, 60.0, 
127.0, 127.6, 128.0, 129.1, 129.4, 129.6, 129.9, 135.2, 168.9, 171.9, 175.5, δF (376 
MHz, CD3CN) -62.9 (d, 1F, J = 30.0 Hz), -110.8 (d, 1F, J = 26.0 Hz),  Acc Mass: found 
m/z [M+H]+ 591.1373, calcd 591.1370. 
 
6.9.12 Ac-hCys(SPh)2-Ala-NH2 (208) 
Compound 208 was synthesised using the reaction conditions 
described in Section 6.6 on a using 10 mg of 191 and purified 
using preparative TLC plates using solvent system 
EtOAc:MeOH 9:1 to yield 208 as a white solid (3 mg, 20%); 
δH (400 MHz, CD3CN) 1.30 (d, 3H, J = 8.0 Hz, CH3), 1.94 (s, 
3H, CH3), 3.19 (t, 2H, J = 8.0 Hz, CH2), 4.22 (q, 1H, J = 4.0 
Hz, H-𝛼), 4.29 (dd, 1H, J = 4.0 Hz, 8.0 Hz, H-𝛼), 7.15- 7.58 (m, 10H, CH-aromatic), δC 
(100 MHz, CD3CN) 17.0, 21.9, 48.9, 52.6, 129.9, 127.8, 129.5, 129.6, 129.9, 135.9,  δF 
(376 MHz, CD3CN) -66.9 (d, 1F, J = 30.0 Hz), -121.1 (d, 1F, J = 26.0 Hz), Acc Mass: 
found m/z [M+H]+ 577.1229, calcd 577.1202. 
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6.10 Synthesis of Native OT and VP and PFP-tagged OT and VP analogues 
6.10.1 Peptide 209 
Sequence CYIQNCPLG-NH2 was synthesised 
via manual Fmoc-SPPS at rt on a 0.1 mmol scale 
on RINK amide resin (0.82 mg/mmol loading). 
Amino acids CYIQNCPLG were coupled using 
60 min single couplings using the reaction 
condition described in Section 6.4.1. Cleavage 
of peptide from the resin and removal of the 
Acm group/cyclisation were carried out according to Section 6.4.3 and 6.4.4.  Accurate 
mass: found m/z 1007.4471 [M+H]+, calcd 1006.4365, analytical HPLC retention time 
10.9 min. Analytical HPLC 100% solvent A-100% solvent B gradient over 20 min, 
observed at 220 nm. 
 
6.10.2 Peptide 220 
Sequence (PFP)CYIQNCPLG-NH2 was 
synthesised via manual Fmoc-SPPS at rt on a 
0.1 mmol scale on RINK amide resin (0.82 
mg/mmol loading). Amino acids CYIQNCPLG 
were coupled using 60 min single couplings 
using the reaction condition described in 
Section 6.4.1.  Tagging of the peptide on resin was carried out using the reaction 
conditions described in Section 6.5.3. Cleavage of peptide from the resin and removal 
of the Acm group/cyclisation were carried out according to Section 6.4.3 and 6.4.4. δF 
(376 MHz, CD3CN) -96.2 (m, 2F), -161.9 (m, 2F), Accurate mass: found m/z 1156.4331 
[M+H]+, calcd 1155.4253, analytical HPLC retention time 15.5 min. Analytical HPLC 
100% solvent A-100% solvent B gradient over 20 min, observed at 220 nm. 
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6.10.3 Peptide 221 
Sequence (PFP)CY(PFP)IQNCPLG-NH2 
was synthesised via manual Fmoc-SPPS at rt 
on a 0.1 mmol scale on RINK amide resin 
(0.82 mg/mmol loading). Amino acids 
CYIQNCPLG were coupled using 60 min 
single couplings using the reaction condition 
described in Section 6.4.1.  Tagging of the 
peptide in solution was carried out using the reaction conditions described in Section 
6.5.2. Cleavage of peptide from the resin and removal of the Acm group/cyclisation 
were carried out according to Section 6.4.3 and 6.4.4. δF (376 MHz, CD3CN) -91.4 (m, 
2F), -96.3 (m, 2F), -156.0 (m, 2F), -161.9 (m, 2F), Accurate mass: found m/z 1305.4235  
[M+H]+, calcd 1304.4124, analytical HPLC retention time 20.4 min. Analytical HPLC 
100% solvent A-100% solvent B gradient over 20 min, observed at 220 nm. 
 
6.10.4 Peptide 210 
Sequence CYFQNCPRG-NH2 was 
synthesised was synthesised via manual Fmoc-
SPPS at rt on a 0.1 mmol scale on RINK amide 
resin (0.82 mg/mmol loading). Amino acids 
CYFQNCPRG were coupled using 60 min 
single couplings using the reaction condition 
described in Section 6.4.1. Cleavage of peptide 
from the resin and removal of the Acm group/cyclisation were carried out according to 
Section 6.4.3 and 6.4.4.  Accurate mass: found m/z 1084.4453 [M+H]+, calcd 
1084.2390, analytical HPLC retention time 9.8 min. Analytical HPLC 100% solvent A-
100% solvent B gradient over 20 min, observed at 220 nm. 
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6.10.5 Peptide 222 
Sequence (PFP)CYFQNCPRG-NH2 was 
synthesised via manual Fmoc-SPPS at rt on 
a 0.1 mmol scale on RINK amide resin 
(0.82 mg/mmol loading). Amino acids 
CYFQNCPRG were coupled using 60 min 
single couplings using the reaction 
condition described in Section 6.4.1.  
Tagging of the peptide on resin was carried 
out using the reaction conditions described in Section 6.5.3. Cleavage of peptide from 
the resin and removal of the Acm group/cyclisation were carried out according to 
Section 6.4.3 and 6.4.4. δF (376 MHz, CD3CN) -96.2 (m, 2F), -191.9 (m, 2F), Accurate 
mass: found m/z 1233.4437 [M+H]+, calcd 1232.4267, analytical HPLC retention time 
14.5 min. Analytical HPLC 100% solvent A-100% solvent B gradient over 20 min, 
observed at 220 nm. 
 
6.10.6 Peptide 223 
Sequence (PFP)CY(PFP)FQNCPRG-
NH2 was synthesised via manual Fmoc-
SPPS at rt on a 0.1 mmol scale on RINK 
amide resin (0.82 mg/mmol loading). 
Amino acids CYFQNCPRG were 
coupled using 60 min single couplings 
using the reaction condition described in 
Section 6.4.1.  Tagging of the peptide in 
solution was carried out using the reaction conditions described in Section 6.5.2. 
Cleavage of peptide from the resin and removal of the Acm group/cyclisation were 
carried out according to Section 6.4.3 and 6.4.4. δF (376 MHz, CD3CN) -91.3 (m, 2F), -
96.2 (m, 2F), -155.9 (m, 2F), -161.9 (m, 2F), Accurate mass: found m/z 1381.4156 
[M+H]+, calcd 1382.4240, analytical HPLC retention time 19.1 min. Analytical HPLC 
100% solvent A-100% solvent B gradient over 20 min, observed at 220 nm. 
220 
 
6.11 Synthesis of GLP-1 and GLP-1 analogues 
6.11.1 Peptide 245 
 
Sequence HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-NH2 was synthesised via 
automated Fmoc-SPPS at rt on a 0.05 mmol scale (according to Section 6.3) on RINK 
Amide resin (0.82 mg/mmol loading). Amino acids EFIAWLVKGR were coupled 
using 30 min single couplings + 10 min mW, amino acids TFTSDVSSYLEGQAAK 
were coupled using 60 min single couplings + 10 min mW and amino acids HAEG were 
coupled using double 60 min couplings + 10 min mW. Cleavage of peptide from the 
resin was carried out following the procedure detailed in Section 6.3.5 and the peptide 
purified using preparative HPLC as described in Section 6.7.1. MALDI-ToF mas: 
found m/z 3296.4 [M+H]+ analytical HPLC retention time 16.1 min. Analytical HPLC 
100% solvent A- 100% solvent B gradient over 20 min, observed at 220 nm. 
 
6.11.2 Peptide 259 
 
Sequence GQAACEFIAWLVKGR-NH2 was synthesised via automated Fmoc-SPPS 
at rt on a 0.1 mmol scale (according to Section 6.3) on RINK Amide resin (0.82 
mg/mmol loading). Amino acids GQAAEFIAWLVKGR were coupled using 30 min 
single couplings + 10 min mW. For the coupling of C, HATU manual coupling 
conditions were adopted according to Section 6.4.2. Cleavage of peptide from the resin 
was carried out following the procedure detailed in Section 6.3.5 and the peptide 
purified using preparative HPLC as described in Section 6.7.1. LCMS mass: found m/z 
1690.2 [M+H]+. 
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6.11.3 Peptide 261 
 
Sequence GQAAC(Pfp)EFIAWLVKGR-NH2 was synthesised using peptide 259 (0.05 
mmol) and following the procedure for selective tagging described in Section 6.5.1 and 
the tube was shaken at rt for 4.5 h. After removal of volatiles under reduced pressure, 
dissolved in a 1:1 mixture of H2O and MeCN (1 mL) and purified via preparative HPLC 
according to Section 6.7.1.  LCMS mass: found 1840.4 [M+H]+, analytical HPLC 
retention time 20.5 min. Analytical HPLC 100% solvent A- 100% solvent B gradient 
over 20 min, observed at 220 nm. 
 
6.11.4 Peptide 260 
 
Sequence GQAAC(Pfp)EFIAWLVKGR-NH2 was synthesised using peptide 259 (0.05 
mmol) and following the procedure for non-selective tagging described in Section 6.5.2 
and the tube was shaken at rt for 4.5 h. After removal of volatiles under vacuum, 
dissolved in a 1:1 mixture of H2O and MeCN (1 ml) and purified via preparative HPLC 
according to Section 6.7.1. LCMS mass: found 1970. 0 [M+H]+. 
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6.11.5 Peptide 263 
 
Sequence GQAAKEFIAWLVKGR-NH2 was synthesised via automated Fmoc-SPPS 
at rt on a 0.1 mmol scale (according to Section 6.3) on RINK Amide resin (0.82 
mg/mmol loading). Amino acids GQAAEFIAWLVKGR were coupled using 30 min 
single couplings + 10 min mW. Cleavage of peptide from the resin was carried out 
following the procedure detailed in Section 6.3.5 and the peptide purified using 
preparative HPLC as described in Section 6.7.1. LCMS mass: found m/z 1715.3 
[M+H]+ , analytical HPLC retention time 15.4 min. Analytical HPLC 100% solvent A-
100% solvent B gradient over 20 min, observed at 220 nm. 
 
6.11.6 Peptide 250 
 
Sequence HAEGTFTSDVSSYLEGQAACEFIAWLVKGR-NH2 was synthesised via 
automated Fmoc-SPPS at rt on a 0.05 mmol scale (according to Section 6.3) on RINK 
Amide resin (0.82 mg/mmol loading). Amino acids EFIAWLVKGR were coupled 
using 30 min single couplings + 10 min mW, amino acid C was coupled manually using 
reaction condition described in Section 6.4.2 and using HATU, amino acids 
TFTSDVSSYLEGQAA were coupled using 60 min single couplings + 10 min mW,  
amino acids AEG were coupled using double 60 min couplings +10 min mW and amino 
acid H was coupled manually using HATU and the conditions described in Section 
6.4.2. Cleavage of peptide from the resin was carried out following the procedure 
detailed in Section 6.3.5 and the peptide purified using preparative HPLC as described 
in Section 6.7.1. MALDI-ToF mass: found m/z 3274.0 [M+H]+ 
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